<html lang="en-US"><head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <link rel="profile" href="https://gmpg.org/xfn/11">
	<meta property="og:image" content="https://www.ionispharma.com/wp-content/themes/ionis-2/screenshot.png">
    <link rel="apple-touch-icon" sizes="57x57" href="https://www.ionispharma.com/apple-icon-57x57.png">
<link rel="apple-touch-icon" sizes="60x60" href="https://www.ionispharma.com/apple-icon-60x60.png">
<link rel="apple-touch-icon" sizes="72x72" href="https://www.ionispharma.com/apple-icon-72x72.png">
<link rel="apple-touch-icon" sizes="76x76" href="https://www.ionispharma.com/apple-icon-76x76.png">
<link rel="apple-touch-icon" sizes="114x114" href="https://www.ionispharma.com/apple-icon-114x114.png">
<link rel="apple-touch-icon" sizes="120x120" href="https://www.ionispharma.com/apple-icon-120x120.png">
<link rel="apple-touch-icon" sizes="144x144" href="https://www.ionispharma.com/apple-icon-144x144.png">
<link rel="apple-touch-icon" sizes="152x152" href="https://www.ionispharma.com/apple-icon-152x152.png">
<link rel="apple-touch-icon" sizes="180x180" href="https://www.ionispharma.com/apple-icon-180x180.png">
<link rel="icon" type="image/png" sizes="192x192" href="https://www.ionispharma.com/android-icon-192x192.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://www.ionispharma.com/favicon-32x32.png">
<link rel="icon" type="image/png" sizes="96x96" href="https://www.ionispharma.com/favicon-96x96.png">
<link rel="icon" type="image/png" sizes="16x16" href="https://www.ionispharma.com/favicon-16x16.png">
<link rel="manifest" href="https://www.ionispharma.com/manifest.json">
<meta name="msapplication-TileColor" content="#ffffff">
<meta name="msapplication-TileImage" content="https://www.ionispharma.com/ms-icon-144x144.png">
<meta name="theme-color" content="#ffffff">

   <!-- Google Tag Manager -->
<script type="text/javascript" async="" src="https://snap.licdn.com/li.lms-analytics/insight.min.js"></script><script type="text/javascript" async="" src="https://static.hotjar.com/c/hotjar-1838848.js?sv=7"></script><script type="text/javascript" async="" src="https://www.google-analytics.com/analytics.js"></script><script async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-NWNTN68"></script><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-NWNTN68');</script>
<!-- End Google Tag Manager -->
    
    <meta name="robots" content="index, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1">

	<!-- This site is optimized with the Yoast SEO Premium plugin v19.1 (Yoast SEO v19.5.1) - https://yoast.com/wordpress/plugins/seo/ -->
	<title>Ionis Pipeline: Antisense Drugs for a Broad Range of Diseases</title>
	<meta name="description" content="Review the Ionis pipeline of antisense drugs for a wide range of diseases including neurological, rare, cardiometabolic &amp; renal, and cancer.">
	<link rel="canonical" href="https://www.ionispharma.com/ionis-innovation/pipeline/">
	<meta property="og:locale" content="en_US">
	<meta property="og:type" content="article">
	<meta property="og:title" content="Pipeline">
	<meta property="og:description" content="Review the Ionis pipeline of antisense drugs for a wide range of diseases including neurological, rare, cardiometabolic &amp; renal, and cancer.">
	<meta property="og:url" content="https://www.ionispharma.com/ionis-innovation/pipeline/">
	<meta property="og:site_name" content="Ionis Pharmaceuticals, Inc.">
	<meta property="article:modified_time" content="2021-01-26T17:45:07+00:00">
	<meta name="twitter:card" content="summary_large_image">
	<!-- / Yoast SEO Premium plugin. -->


<link rel="dns-prefetch" href="//s.w.org">
<link rel="alternate" type="application/rss+xml" title="Ionis Pharmaceuticals, Inc. » Feed" href="https://www.ionispharma.com/feed/">
<link rel="alternate" type="application/rss+xml" title="Ionis Pharmaceuticals, Inc. » Comments Feed" href="https://www.ionispharma.com/comments/feed/">
<script type="text/javascript">
window._wpemojiSettings = {"baseUrl":"https:\/\/s.w.org\/images\/core\/emoji\/13.1.0\/72x72\/","ext":".png","svgUrl":"https:\/\/s.w.org\/images\/core\/emoji\/13.1.0\/svg\/","svgExt":".svg","source":{"concatemoji":"https:\/\/www.ionispharma.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=5.9.3"}};
/*! This file is auto-generated */
!function(e,a,t){var n,r,o,i=a.createElement("canvas"),p=i.getContext&&i.getContext("2d");function s(e,t){var a=String.fromCharCode;p.clearRect(0,0,i.width,i.height),p.fillText(a.apply(this,e),0,0);e=i.toDataURL();return p.clearRect(0,0,i.width,i.height),p.fillText(a.apply(this,t),0,0),e===i.toDataURL()}function c(e){var t=a.createElement("script");t.src=e,t.defer=t.type="text/javascript",a.getElementsByTagName("head")[0].appendChild(t)}for(o=Array("flag","emoji"),t.supports={everything:!0,everythingExceptFlag:!0},r=0;r<o.length;r++)t.supports[o[r]]=function(e){if(!p||!p.fillText)return!1;switch(p.textBaseline="top",p.font="600 32px Arial",e){case"flag":return s([127987,65039,8205,9895,65039],[127987,65039,8203,9895,65039])?!1:!s([55356,56826,55356,56819],[55356,56826,8203,55356,56819])&&!s([55356,57332,56128,56423,56128,56418,56128,56421,56128,56430,56128,56423,56128,56447],[55356,57332,8203,56128,56423,8203,56128,56418,8203,56128,56421,8203,56128,56430,8203,56128,56423,8203,56128,56447]);case"emoji":return!s([10084,65039,8205,55357,56613],[10084,65039,8203,55357,56613])}return!1}(o[r]),t.supports.everything=t.supports.everything&&t.supports[o[r]],"flag"!==o[r]&&(t.supports.everythingExceptFlag=t.supports.everythingExceptFlag&&t.supports[o[r]]);t.supports.everythingExceptFlag=t.supports.everythingExceptFlag&&!t.supports.flag,t.DOMReady=!1,t.readyCallback=function(){t.DOMReady=!0},t.supports.everything||(n=function(){t.readyCallback()},a.addEventListener?(a.addEventListener("DOMContentLoaded",n,!1),e.addEventListener("load",n,!1)):(e.attachEvent("onload",n),a.attachEvent("onreadystatechange",function(){"complete"===a.readyState&&t.readyCallback()})),(n=t.source||{}).concatemoji?c(n.concatemoji):n.wpemoji&&n.twemoji&&(c(n.twemoji),c(n.wpemoji)))}(window,document,window._wpemojiSettings);
</script><script src="https://www.ionispharma.com/wp-includes/js/wp-emoji-release.min.js?ver=5.9.3" type="text/javascript" defer=""></script>
<style type="text/css">
img.wp-smiley,
img.emoji {
	display: inline !important;
	border: none !important;
	box-shadow: none !important;
	height: 1em !important;
	width: 1em !important;
	margin: 0 0.07em !important;
	vertical-align: -0.1em !important;
	background: none !important;
	padding: 0 !important;
}
</style>
	<link rel="stylesheet" id="wp-block-library-css" href="https://www.ionispharma.com/wp-includes/css/dist/block-library/style.min.css?ver=5.9.3" type="text/css" media="all">
<style id="global-styles-inline-css" type="text/css">
body{--wp--preset--color--black: #000000;--wp--preset--color--cyan-bluish-gray: #abb8c3;--wp--preset--color--white: #ffffff;--wp--preset--color--pale-pink: #f78da7;--wp--preset--color--vivid-red: #cf2e2e;--wp--preset--color--luminous-vivid-orange: #ff6900;--wp--preset--color--luminous-vivid-amber: #fcb900;--wp--preset--color--light-green-cyan: #7bdcb5;--wp--preset--color--vivid-green-cyan: #00d084;--wp--preset--color--pale-cyan-blue: #8ed1fc;--wp--preset--color--vivid-cyan-blue: #0693e3;--wp--preset--color--vivid-purple: #9b51e0;--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple: linear-gradient(135deg,rgba(6,147,227,1) 0%,rgb(155,81,224) 100%);--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan: linear-gradient(135deg,rgb(122,220,180) 0%,rgb(0,208,130) 100%);--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange: linear-gradient(135deg,rgba(252,185,0,1) 0%,rgba(255,105,0,1) 100%);--wp--preset--gradient--luminous-vivid-orange-to-vivid-red: linear-gradient(135deg,rgba(255,105,0,1) 0%,rgb(207,46,46) 100%);--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray: linear-gradient(135deg,rgb(238,238,238) 0%,rgb(169,184,195) 100%);--wp--preset--gradient--cool-to-warm-spectrum: linear-gradient(135deg,rgb(74,234,220) 0%,rgb(151,120,209) 20%,rgb(207,42,186) 40%,rgb(238,44,130) 60%,rgb(251,105,98) 80%,rgb(254,248,76) 100%);--wp--preset--gradient--blush-light-purple: linear-gradient(135deg,rgb(255,206,236) 0%,rgb(152,150,240) 100%);--wp--preset--gradient--blush-bordeaux: linear-gradient(135deg,rgb(254,205,165) 0%,rgb(254,45,45) 50%,rgb(107,0,62) 100%);--wp--preset--gradient--luminous-dusk: linear-gradient(135deg,rgb(255,203,112) 0%,rgb(199,81,192) 50%,rgb(65,88,208) 100%);--wp--preset--gradient--pale-ocean: linear-gradient(135deg,rgb(255,245,203) 0%,rgb(182,227,212) 50%,rgb(51,167,181) 100%);--wp--preset--gradient--electric-grass: linear-gradient(135deg,rgb(202,248,128) 0%,rgb(113,206,126) 100%);--wp--preset--gradient--midnight: linear-gradient(135deg,rgb(2,3,129) 0%,rgb(40,116,252) 100%);--wp--preset--duotone--dark-grayscale: url('#wp-duotone-dark-grayscale');--wp--preset--duotone--grayscale: url('#wp-duotone-grayscale');--wp--preset--duotone--purple-yellow: url('#wp-duotone-purple-yellow');--wp--preset--duotone--blue-red: url('#wp-duotone-blue-red');--wp--preset--duotone--midnight: url('#wp-duotone-midnight');--wp--preset--duotone--magenta-yellow: url('#wp-duotone-magenta-yellow');--wp--preset--duotone--purple-green: url('#wp-duotone-purple-green');--wp--preset--duotone--blue-orange: url('#wp-duotone-blue-orange');--wp--preset--font-size--small: 13px;--wp--preset--font-size--medium: 20px;--wp--preset--font-size--large: 36px;--wp--preset--font-size--x-large: 42px;}.has-black-color{color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-color{color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-color{color: var(--wp--preset--color--white) !important;}.has-pale-pink-color{color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-color{color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-color{color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-color{color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-color{color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-color{color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-color{color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-color{color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-color{color: var(--wp--preset--color--vivid-purple) !important;}.has-black-background-color{background-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-background-color{background-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-background-color{background-color: var(--wp--preset--color--white) !important;}.has-pale-pink-background-color{background-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-background-color{background-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-background-color{background-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-background-color{background-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-background-color{background-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-background-color{background-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-background-color{background-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-background-color{background-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-background-color{background-color: var(--wp--preset--color--vivid-purple) !important;}.has-black-border-color{border-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-border-color{border-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-border-color{border-color: var(--wp--preset--color--white) !important;}.has-pale-pink-border-color{border-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-border-color{border-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-border-color{border-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-border-color{border-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-border-color{border-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-border-color{border-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-border-color{border-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-border-color{border-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-border-color{border-color: var(--wp--preset--color--vivid-purple) !important;}.has-vivid-cyan-blue-to-vivid-purple-gradient-background{background: var(--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple) !important;}.has-light-green-cyan-to-vivid-green-cyan-gradient-background{background: var(--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan) !important;}.has-luminous-vivid-amber-to-luminous-vivid-orange-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange) !important;}.has-luminous-vivid-orange-to-vivid-red-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-orange-to-vivid-red) !important;}.has-very-light-gray-to-cyan-bluish-gray-gradient-background{background: var(--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray) !important;}.has-cool-to-warm-spectrum-gradient-background{background: var(--wp--preset--gradient--cool-to-warm-spectrum) !important;}.has-blush-light-purple-gradient-background{background: var(--wp--preset--gradient--blush-light-purple) !important;}.has-blush-bordeaux-gradient-background{background: var(--wp--preset--gradient--blush-bordeaux) !important;}.has-luminous-dusk-gradient-background{background: var(--wp--preset--gradient--luminous-dusk) !important;}.has-pale-ocean-gradient-background{background: var(--wp--preset--gradient--pale-ocean) !important;}.has-electric-grass-gradient-background{background: var(--wp--preset--gradient--electric-grass) !important;}.has-midnight-gradient-background{background: var(--wp--preset--gradient--midnight) !important;}.has-small-font-size{font-size: var(--wp--preset--font-size--small) !important;}.has-medium-font-size{font-size: var(--wp--preset--font-size--medium) !important;}.has-large-font-size{font-size: var(--wp--preset--font-size--large) !important;}.has-x-large-font-size{font-size: var(--wp--preset--font-size--x-large) !important;}
</style>
<link rel="stylesheet" id="contact-form-7-css" href="https://www.ionispharma.com/wp-content/plugins/contact-form-7/includes/css/styles.css?ver=5.6.2" type="text/css" media="all">
<link rel="stylesheet" id="default-style-css" href="https://www.ionispharma.com/wp-content/themes/ionis-2/dist/css/pages/default.css?ver=1629314834" type="text/css" media="all">
<link rel="stylesheet" id="hero-full-section-style-css" href="https://www.ionispharma.com/wp-content/themes/ionis-2/dist/css/modules/hero-full-section.css?ver=1557295769" type="text/css" media="all">
<link rel="stylesheet" id="content-block-section-style-css" href="https://www.ionispharma.com/wp-content/themes/ionis-2/dist/css/modules/content-block-section.css?ver=1597888260" type="text/css" media="all">
<link rel="stylesheet" id="pipeline-new-section-style-css" href="https://www.ionispharma.com/wp-content/themes/ionis-2/dist/css/modules/pipeline-new-section.css?ver=1619030809" type="text/css" media="all">
<link rel="stylesheet" id="cards-section-style-css" href="https://www.ionispharma.com/wp-content/themes/ionis-2/dist/css/modules/cards-section.css?ver=1557295770" type="text/css" media="all">
<link rel="stylesheet" id="fancybox-css" href="https://www.ionispharma.com/wp-content/plugins/easy-fancybox/css/jquery.fancybox.min.css?ver=1.3.24" type="text/css" media="screen">
<link rel="stylesheet" id="cf7cf-style-css" href="https://www.ionispharma.com/wp-content/plugins/cf7-conditional-fields/style.css?ver=2.2.3" type="text/css" media="all">
<link rel="stylesheet" id="moove_gdpr_frontend-css" href="https://www.ionispharma.com/wp-content/plugins/gdpr-cookie-compliance/dist/styles/gdpr-main.css?ver=4.8.12" type="text/css" media="all">
<style id="moove_gdpr_frontend-inline-css" type="text/css">
#moove_gdpr_cookie_modal,#moove_gdpr_cookie_info_bar,.gdpr_cookie_settings_shortcode_content{font-family:Nunito,sans-serif}#moove_gdpr_save_popup_settings_button{background-color:#373737;color:#fff}#moove_gdpr_save_popup_settings_button:hover{background-color:#000}#moove_gdpr_cookie_info_bar .moove-gdpr-info-bar-container .moove-gdpr-info-bar-content a.mgbutton,#moove_gdpr_cookie_info_bar .moove-gdpr-info-bar-container .moove-gdpr-info-bar-content button.mgbutton{background-color:#a01f5e}#moove_gdpr_cookie_modal .moove-gdpr-modal-content .moove-gdpr-modal-footer-content .moove-gdpr-button-holder a.mgbutton,#moove_gdpr_cookie_modal .moove-gdpr-modal-content .moove-gdpr-modal-footer-content .moove-gdpr-button-holder button.mgbutton,.gdpr_cookie_settings_shortcode_content .gdpr-shr-button.button-green{background-color:#a01f5e;border-color:#a01f5e}#moove_gdpr_cookie_modal .moove-gdpr-modal-content .moove-gdpr-modal-footer-content .moove-gdpr-button-holder a.mgbutton:hover,#moove_gdpr_cookie_modal .moove-gdpr-modal-content .moove-gdpr-modal-footer-content .moove-gdpr-button-holder button.mgbutton:hover,.gdpr_cookie_settings_shortcode_content .gdpr-shr-button.button-green:hover{background-color:#fff;color:#a01f5e}#moove_gdpr_cookie_modal .moove-gdpr-modal-content .moove-gdpr-modal-close i,#moove_gdpr_cookie_modal .moove-gdpr-modal-content .moove-gdpr-modal-close span.gdpr-icon{background-color:#a01f5e;border:1px solid #a01f5e}#moove_gdpr_cookie_info_bar span.change-settings-button.focus-g,#moove_gdpr_cookie_info_bar span.change-settings-button:focus{-webkit-box-shadow:0 0 1px 3px #a01f5e;-moz-box-shadow:0 0 1px 3px #a01f5e;box-shadow:0 0 1px 3px #a01f5e}#moove_gdpr_cookie_modal .moove-gdpr-modal-content .moove-gdpr-modal-close i:hover,#moove_gdpr_cookie_modal .moove-gdpr-modal-content .moove-gdpr-modal-close span.gdpr-icon:hover,#moove_gdpr_cookie_info_bar span[data-href]>u.change-settings-button{color:#a01f5e}#moove_gdpr_cookie_modal .moove-gdpr-modal-content .moove-gdpr-modal-left-content #moove-gdpr-menu li.menu-item-selected a span.gdpr-icon,#moove_gdpr_cookie_modal .moove-gdpr-modal-content .moove-gdpr-modal-left-content #moove-gdpr-menu li.menu-item-selected button span.gdpr-icon{color:inherit}#moove_gdpr_cookie_modal .moove-gdpr-modal-content .moove-gdpr-modal-left-content #moove-gdpr-menu li a span.gdpr-icon,#moove_gdpr_cookie_modal .moove-gdpr-modal-content .moove-gdpr-modal-left-content #moove-gdpr-menu li button span.gdpr-icon{color:inherit}#moove_gdpr_cookie_modal .gdpr-acc-link{line-height:0;font-size:0;color:transparent;position:absolute}#moove_gdpr_cookie_modal .moove-gdpr-modal-content .moove-gdpr-modal-close:hover i,#moove_gdpr_cookie_modal .moove-gdpr-modal-content .moove-gdpr-modal-left-content #moove-gdpr-menu li a,#moove_gdpr_cookie_modal .moove-gdpr-modal-content .moove-gdpr-modal-left-content #moove-gdpr-menu li button,#moove_gdpr_cookie_modal .moove-gdpr-modal-content .moove-gdpr-modal-left-content #moove-gdpr-menu li button i,#moove_gdpr_cookie_modal .moove-gdpr-modal-content .moove-gdpr-modal-left-content #moove-gdpr-menu li a i,#moove_gdpr_cookie_modal .moove-gdpr-modal-content .moove-gdpr-tab-main .moove-gdpr-tab-main-content a:hover,#moove_gdpr_cookie_info_bar.moove-gdpr-dark-scheme .moove-gdpr-info-bar-container .moove-gdpr-info-bar-content a.mgbutton:hover,#moove_gdpr_cookie_info_bar.moove-gdpr-dark-scheme .moove-gdpr-info-bar-container .moove-gdpr-info-bar-content button.mgbutton:hover,#moove_gdpr_cookie_info_bar.moove-gdpr-dark-scheme .moove-gdpr-info-bar-container .moove-gdpr-info-bar-content a:hover,#moove_gdpr_cookie_info_bar.moove-gdpr-dark-scheme .moove-gdpr-info-bar-container .moove-gdpr-info-bar-content button:hover,#moove_gdpr_cookie_info_bar.moove-gdpr-dark-scheme .moove-gdpr-info-bar-container .moove-gdpr-info-bar-content span.change-settings-button:hover,#moove_gdpr_cookie_info_bar.moove-gdpr-dark-scheme .moove-gdpr-info-bar-container .moove-gdpr-info-bar-content u.change-settings-button:hover,#moove_gdpr_cookie_info_bar span[data-href]>u.change-settings-button,#moove_gdpr_cookie_info_bar.moove-gdpr-dark-scheme .moove-gdpr-info-bar-container .moove-gdpr-info-bar-content a.mgbutton.focus-g,#moove_gdpr_cookie_info_bar.moove-gdpr-dark-scheme .moove-gdpr-info-bar-container .moove-gdpr-info-bar-content button.mgbutton.focus-g,#moove_gdpr_cookie_info_bar.moove-gdpr-dark-scheme .moove-gdpr-info-bar-container .moove-gdpr-info-bar-content a.focus-g,#moove_gdpr_cookie_info_bar.moove-gdpr-dark-scheme .moove-gdpr-info-bar-container .moove-gdpr-info-bar-content button.focus-g,#moove_gdpr_cookie_info_bar.moove-gdpr-dark-scheme .moove-gdpr-info-bar-container .moove-gdpr-info-bar-content a.mgbutton:focus,#moove_gdpr_cookie_info_bar.moove-gdpr-dark-scheme .moove-gdpr-info-bar-container .moove-gdpr-info-bar-content button.mgbutton:focus,#moove_gdpr_cookie_info_bar.moove-gdpr-dark-scheme .moove-gdpr-info-bar-container .moove-gdpr-info-bar-content a:focus,#moove_gdpr_cookie_info_bar.moove-gdpr-dark-scheme .moove-gdpr-info-bar-container .moove-gdpr-info-bar-content button:focus,#moove_gdpr_cookie_info_bar.moove-gdpr-dark-scheme .moove-gdpr-info-bar-container .moove-gdpr-info-bar-content span.change-settings-button.focus-g,span.change-settings-button:focus,#moove_gdpr_cookie_info_bar.moove-gdpr-dark-scheme .moove-gdpr-info-bar-container .moove-gdpr-info-bar-content u.change-settings-button.focus-g,#moove_gdpr_cookie_info_bar.moove-gdpr-dark-scheme .moove-gdpr-info-bar-container .moove-gdpr-info-bar-content u.change-settings-button:focus{color:#a01f5e}#moove_gdpr_cookie_modal.gdpr_lightbox-hide{display:none}
</style>
<script type="text/javascript" src="https://www.ionispharma.com/wp-includes/js/jquery/jquery.min.js?ver=3.6.0" id="jquery-core-js"></script>
<script type="text/javascript" src="https://www.ionispharma.com/wp-includes/js/jquery/jquery-migrate.min.js?ver=3.3.2" id="jquery-migrate-js"></script>
<link rel="https://api.w.org/" href="https://www.ionispharma.com/wp-json/"><link rel="alternate" type="application/json" href="https://www.ionispharma.com/wp-json/wp/v2/pages/538"><link rel="EditURI" type="application/rsd+xml" title="RSD" href="https://www.ionispharma.com/xmlrpc.php?rsd">
<link rel="wlwmanifest" type="application/wlwmanifest+xml" href="https://www.ionispharma.com/wp-includes/wlwmanifest.xml"> 
<link rel="shortlink" href="https://www.ionispharma.com/?p=538">
<link rel="alternate" type="application/json+oembed" href="https://www.ionispharma.com/wp-json/oembed/1.0/embed?url=https%3A%2F%2Fwww.ionispharma.com%2Fionis-innovation%2Fpipeline%2F">
<link rel="alternate" type="text/xml+oembed" href="https://www.ionispharma.com/wp-json/oembed/1.0/embed?url=https%3A%2F%2Fwww.ionispharma.com%2Fionis-innovation%2Fpipeline%2F&amp;format=xml">

<!-- Schema & Structured Data For WP v1.9.100 - -->
<script type="application/ld+json" class="saswp-schema-markup-output">
[{"@context":"https://schema.org","@graph":[{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Home","url":"https://www.ionispharma.com/"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"About","url":"https://www.ionispharma.com/about/"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Back To Main","url":"#"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Ionis: A force for life","url":"/about/#force"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Executive & Leadership Team","url":"/about/#team"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Board of Directors","url":"/about/#team"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Akcea Therapeutics","url":"/about/#akcea"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Ionis Innovation","url":"https://www.ionispharma.com/ionis-innovation/antisense-technology/"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Back To Main","url":"#"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Antisense Technology","url":"https://www.ionispharma.com/ionis-innovation/antisense-technology/"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Optimizing Antisense","url":"https://www.ionispharma.com/ionis-innovation/optimizing-antisense/"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Pipeline","url":"https://www.ionispharma.com/ionis-innovation/pipeline/"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Ion-ARPA Initiative","url":"https://www.ionispharma.com/ionis-innovation/ion-arpa-initiative/"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Our Medicines","url":"https://www.ionispharma.com/our-medicines/"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Patients &#038; Community","url":"https://www.ionispharma.com/patients-community/"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Back To Main","url":"#"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Overview","url":"https://www.ionispharma.com/patients-community/"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Patient Resources","url":"https://www.ionispharma.com/patients-community/patient-resources/"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Community Engagement","url":"https://www.ionispharma.com/patients-community/community-engagement/"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Patient Experiences","url":"https://www.ionispharma.com/patients-community/patient-experiences/"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Investors & media","url":"https://ir.ionispharma.com/"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Back To Main","url":"#"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Overview","url":"https://ir.ionispharma.com/"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Newsroom","url":"http://ir.ionispharma.com/news-releases"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Back To Main","url":"#"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Investors & Media","url":"#"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Press Releases","url":"http://ir.ionispharma.com/news-releases"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"InBriefs","url":"https://ir.ionispharma.com/inbriefs"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Media Center","url":"https://www.ionispharma.com/media-center/"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Stock Information","url":"http://ir.ionispharma.com/stock-information/stock-quote"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Back To Main","url":"#"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Investors & Media","url":"#"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Stock Quote & Chart","url":"http://ir.ionispharma.com/stock-information/stock-quote"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Analyst Coverage","url":"http://ir.ionispharma.com/stock-information/analyst-coverage"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Ownership Profile","url":"http://ir.ionispharma.com/stock-information/institutional-ownership"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Financials","url":"http://ir.ionispharma.com/financial-information/sec-filings"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Back To Main","url":"#"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Investors & Media","url":"#"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"SEC Filings","url":"http://ir.ionispharma.com/financial-information/sec-filings"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Annual Reports","url":"http://ir.ionispharma.com/financial-information/annual-reports"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Governance","url":"http://ir.ionispharma.com/corporate-governance/highlights"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Back To Main","url":"#"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Investors & Media","url":"#"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Governance Documents","url":"http://ir.ionispharma.com/corporate-governance/highlights"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Committee Composition","url":"http://ir.ionispharma.com/corporate-governance/committee-composition"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Investor Resources","url":"http://ir.ionispharma.com/shareholder-services/investor-faqs"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Back To Main","url":"#"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Investors & Media","url":"#"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Investor FAQs","url":"http://ir.ionispharma.com/shareholder-services/investor-faqs"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Settlement Information","url":"https://ir.ionispharma.com/settlement-information"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Contact Us","url":"http://ir.ionispharma.com/shareholder-services/contact-ir"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Events","url":"http://ir.ionispharma.com/events-and-presentations/upcoming-events"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Back To Main","url":"#"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Investors & Media","url":"#"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Events","url":"http://ir.ionispharma.com/events-and-presentations/upcoming-events"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Careers","url":"https://www.ionispharma.com/careers/"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Back To Main","url":"#"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Overview","url":"https://www.ionispharma.com/careers/"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Working at Ionis","url":"https://www.ionispharma.com/careers/working-at-ionis/"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Employee Spotlight","url":"https://www.ionispharma.com/careers/employee-spotlight/"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Volunteerism &#038; Philanthropy","url":"https://www.ionispharma.com/careers/volunteerism-philanthropy/"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Investments in You","url":"https://www.ionispharma.com/careers/investments-in-you/"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Intern Program","url":"https://www.ionispharma.com/careers/intern-program/"},{"@context":"https://schema.org","@type":"SiteNavigationElement","@id":"https://www.ionispharma.com/#Main Menu","name":"Postdoctoral Program","url":"https://www.ionispharma.com/careers/post-doctoral/"}]},

{"@context":"https://schema.org","@type":"WebSite","@id":"https://www.ionispharma.com#website","headline":"Ionis Pharmaceuticals, Inc.","name":"Ionis Pharmaceuticals, Inc.","description":"","url":"https://www.ionispharma.com","potentialAction":{"@type":"SearchAction","target":"https://www.ionispharma.com/?s={search_term_string}","query-input":"required name=search_term_string"}},

{"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.ionispharma.com/ionis-innovation/pipeline/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://www.ionispharma.com","name":"Ionis Pharmaceuticals, Inc."}},{"@type":"ListItem","position":2,"item":{"@id":"https://www.ionispharma.com/ionis-innovation/","name":"Ionis Innovation"}},{"@type":"ListItem","position":3,"item":{"@id":"https://www.ionispharma.com/ionis-innovation/pipeline/","name":"Ionis Pipeline: Antisense Drugs for a Broad Range of Diseases"}}]},

{"@context":"https://schema.org","@type":"MedicalOrganization","@id":"https://www.ionispharma.com#Organization","name":"Ionis Pharmaceuticals, Inc.","url":"https://www.ionispharma.com","sameAs":["https://www.linkedin.com/company/ionis-pharmaceuticals","https://twitter.com/ionispharma?lang=en","https://www.youtube.com/channel/UC--ViR02TJJAIXua15j87WQ"],"logo":{"@type":"ImageObject","url":"https://www.ionispharma.com/wp-content/uploads/2019/03/ionis-logo.png","width":"574","height":"196"},"contactPoint":{"@type":"ContactPoint","contactType":"customer support","telephone":"+1-760-931-9200","url":"https://www.ionispharma.com/contact-us/"}}]
</script>

<link rel="icon" href="https://www.ionispharma.com/wp-content/uploads/2019/05/favicon-96x96.png" sizes="32x32">
<link rel="icon" href="https://www.ionispharma.com/wp-content/uploads/2019/05/favicon-96x96.png" sizes="192x192">
<link rel="apple-touch-icon" href="https://www.ionispharma.com/wp-content/uploads/2019/05/favicon-96x96.png">
<meta name="msapplication-TileImage" content="https://www.ionispharma.com/wp-content/uploads/2019/05/favicon-96x96.png">
		<style type="text/css" id="wp-custom-css">
			.content-block-section__text h5 {margin-bottom:15px;}
#scrip-award {
	margin-bottom:20px;
	padding-bottom:10px
}
#scamannouncement {
	position:absolute;
	top:140%;
	right:0;
	left:66px;
	color:red;
	visibility:hidden;
}
#scamannouncement2 {
		color:red;
	position:relative;
margin-left: 66px;
margin-top: 26px;
}
#scamannouncement:before,
#scamannouncement2:before{
	content:"!";
	color:red;
	font-size:150px;
	font-weight:bold;
	left:-75px;
	top:-18px;
	position:absolute;
	line-height:1;
}
.page-id-2 #text-and-image-last .text-content__text {
	position: relative;	
}

.page-id-312 .badge-with-text-section .badge__text,
.page-id-359 .badge-with-text-section .badge__text,
.page-id-2810 .badge-with-text-section .badge__text,
.page-id-392 .badge-with-text-section .badge__text,
.page-id-334 .badge-with-text-section .badge__text {
	padding-top:12px;
	padding-bottom:12px;
	max-width: 78%;
	font-weight:normal;
	font-size:18px
}
.page-id-312 #Alert .badge,
.page-id-359 #Alert .badge,
.page-id-2810 #Alert .badge,
.page-id-392 #Alert .badge,
.page-id-334 #Alert .badge {
	background-color:#d2216a;
}
.page-id-312 #Alert .badge__image,
.page-id-359 #Alert .badge__image,
.page-id-2810 #Alert .badge__image,
.page-id-392 #Alert .badge__image,
.page-id-334 #Alert .badge__image {
	display:none;
}
@media all and (max-width: 1659px) {
	#scamannouncement {
		position:relative;
		display:none;
	}
	#scamannouncement2 { 
		color:red;
		margin-left:66px;
		position:relative;
		margin-top: 24px;
	}
}
@media all and (max-width:1292px) {
	
	.page-id-312 .badge-with-text-section .badge__text,
	.page-id-359 .badge-with-text-section .badge__text,
	.page-id-2810 .badge-with-text-section .badge__text,
	.page-id-392 .badge-with-text-section .badge__text,
	.page-id-334 .badge-with-text-section .badge__text {
		max-width: 100%;
		font-size:16px
	}
	.page-id-312 .badge-with-text-section .badge__text,
	.page-id-359 .badge-with-text-section .badge__text,
	.page-id-2810 .badge-with-text-section .badge__text,
	.page-id-392 .badge-with-text-section .badge__text,
	.page-id-334 .badge-with-text-section .badge__text {
		z-index:2;
		background:none;
		color:#d2216a;
		padding:20px 0 0 0;
	}
	/* Careers Page and child-pages */
	.page-id-312 .content-block-section,
	.parent-pageid-312 .content-block-section {
		padding-top:15px;
	}
}
@media all and (max-width:1292px) {
	.page-id-312 #Alert,
	.page-id-359 #Alert,
	.page-id-2810 #Alert,
	.page-id-392 #Alert,
	.page-id-334 #Alert {
		display:none;
	}
}		</style>
			<link rel="stylesheet" id="new-style" href="https://www.ionispharma.com/wp-content/themes/ionis-2/style.css?ver=2" type="text/css" media="all">
</head>

<body class="page-template-default page page-id-538 page-child parent-pageid-512 chrome desktop-device windows">

<!-- Google Tag Manager (noscript) -->
<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-NWNTN68"
height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<!-- End Google Tag Manager (noscript) -->
	
<div id="page" class="site">
    <a class="sr-only sr-only-focusable" href="#content">Skip to content</a>

    <header id="main-header-desktop" class="main-header headroom headroom--top headroom--not-bottom">
    <div class="container">
        <div class="inner">
            <a class="logo" href="https://www.ionispharma.com">
                            </a>
            <div class="main-menu-wrapper">
                <div class="menu main-menu"><ul id="main-menu" class="menu-list"><li id="menu-item-51" class="d-lg-none menu-item menu-item-type-post_type menu-item-object-page menu-item-home menu-item-51"><a href="https://www.ionispharma.com/">Home</a></li>
<li id="menu-item-69" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-69"><a href="https://www.ionispharma.com/about/">About</a>
<ul class="sub-menu">
	<li id="menu-item-3185" class="sub-menu-back menu-item menu-item-type-custom menu-item-object-custom menu-item-3185"><a href="#">Back To Main</a></li>
	<li id="menu-item-3186" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3186"><a href="/about/#force">Ionis: A force for life</a></li>
	<li id="menu-item-3187" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3187"><a href="/about/#team">Executive &amp; Leadership Team</a></li>
	<li id="menu-item-3188" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3188"><a href="/about/#team">Board of Directors</a></li>
	<li id="menu-item-3189" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3189"><a href="/about/#akcea">Akcea Therapeutics</a></li>
</ul>
</li>
<li id="menu-item-2833" class="menu-item menu-item-type-post_type menu-item-object-page current-menu-ancestor current-menu-parent current_page_parent current_page_ancestor menu-item-has-children menu-item-2833"><a href="https://www.ionispharma.com/ionis-innovation/antisense-technology/">Ionis Innovation</a>
<ul class="sub-menu">
	<li id="menu-item-52" class="sub-menu-back menu-item menu-item-type-custom menu-item-object-custom menu-item-52"><a href="#">Back To Main</a></li>
	<li id="menu-item-531" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-531"><a href="https://www.ionispharma.com/ionis-innovation/antisense-technology/">Antisense Technology</a></li>
	<li id="menu-item-532" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-532"><a href="https://www.ionispharma.com/ionis-innovation/optimizing-antisense/">Optimizing Antisense</a></li>
	<li id="menu-item-539" class="menu-item menu-item-type-post_type menu-item-object-page current-menu-item page_item page-item-538 current_page_item menu-item-539"><a href="https://www.ionispharma.com/ionis-innovation/pipeline/" aria-current="page">Pipeline</a></li>
	<li id="menu-item-3273" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3273"><a href="https://www.ionispharma.com/ionis-innovation/ion-arpa-initiative/">Ion-ARPA Initiative</a></li>
</ul>
</li>
<li id="menu-item-540" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-540"><a href="https://www.ionispharma.com/our-medicines/">Our Medicines</a></li>
<li id="menu-item-1969" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-1969"><a href="https://www.ionispharma.com/patients-community/">Patients &amp; Community</a>
<ul class="sub-menu">
	<li id="menu-item-53" class="sub-menu-back menu-item menu-item-type-custom menu-item-object-custom menu-item-53"><a href="#">Back To Main</a></li>
	<li id="menu-item-689" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-689"><a href="https://www.ionispharma.com/patients-community/">Overview</a></li>
	<li id="menu-item-691" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-691"><a href="https://www.ionispharma.com/patients-community/patient-resources/">Patient Resources</a></li>
	<li id="menu-item-690" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-690"><a href="https://www.ionispharma.com/patients-community/community-engagement/">Community Engagement</a></li>
	<li id="menu-item-692" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-692"><a href="https://www.ionispharma.com/patients-community/patient-experiences/">Patient Experiences</a></li>
</ul>
</li>
<li id="menu-item-25" class="menu-item-has-submenus-with-children menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-25"><a href="https://ir.ionispharma.com/">Investors &amp; media</a>
<ul class="sub-menu">
	<li id="menu-item-60" class="sub-menu-back menu-item menu-item-type-custom menu-item-object-custom menu-item-60"><a href="#">Back To Main</a></li>
	<li id="menu-item-26" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-26"><a href="https://ir.ionispharma.com/">Overview</a></li>
	<li id="menu-item-27" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-27"><a href="http://ir.ionispharma.com/news-releases">Newsroom</a>
	<ul class="sub-menu">
		<li id="menu-item-59" class="sub-menu-back menu-item menu-item-type-custom menu-item-object-custom menu-item-59"><a href="#">Back To Main</a></li>
		<li id="menu-item-65" class="back-to-main menu-item menu-item-type-custom menu-item-object-custom menu-item-65"><a href="#">Investors &amp; Media</a></li>
		<li id="menu-item-29" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-29"><a href="http://ir.ionispharma.com/news-releases">Press Releases</a></li>
		<li id="menu-item-2738" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-2738"><a href="https://ir.ionispharma.com/inbriefs">InBriefs</a></li>
		<li id="menu-item-583" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-583"><a href="https://www.ionispharma.com/media-center/">Media Center</a></li>
	</ul>
</li>
	<li id="menu-item-31" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-31"><a href="http://ir.ionispharma.com/stock-information/stock-quote">Stock Information</a>
	<ul class="sub-menu">
		<li id="menu-item-58" class="sub-menu-back menu-item menu-item-type-custom menu-item-object-custom menu-item-58"><a href="#">Back To Main</a></li>
		<li id="menu-item-66" class="back-to-main menu-item menu-item-type-custom menu-item-object-custom menu-item-66"><a href="#">Investors &amp; Media</a></li>
		<li id="menu-item-32" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-32"><a href="http://ir.ionispharma.com/stock-information/stock-quote">Stock Quote &amp; Chart</a></li>
		<li id="menu-item-33" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-33"><a href="http://ir.ionispharma.com/stock-information/analyst-coverage">Analyst Coverage</a></li>
		<li id="menu-item-34" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-34"><a href="http://ir.ionispharma.com/stock-information/institutional-ownership">Ownership Profile</a></li>
	</ul>
</li>
	<li id="menu-item-35" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-35"><a href="http://ir.ionispharma.com/financial-information/sec-filings">Financials</a>
	<ul class="sub-menu">
		<li id="menu-item-57" class="sub-menu-back menu-item menu-item-type-custom menu-item-object-custom menu-item-57"><a href="#">Back To Main</a></li>
		<li id="menu-item-64" class="back-to-main menu-item menu-item-type-custom menu-item-object-custom menu-item-64"><a href="#">Investors &amp; Media</a></li>
		<li id="menu-item-36" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-36"><a href="http://ir.ionispharma.com/financial-information/sec-filings">SEC Filings</a></li>
		<li id="menu-item-37" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-37"><a href="http://ir.ionispharma.com/financial-information/annual-reports">Annual Reports</a></li>
	</ul>
</li>
	<li id="menu-item-38" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-38"><a href="http://ir.ionispharma.com/corporate-governance/highlights">Governance</a>
	<ul class="sub-menu">
		<li id="menu-item-56" class="sub-menu-back menu-item menu-item-type-custom menu-item-object-custom menu-item-56"><a href="#">Back To Main</a></li>
		<li id="menu-item-63" class="back-to-main menu-item menu-item-type-custom menu-item-object-custom menu-item-63"><a href="#">Investors &amp; Media</a></li>
		<li id="menu-item-39" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-39"><a href="http://ir.ionispharma.com/corporate-governance/highlights">Governance Documents</a></li>
		<li id="menu-item-40" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-40"><a href="http://ir.ionispharma.com/corporate-governance/committee-composition">Committee Composition</a></li>
	</ul>
</li>
	<li id="menu-item-43" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-43"><a href="http://ir.ionispharma.com/shareholder-services/investor-faqs">Investor Resources</a>
	<ul class="sub-menu">
		<li id="menu-item-54" class="sub-menu-back menu-item menu-item-type-custom menu-item-object-custom menu-item-54"><a href="#">Back To Main</a></li>
		<li id="menu-item-62" class="back-to-main menu-item menu-item-type-custom menu-item-object-custom menu-item-62"><a href="#">Investors &amp; Media</a></li>
		<li id="menu-item-44" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-44"><a href="http://ir.ionispharma.com/shareholder-services/investor-faqs">Investor FAQs</a></li>
		<li id="menu-item-3571" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3571"><a href="https://ir.ionispharma.com/settlement-information">Settlement Information</a></li>
		<li id="menu-item-45" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-45"><a href="http://ir.ionispharma.com/shareholder-services/contact-ir">Contact Us</a></li>
	</ul>
</li>
	<li id="menu-item-46" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-46"><a href="http://ir.ionispharma.com/events-and-presentations/upcoming-events">Events</a>
	<ul class="sub-menu">
		<li id="menu-item-55" class="sub-menu-back menu-item menu-item-type-custom menu-item-object-custom menu-item-55"><a href="#">Back To Main</a></li>
		<li id="menu-item-61" class="back-to-main menu-item menu-item-type-custom menu-item-object-custom menu-item-61"><a href="#">Investors &amp; Media</a></li>
		<li id="menu-item-47" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-47"><a href="http://ir.ionispharma.com/events-and-presentations/upcoming-events">Events</a></li>
	</ul>
</li>
</ul>
</li>
<li id="menu-item-1968" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-1968"><a href="https://www.ionispharma.com/careers/">Careers</a>
<ul class="sub-menu">
	<li id="menu-item-544" class="sub-menu-back menu-item menu-item-type-custom menu-item-object-custom menu-item-544"><a href="#">Back To Main</a></li>
	<li id="menu-item-533" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-533"><a href="https://www.ionispharma.com/careers/">Overview</a></li>
	<li id="menu-item-543" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-543"><a href="https://www.ionispharma.com/careers/working-at-ionis/">Working at Ionis</a></li>
	<li id="menu-item-2941" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2941"><a href="https://www.ionispharma.com/careers/employee-spotlight/">Employee Spotlight</a></li>
	<li id="menu-item-3388" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3388"><a href="https://www.ionispharma.com/careers/volunteerism-philanthropy/">Volunteerism &amp; Philanthropy</a></li>
	<li id="menu-item-2845" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2845"><a href="https://www.ionispharma.com/careers/investments-in-you/">Investments in You</a></li>
	<li id="menu-item-541" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-541"><a href="https://www.ionispharma.com/careers/intern-program/">Intern Program</a></li>
	<li id="menu-item-542" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-542"><a href="https://www.ionispharma.com/careers/post-doctoral/">Postdoctoral Program</a></li>
</ul>
</li>
</ul></div>                <div class="search-wrapper">
                    <form class="search-form" role="search" method="get" action="https://www.ionispharma.com" autocomplete="off">
                        <input class="search-box" type="search" placeholder="Search ionispharma.com" value="" name="s" autocomplete="off">
                        <span class="close-button"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 47.42218 47.42249">
    <path fill-rule="evenodd" d="M47.422 44l-20.58-20.58L47.016 3.246l-2.84-2.84L24.002 20.58 3.422 0 .594 2.83l20.58 20.58L0 44.582l2.84 2.84 21.174-21.175 20.58 20.58L47.422 44"></path>
</svg></span>
                    </form>
                    <span class="search-icon"></span>
                </div>
                <div class="social-wrap">
    <p>Follow Us</p>
    <div class="icons-wrap">
                        <a class="social-icon linkedin" href="https://www.linkedin.com/company/ionis-pharmaceuticals" target="_blank"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32">
    <defs>
        <style>.cls-social-linkedin{fill:#a4a3a4}</style>
    </defs>
    <g id="Layer_2" data-name="Layer 2">
        <path class="cls-social-linkedin" d="M16 0a16 16 0 1 0 16 16A16 16 0 0 0 16 0zm-4.37 23.65H8.2V13.33h3.43zM9.92 11.92A1.77 1.77 0 0 1 8 10.14a1.79 1.79 0 0 1 1.94-1.79 1.79 1.79 0 1 1 0 3.57zM24 23.65h-3.43v-5.52c0-1.39-.5-2.34-1.74-2.34a1.89 1.89 0 0 0-1.76 1.26 2.32 2.32 0 0 0-.11.83v5.77h-3.43V13.33H17v1.46a3.41 3.41 0 0 1 3.09-1.7c2.26 0 3.95 1.47 3.95 4.64z" id="Layer_1-2" data-name="Layer 1"></path>
    </g>
</svg></a>
                            <a class="social-icon twitter" href="https://twitter.com/ionispharma?lang=en" target="_blank"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32">
    <defs>
        <style>.cls-social-twitter{fill:#a4a3a4}</style>
    </defs>
    <title>twitter-grey</title>
    <g id="Layer_2" data-name="Layer 2">
        <path class="cls-social-twitter" d="M16 0a16 16 0 1 0 16 16A16 16 0 0 0 16 0zm6.36 12.74v.42A9.34 9.34 0 0 1 8 21a6.79 6.79 0 0 0 .78 0 6.58 6.58 0 0 0 4.08-1.4 3.3 3.3 0 0 1-3.07-2.28 3.22 3.22 0 0 0 1.49-.06 3.29 3.29 0 0 1-2.64-3.22 3.29 3.29 0 0 0 1.49.41 3.29 3.29 0 0 1-1-4.38 9.32 9.32 0 0 0 6.77 3.43 3.08 3.08 0 0 1-.09-.75 3.28 3.28 0 0 1 5.68-2.24 6.62 6.62 0 0 0 2.09-.8 3.29 3.29 0 0 1-1.44 1.81A6.31 6.31 0 0 0 24 11a6.63 6.63 0 0 1-1.64 1.74z" id="Layer_1-2" data-name="Layer 1"></path>
    </g>
</svg></a>
                            <a class="social-icon facebook" href="https://www.facebook.com/Ionis-Pharmaceuticals-108946637429610" target="_blank"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32">
  <defs>
      <style>.cls-social-facebook{fill:#a4a3a4}</style>
  </defs>
  <title>facebook-grey</title>
  <g id="Layer_2" data-name="Layer 2">
    <path class="cls-social-facebook" d="M12 0c-6.627 0-12 5.373-12 12s5.373 12 12 12 12-5.373 12-12-5.373-12-12-12zm3 8h-1.35c-.538 0-.65.221-.65.778v1.222h2l-.209 2h-1.791v7h-3v-7h-2v-2h2v-2.308c0-1.769.931-2.692 3.029-2.692h1.971v3z" id="Layer_1-2" data-name="Layer 1"></path>
  </g>
</svg>
</a>
                </div>
</div>


            </div>
        </div>
    </div>
</header>
<header id="main-header-mobile" class="main-header headroom headroom--top headroom--not-bottom">
    <div class="container">
        <div class="inner">
            <div class="logo-wrapper">
                <a class="logo" href="https://www.ionispharma.com">
                                    </a>
            </div>
            <div class="main-menu-open">
                <span class="line line-1"></span>
                <span class="line line-2"></span>
                <span class="line line-3"></span>
                <span class="text">menu</span>
            </div>
            <div class="main-menu-wrapper">

                <div class="top-menu">
                    <div class="main-menu-close">
                        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 47.42218 47.42249">
                            <path fill-rule="evenodd" d="M47.422 44l-20.58-20.58L47.016 3.246l-2.84-2.84L24.002 20.58 3.422 0 .594 2.83l20.58 20.58L0 44.582l2.84 2.84 21.174-21.175 20.58 20.58L47.422 44"></path>
                        </svg>
                    </div>
                </div>
                <div class="navigation-wrapper">
                    <form class="search-form" role="search" method="get" action="https://www.ionispharma.com" autocomplete="off">
                        <input class="search-box" type="search" placeholder="Search ionispharma.com" value="" name="s" autocomplete="off">
                    </form>
                    <div class="menu main-menu"><ul id="main-menu" class="menu-list"><li class="d-lg-none menu-item menu-item-type-post_type menu-item-object-page menu-item-home menu-item-51"><a href="https://www.ionispharma.com/">Home</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-69"><a href="https://www.ionispharma.com/about/">About</a>
<ul class="sub-menu">
	<li class="sub-menu-back menu-item menu-item-type-custom menu-item-object-custom menu-item-3185"><a href="#">Back To Main</a></li>
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3186"><a href="/about/#force">Ionis: A force for life</a></li>
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3187"><a href="/about/#team">Executive &amp; Leadership Team</a></li>
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3188"><a href="/about/#team">Board of Directors</a></li>
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3189"><a href="/about/#akcea">Akcea Therapeutics</a></li>
</ul>
</li>
<li class="menu-item menu-item-type-post_type menu-item-object-page current-menu-ancestor current-menu-parent current_page_parent current_page_ancestor menu-item-has-children menu-item-2833"><a href="https://www.ionispharma.com/ionis-innovation/antisense-technology/">Ionis Innovation</a>
<ul class="sub-menu active">
	<li class="sub-menu-back menu-item menu-item-type-custom menu-item-object-custom menu-item-52"><a href="#">Back To Main</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-531"><a href="https://www.ionispharma.com/ionis-innovation/antisense-technology/">Antisense Technology</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-532"><a href="https://www.ionispharma.com/ionis-innovation/optimizing-antisense/">Optimizing Antisense</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-page current-menu-item page_item page-item-538 current_page_item menu-item-539"><a href="https://www.ionispharma.com/ionis-innovation/pipeline/" aria-current="page">Pipeline</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3273"><a href="https://www.ionispharma.com/ionis-innovation/ion-arpa-initiative/">Ion-ARPA Initiative</a></li>
</ul>
</li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-540"><a href="https://www.ionispharma.com/our-medicines/">Our Medicines</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-1969"><a href="https://www.ionispharma.com/patients-community/">Patients &amp; Community</a>
<ul class="sub-menu">
	<li class="sub-menu-back menu-item menu-item-type-custom menu-item-object-custom menu-item-53"><a href="#">Back To Main</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-689"><a href="https://www.ionispharma.com/patients-community/">Overview</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-691"><a href="https://www.ionispharma.com/patients-community/patient-resources/">Patient Resources</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-690"><a href="https://www.ionispharma.com/patients-community/community-engagement/">Community Engagement</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-692"><a href="https://www.ionispharma.com/patients-community/patient-experiences/">Patient Experiences</a></li>
</ul>
</li>
<li class="menu-item-has-submenus-with-children menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-25"><a href="https://ir.ionispharma.com/">Investors &amp; media</a>
<ul class="sub-menu">
	<li class="sub-menu-back menu-item menu-item-type-custom menu-item-object-custom menu-item-60"><a href="#">Back To Main</a></li>
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-26"><a href="https://ir.ionispharma.com/">Overview</a></li>
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-27"><a href="http://ir.ionispharma.com/news-releases">Newsroom</a>
	<ul class="sub-menu">
		<li class="sub-menu-back menu-item menu-item-type-custom menu-item-object-custom menu-item-59"><a href="#">Back To Main</a></li>
		<li class="back-to-main menu-item menu-item-type-custom menu-item-object-custom menu-item-65"><a href="#">Investors &amp; Media</a></li>
		<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-29"><a href="http://ir.ionispharma.com/news-releases">Press Releases</a></li>
		<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-2738"><a href="https://ir.ionispharma.com/inbriefs">InBriefs</a></li>
		<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-583"><a href="https://www.ionispharma.com/media-center/">Media Center</a></li>
	</ul>
</li>
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-31"><a href="http://ir.ionispharma.com/stock-information/stock-quote">Stock Information</a>
	<ul class="sub-menu">
		<li class="sub-menu-back menu-item menu-item-type-custom menu-item-object-custom menu-item-58"><a href="#">Back To Main</a></li>
		<li class="back-to-main menu-item menu-item-type-custom menu-item-object-custom menu-item-66"><a href="#">Investors &amp; Media</a></li>
		<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-32"><a href="http://ir.ionispharma.com/stock-information/stock-quote">Stock Quote &amp; Chart</a></li>
		<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-33"><a href="http://ir.ionispharma.com/stock-information/analyst-coverage">Analyst Coverage</a></li>
		<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-34"><a href="http://ir.ionispharma.com/stock-information/institutional-ownership">Ownership Profile</a></li>
	</ul>
</li>
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-35"><a href="http://ir.ionispharma.com/financial-information/sec-filings">Financials</a>
	<ul class="sub-menu">
		<li class="sub-menu-back menu-item menu-item-type-custom menu-item-object-custom menu-item-57"><a href="#">Back To Main</a></li>
		<li class="back-to-main menu-item menu-item-type-custom menu-item-object-custom menu-item-64"><a href="#">Investors &amp; Media</a></li>
		<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-36"><a href="http://ir.ionispharma.com/financial-information/sec-filings">SEC Filings</a></li>
		<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-37"><a href="http://ir.ionispharma.com/financial-information/annual-reports">Annual Reports</a></li>
	</ul>
</li>
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-38"><a href="http://ir.ionispharma.com/corporate-governance/highlights">Governance</a>
	<ul class="sub-menu">
		<li class="sub-menu-back menu-item menu-item-type-custom menu-item-object-custom menu-item-56"><a href="#">Back To Main</a></li>
		<li class="back-to-main menu-item menu-item-type-custom menu-item-object-custom menu-item-63"><a href="#">Investors &amp; Media</a></li>
		<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-39"><a href="http://ir.ionispharma.com/corporate-governance/highlights">Governance Documents</a></li>
		<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-40"><a href="http://ir.ionispharma.com/corporate-governance/committee-composition">Committee Composition</a></li>
	</ul>
</li>
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-43"><a href="http://ir.ionispharma.com/shareholder-services/investor-faqs">Investor Resources</a>
	<ul class="sub-menu">
		<li class="sub-menu-back menu-item menu-item-type-custom menu-item-object-custom menu-item-54"><a href="#">Back To Main</a></li>
		<li class="back-to-main menu-item menu-item-type-custom menu-item-object-custom menu-item-62"><a href="#">Investors &amp; Media</a></li>
		<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-44"><a href="http://ir.ionispharma.com/shareholder-services/investor-faqs">Investor FAQs</a></li>
		<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3571"><a href="https://ir.ionispharma.com/settlement-information">Settlement Information</a></li>
		<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-45"><a href="http://ir.ionispharma.com/shareholder-services/contact-ir">Contact Us</a></li>
	</ul>
</li>
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-46"><a href="http://ir.ionispharma.com/events-and-presentations/upcoming-events">Events</a>
	<ul class="sub-menu">
		<li class="sub-menu-back menu-item menu-item-type-custom menu-item-object-custom menu-item-55"><a href="#">Back To Main</a></li>
		<li class="back-to-main menu-item menu-item-type-custom menu-item-object-custom menu-item-61"><a href="#">Investors &amp; Media</a></li>
		<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-47"><a href="http://ir.ionispharma.com/events-and-presentations/upcoming-events">Events</a></li>
	</ul>
</li>
</ul>
</li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-1968"><a href="https://www.ionispharma.com/careers/">Careers</a>
<ul class="sub-menu">
	<li class="sub-menu-back menu-item menu-item-type-custom menu-item-object-custom menu-item-544"><a href="#">Back To Main</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-533"><a href="https://www.ionispharma.com/careers/">Overview</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-543"><a href="https://www.ionispharma.com/careers/working-at-ionis/">Working at Ionis</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2941"><a href="https://www.ionispharma.com/careers/employee-spotlight/">Employee Spotlight</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3388"><a href="https://www.ionispharma.com/careers/volunteerism-philanthropy/">Volunteerism &amp; Philanthropy</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2845"><a href="https://www.ionispharma.com/careers/investments-in-you/">Investments in You</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-541"><a href="https://www.ionispharma.com/careers/intern-program/">Intern Program</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-542"><a href="https://www.ionispharma.com/careers/post-doctoral/">Postdoctoral Program</a></li>
</ul>
</li>
</ul></div>                </div>
                <div class="social-wrap">
    <p>Follow Us</p>
    <div class="icons-wrap">
                        <a class="social-icon linkedin" href="https://www.linkedin.com/company/ionis-pharmaceuticals" target="_blank"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32">
    <defs>
        <style>.cls-social-linkedin{fill:#a4a3a4}</style>
    </defs>
    <g id="Layer_2" data-name="Layer 2">
        <path class="cls-social-linkedin" d="M16 0a16 16 0 1 0 16 16A16 16 0 0 0 16 0zm-4.37 23.65H8.2V13.33h3.43zM9.92 11.92A1.77 1.77 0 0 1 8 10.14a1.79 1.79 0 0 1 1.94-1.79 1.79 1.79 0 1 1 0 3.57zM24 23.65h-3.43v-5.52c0-1.39-.5-2.34-1.74-2.34a1.89 1.89 0 0 0-1.76 1.26 2.32 2.32 0 0 0-.11.83v5.77h-3.43V13.33H17v1.46a3.41 3.41 0 0 1 3.09-1.7c2.26 0 3.95 1.47 3.95 4.64z" id="Layer_1-2" data-name="Layer 1"></path>
    </g>
</svg></a>
                            <a class="social-icon twitter" href="https://twitter.com/ionispharma?lang=en" target="_blank"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32">
    <defs>
        <style>.cls-social-twitter{fill:#a4a3a4}</style>
    </defs>
    <title>twitter-grey</title>
    <g id="Layer_2" data-name="Layer 2">
        <path class="cls-social-twitter" d="M16 0a16 16 0 1 0 16 16A16 16 0 0 0 16 0zm6.36 12.74v.42A9.34 9.34 0 0 1 8 21a6.79 6.79 0 0 0 .78 0 6.58 6.58 0 0 0 4.08-1.4 3.3 3.3 0 0 1-3.07-2.28 3.22 3.22 0 0 0 1.49-.06 3.29 3.29 0 0 1-2.64-3.22 3.29 3.29 0 0 0 1.49.41 3.29 3.29 0 0 1-1-4.38 9.32 9.32 0 0 0 6.77 3.43 3.08 3.08 0 0 1-.09-.75 3.28 3.28 0 0 1 5.68-2.24 6.62 6.62 0 0 0 2.09-.8 3.29 3.29 0 0 1-1.44 1.81A6.31 6.31 0 0 0 24 11a6.63 6.63 0 0 1-1.64 1.74z" id="Layer_1-2" data-name="Layer 1"></path>
    </g>
</svg></a>
                            <a class="social-icon facebook" href="https://www.facebook.com/Ionis-Pharmaceuticals-108946637429610" target="_blank"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32">
  <defs>
      <style>.cls-social-facebook{fill:#a4a3a4}</style>
  </defs>
  <title>facebook-grey</title>
  <g id="Layer_2" data-name="Layer 2">
    <path class="cls-social-facebook" d="M12 0c-6.627 0-12 5.373-12 12s5.373 12 12 12 12-5.373 12-12-5.373-12-12-12zm3 8h-1.35c-.538 0-.65.221-.65.778v1.222h2l-.209 2h-1.791v7h-3v-7h-2v-2h2v-2.308c0-1.769.931-2.692 3.029-2.692h1.971v3z" id="Layer_1-2" data-name="Layer 1"></path>
  </g>
</svg>
</a>
                </div>
</div>


            </div>
        </div>
    </div>
</header>
<div class="interstitial-popup mfp-hide">
    <div class="interstitial-popup__close">
        <div class="mfp-close">
            <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 47.42218 47.42249">
    <path fill-rule="evenodd" d="M47.422 44l-20.58-20.58L47.016 3.246l-2.84-2.84L24.002 20.58 3.422 0 .594 2.83l20.58 20.58L0 44.582l2.84 2.84 21.174-21.175 20.58 20.58L47.422 44"></path>
</svg>        </div>
    </div>
    <div class="interstitial-popup__text">
        You are now leaving https://www.ionispharma.com to visit <span class="interstitial-popup__target"></span>
    </div>
    <div class="interstitial-popup__buttons">
        <a class="interstitial-popup__buttons__continue btn btn--gradient btn--size-small" href="#">
            <span class="text">Continue to site</span>
        </a>
        <a class="interstitial-popup__buttons__cancel color--orange weight-bold base" href="#">Cancel</a>
    </div>
</div>

    <div id="content" class="site-content" tabindex="-1">

    <div id="primary" class="content-area">
        <main id="main" class="site-main">

            
<section class="hero-section-full" style="background-image: url('https://www.ionispharma.com/wp-content/uploads/2019/04/innovation-mobile-hero.jpg');">
            <div class="hero-section-full__title">
            <div class="container">
                <h4 class="weight-bold color--white">Ionis Innovation</h4>
            </div>
        </div>
    </section>



<section class="content-block-section">
    <div class="container">
        <div class="row justify-content-center">
            <div class="col-lg-10">
                                    <h2 class="content-block-section__title color--secondary weight-black">The Ionis antisense pipeline</h2>
                
                                    <div class="content-block-section__text">
                        <p>Our <a href="https://www.ionispharma.com/ionis-innovation/antisense-technology/">antisense technology platform</a> has served as a springboard for drug discovery and realized hope for patients with unmet needs. Our broad, diverse pipeline has more than 40 first-in-class and/or best-in-class medicines designed to treat a broad range of diseases including cancer and cardiovascular, neurological, infectious and pulmonary diseases.</p>
<p>The result of 30 years of perfecting and advancing <a href="https://www.ionispharma.com/ionis-innovation/optimizing-antisense/">RNA targeted drug discovery and development</a>, our proprietary platform now provides a fast and efficient path from identification of potential causes of human diseases to the discovery of potentially life-saving medicines.</p>
<p><!--Learn more about <a href="https://ionistrials.com/" target="_blank" rel="noopener">Ionis Clinical Trials</a>.--></p>
                    </div>
                
                <div class="content-block-section__button">
                                                        </div>

            </div>
        </div>
    </div>
</section>
<link rel="stylesheet" id="pipeline-section-style-css" href="/wp-content/themes/ionis-2/dist/css/modules/pipeline-new-section.css?ver=1605555464" type="text/css" media="all">

<!--<script type='text/javascript' src='/wp-content/themes/ionis-2/dist/js/modules/pipeline-new-section.js?ver=1607094143' id='pipeline-section-script-js'></script>-->
<div style="display:none;">Array
(
    [0] =&gt; WP_Term Object
        (
            [term_id] =&gt; 95
            [name] =&gt; Preclinical
            [slug] =&gt; phase-0
            [term_group] =&gt; 0
            [term_taxonomy_id] =&gt; 95
            [taxonomy] =&gt; phases
            [description] =&gt; 
            [parent] =&gt; 0
            [count] =&gt; 0
            [filter] =&gt; raw
            [term_order] =&gt; 1
        )

    [1] =&gt; WP_Term Object
        (
            [term_id] =&gt; 10
            [name] =&gt; Phase 1
            [slug] =&gt; phase-1
            [term_group] =&gt; 0
            [term_taxonomy_id] =&gt; 10
            [taxonomy] =&gt; phases
            [description] =&gt; 
            [parent] =&gt; 0
            [count] =&gt; 7
            [filter] =&gt; raw
            [term_order] =&gt; 2
        )

    [2] =&gt; WP_Term Object
        (
            [term_id] =&gt; 11
            [name] =&gt; Phase 2
            [slug] =&gt; phase-2
            [term_group] =&gt; 0
            [term_taxonomy_id] =&gt; 11
            [taxonomy] =&gt; phases
            [description] =&gt; 
            [parent] =&gt; 0
            [count] =&gt; 23
            [filter] =&gt; raw
            [term_order] =&gt; 3
        )

    [3] =&gt; WP_Term Object
        (
            [term_id] =&gt; 12
            [name] =&gt; Phase 3
            [slug] =&gt; phase-3
            [term_group] =&gt; 0
            [term_taxonomy_id] =&gt; 12
            [taxonomy] =&gt; phases
            [description] =&gt; 
            [parent] =&gt; 0
            [count] =&gt; 9
            [filter] =&gt; raw
            [term_order] =&gt; 4
        )

    [4] =&gt; WP_Term Object
        (
            [term_id] =&gt; 13
            [name] =&gt; Registration
            [slug] =&gt; registration
            [term_group] =&gt; 0
            [term_taxonomy_id] =&gt; 13
            [taxonomy] =&gt; phases
            [description] =&gt; 
            [parent] =&gt; 0
            [count] =&gt; 0
            [filter] =&gt; raw
            [term_order] =&gt; 5
        )

)
here</div>
<section class="pipeline-section1 filter">
	<div class="container">
		<div class="row justify-content-left" style="position: relative;">
			<h2>Search Filter <img class="mtoolsimg" src="/wp-content/themes/ionis-2/template-parts/icons/slider.png"></h2>&nbsp;<p class="mtools topen">Hide Tools »</p>
			<form name="drugsearch" id="drugsearch" onsubmit="return pipeSearchNew()">
				<input type="text" name="searchfilter" id="searchfilter" placeholder="keyword search">
			</form>
		</div>
	</div>
</section>
<section class="pipeline-section2 filter2">
	<div class="container">
		<div class="row justify-content-left" style="position: relative;">
			<div class="col-lg-10x">
			<!--<h4 class="color--white">Rights</h4>-->
							<div class="row justify-content-left" style="position: relative;">
					<div class="col-5">
						<button class="bFilter partSec" data-cat="partner" id="b1">Partnered</button>
					</div>
					<div class="col-5">
						<button class="bFilter partSec" data-cat="partner-Ionis-Owned" id="b2">Ionis-Owned <img src="/wp-content/themes/ionis-2/dist/assets/svg/footer-lines.svg"></button>
					</div>
					<div class="col-5">
					</div>
				</div>
			<h4 class="color--white">Therapeutic Areas</h4>
				<div class="row justify-content-left" style="position: relative;">
					<div class="col-5"><button class="bFilter taSec" data-cat="slot-3" id="b1">Cardio-Renal</button></div><div class="col-5"><button class="bFilter taSec" data-cat="slot-4" id="b2">Metabolic</button></div><div class="col-5"><button class="bFilter taSec" data-cat="slot-5" id="b3">Neurological</button></div><div class="col-5"><button class="bFilter taSec" data-cat="slot-6" id="b4">Infectious Disease</button></div><div class="col-5"><button class="bFilter taSec RARE" data-cat="slot-7" id="b5">Rare</button></div></div><div class="row justify-content-left" style="position: relative;"><div class="col-5"><button class="bFilter taSec" data-cat="slot-8" id="b6">Cancer</button></div><div class="col-5"><button class="bFilter taSec" data-cat="slot-9" id="b7">Ophthalmology</button></div><div class="col-5"><button class="bFilter taSec" data-cat="slot-10" id="b8">Pulmonology &amp; Allergy</button></div><div class="col-5"><button class="bFilter taSec" data-cat="slot-12" id="b9">Hematology</button></div><div class="col-5"></div></div>					
					
				<!--	<div class="col-4">
						<button class="bFilter" data-cat="cardio-renal" id="b3">Cardio-Renal</button>
					</div>
					<div class="col-4">
						<button class="bFilter" data-cat="metabolic" id="b4">Metabolic</button>
					</div>
					<div class="col-4">
						<button class="bFilter" data-cat="neurological" id="b5">Neurological</button>
					</div>
				</div>	
				<div class="row justify-content-left" style="position: relative;">
					<div class="col-4">
						<button class="bFilter" data-cat="infectious-disease" id="b6">Infectious Disease</button>
					</div>
					<div class="col-4">
						<button class="bFilter" data-cat="cancer" id="b7">Cancer</button>
					</div>
					<div class="col-4">
						<button class="bFilter" data-cat="ophthalmology" id="b8">Ophthalmology</button>
					</div>
				</div>
				<div class="row justify-content-left" style="position: relative;">
					<div class="col-4">
						<button class="bFilter" data-cat="pulmonology-allergy" id="b9">Pulmonology and Allergy</button>
					</div>
					<div class="col-4">
						<button class="bFilter" data-cat="hematology" id="b10">Hematology</button>
					</div>
					<div class="col-4">
					</div>
				</div>		-->										
			<h4 class="color--white">Phase</h4>
				<div class="row justify-content-left" style="position: relative;">
					<!--<div class="col-5">
						<button class="bFilter phaseSec" data-cat="phase-0" id="b11">Preclinical</button>
					</div>-->
					<div class="col-5">
						<button class="bFilter phaseSec" data-cat="phase-1" id="b12">Phase 1</button>
					</div>
					<div class="col-5">
						<button class="bFilter phaseSec" data-cat="phase-2" id="b13">Phase 2</button>
					</div>
					<div class="col-5">
						<button class="bFilter phaseSec" data-cat="phase-3" id="b14">Phase 3</button>
					</div>
					<!--<div class="col-5">
						<button class="bFilter phaseSec" data-cat="phase-4" id="b15">Registration</button>
					</div>-->
				</div>			
						
			<button class="apply">Apply</button>&nbsp;<button class="clear">Clear</button>
			</div>
		</div>
	</div>
</section>

<section class="pipeline-section">
    <div class="container">
        <div class="row justify-content-center">
            <div class="col-lg-10x">
                <div class="pipeline-section__filter" style="display:none;">
                                            <div class="pipeline-section__filter--therapeutic-area">
                            <label for="therapeutic-area-select">Therapeutic area</label>
                            <div class="select-wrapper">
                                <select id="therapeutic-area-select">
                                    <option value="all">All</option>
                                                                            <option value="slot-3">Cardio-Renal</option>
                                                                            <option value="slot-4">Metabolic</option>
                                                                            <option value="slot-5">Neurological</option>
                                                                            <option value="slot-6">Infectious Disease</option>
                                                                            <option value="slot-7">Rare</option>
                                                                            <option value="slot-8">Cancer</option>
                                                                            <option value="slot-9">Ophthalmology</option>
                                                                            <option value="slot-10">Pulmonology &amp; Allergy</option>
                                                                            <option value="cardiometabolic-renal">Cardiometabolic &amp; Renal</option>
                                                                            <option value="slot-12">Hematology</option>
                                                                            <option value="slot-11">Other</option>
                                                                    </select>
                            </div>
                        </div>
                                            <div class="pipeline-section__filter--phases">
                            <label for="phases-select">Phase</label>
                            <div class="select-wrapper">
                                <select id="phases-select" data-preclinical-url="https://www.ionispharma.com/ionis-innovation/pipeline-preclinical">
                                    <option value="all">All</option>
                                                                            <option a="" value="phase-0">Preclinical</option>
                                                                            <option a="" value="phase-1">Phase 1</option>
                                                                            <option a="" value="phase-2">Phase 2</option>
                                                                            <option a="" value="phase-3">Phase 3</option>
                                                                            <option a="" value="registration">Registration</option>
                                                                        <option value="preclinical">Preclinical</option>
                                </select>
                            </div>
                        </div>
                                    </div>
                <div class="pipeline-section__content">
                                                <style>
                                .pipeline-section__block:nth-of-type(1) {
                                    background: rgba(210, 33, 106,0.1);
                                }
                                .pipeline-section__block:nth-of-type(1) .pipeline-medicines__item:hover,
                                .pipeline-section__block:nth-of-type(1) .pipeline-medicines__item.active {
                                    background: rgba(210, 33, 106,0.2);
                                }
                            </style>
                            <div id="slot-3" class="pipeline-section__block showme" data-therapeutic-area="slot-3">
                                <h4 class="color--secondary">Cardio-Renal</h4>
                                <div class="pipeline-section__block__header">
                                    <div class="pipeline-section__block__header--space"></div>
                                    <div class="pipeline-section__block__header--partner">Partner</div>
                                    <div class="pipeline-section__block__header--phase d-none d-md-block ishidden pcheader">Preclinical</div>                                       
                                        
                                            <div id="drug-hdr-1" class="pipeline-section__block__header--phase d-md-none">P                                        </div>
                                    		                                     <div class="pipeline-section__block__header--phase d-none d-md-block">Phase 1</div>
		                                                                           
                                        
                                            <div id="drug-hdr-2" class="pipeline-section__block__header--phase d-md-none">P1                                        </div>
                                    		                                     <div class="pipeline-section__block__header--phase d-none d-md-block">Phase 2</div>
		                                                                           
                                        
                                            <div id="drug-hdr-3" class="pipeline-section__block__header--phase d-md-none">P2                                        </div>
                                    		                                     <div class="pipeline-section__block__header--phase d-none d-md-block">Phase 3</div>
		                                                                           
                                        
                                            <div id="drug-hdr-4" class="pipeline-section__block__header--phase d-md-none">P3                                        </div>
                                                                           
                                        
                                            <div id="drug-hdr-5" class="pipeline-section__block__header--phase d-md-none">R                                        </div>
                                                                    </div>
                                <div class="pipeline-medicines">
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
)
</div>                                        <div id="med-slot-3-1875" class="phase-3 slot-3 not_Ionis partner-Novartis pipeline-medicines__item showme" data-phase="phase-3">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>Pelacarsen<sup></sup><sub></sub></strong></div>
                                                                                                    <div>(Apo(a))</div>
                                                                                                    <div>CVD</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">Novartis</div>
                                                                                                                                                                                                                            <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="3" style="background-color: #d2216a">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #d2216a"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2<sup>+</sup> LICA<br>
</small></p>
<p>Pelacarsen, also known as IONIS-APO(a)-L<sub>Rx </sub>, AKCEA-APO(a)-L<sub>Rx </sub>, and TQJ230, is an investigational antisense medicine designed to reduce apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a), or Lp(a), a very atherogenic and thrombogenic form of LDL. Elevated Lp(a) is recognized as an independent, genetic cause of coronary artery disease, heart attack, stroke and peripheral arterial disease. Currently, there is no effective drug therapy to specifically and robustly lower elevated levels of Lp(a). Lp(a) levels are determined at birth and, therefore, lifestyle modification, including diet and exercise, do not impact Lp(a) levels. Even patients who can control their LDL-C remain at high-risk of cardiovascular events if they have high levels of Lp(a).</p>
<p>Pelacarsen is being developed for patients who are at significant risk of CVD because of their elevated Lp(a). We believe pelacarsen&nbsp;is the first and currently only drug in clinical development designed to selectively and robustly inhibit the production of Lp(a).</p>
<p><strong>About Lp(a)</strong></p>
<p>Lp(a) is a lipoprotein particle assembled in the liver that consists of an LDL-C-like particle and apolipoprotein(a). Lp(a) is considered a key driver for cardiovascular disease due to its association with an increased risk of coronary heart disease. There is evidence that elevated Lp(a) levels may contribute directly to heart attacks. Lp(a) levels in blood can vary greatly between individuals primarily due to genetic variations. Because elevated Lp(a) is a genetically determined condition that is not responsive to lifestyle changes, patients are unable to adequately control their Lp(a) levels through improved diet or increased physical activity. Moreover, current therapies are not able to reduce Lp(a) to recommended levels in patients who have high Lp(a). Although Lp(a) can be measured by a routine lipid blood panel, the lack of drugs to effectively lower Lp(a) has made treating patients with Lp(a)-driven cardiovascular disease difficult.</p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/31893580/" class="color--orange weight-bold base" target="_blank">Tsimikas, S.</a>  (2020) Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. N Engl J Med. 382(3):244-255                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/27665230/" class="color--orange weight-bold base" target="_blank">Viney, N.J. et al.</a> (2016)  Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet. 388(10057):2239-2253.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="http://www.ncbi.nlm.nih.gov/pubmed/22898069" class="color--orange weight-bold base" target="_blank">Tsimikas, S. et al.</a> (2012) Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease. J Am Coll Cardiol. 63, 716-721.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="http://www.ncbi.nlm.nih.gov/pubmed/21474042" class="color--orange weight-bold base" target="_blank">Merki, E. et al.</a> (2011) Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. J Am Coll Cardiol. 57, 1611-1621.                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                                                                    </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
)
</div>                                        <div id="med-slot-3-2546" class="phase-3 slot-3 not_Ionis partner- AstraZeneca** pipeline-medicines__item showme" data-phase="phase-3">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>Eplontersen<sup></sup><sub></sub></strong></div>
                                                                                                    <div>(TTR)</div>
                                                                                                    <div>ATTR</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner"> AstraZeneca**</div>
                                                                                                                                                                                                                            <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="3" style="background-color: #d2216a">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #d2216a"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2<sup>+</sup> LICA<br>
</small></p>
<p>Eplontersen, formerly known as IONIS-TTR-L<sub>Rx</sub> and AKCEA-TTR-L<sub>Rx</sub>, is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of transthyretin, or TTR protein, to treat all types of TTR amyloidosis (ATTR), a systemic, progressive and fatal disease. In patients with ATTR, both the mutant and wild type (wt) TTR protein builds up as fibrils in tissues, such as the peripheral nerves, heart, gastrointestinal system, eyes, kidneys, central nervous system, thyroid and bone marrow. The presence of TTR fibrils interferes with the normal functions of these tissues. As the TTR protein fibrils enlarge, more tissue damage occurs and the disease worsens, resulting in poor quality of life and eventually death.</p>
<p><strong>About TTR Amyloidosis (ATTR)</strong></p>
<p>ATTR amyloidosis is a systemic, progressive and fatal disease in which patients experience multiple overlapping clinical manifestations caused by the inappropriate formation and aggregation of TTR amyloid deposits in various tissues and organs, including peripheral nerves, heart, intestinal tract, eyes, kidneys, central nervous system, thyroid and bone marrow. The progressive accumulation of TTR amyloid deposits in these tissues and organs leads to organ failure and eventually death.</p>
<p>Polyneuropathy due to hATTR is caused by the accumulation of misfolded mutated TTR protein in the peripheral nerves. Patients with polyneuropathy due to hATTR experience ongoing debilitating nerve damage throughout their body resulting in the progressive loss of motor functions, such as walking. These patients also accumulate TTR in other major organs, which progressively compromise their function and eventually leading to death within five to fifteen years of disease onset. There are an estimated 10,000 patients with polyneuropathy due to hATTR worldwide.</p>
<p>ATTR cardiomyopathy is caused by the accumulation of misfolded TTR protein in the cardiac muscle. Patients experience ongoing debilitating heart damage resulting in progressive heart failure, which results in death within 3 to 5 years from disease onset. ATTR cardiomyopathy includes both the genetic and wild-type form of the disease. There are an estimated 240,000 patients with ATTR cardiomyopathy worldwide.</p>
<p>Often patients with the polyneuropathy form of TTR amyloidosis will also have TTR build up in the heart and also experience cardiomyopathy symptoms. Similarly, patients with the cardiomyopathy form of TTR amyloidosis may often have TTR build up in their peripheral nerves and can experience nerve damage and progressive difficulty with motor functions.</p>
<p>For more information on the Phase 3 CARDIO-TTRansform study, please visit <a title="https://ionistrials.com/cardio-ttransform/" href="https://ionistrials.com/cardio-ttransform/">https://ionistrials.com/cardio-ttransform/</a></p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="http://www.ncbi.nlm.nih.gov/pubmed/22494066" class="color--orange weight-bold base" target="_blank">Ackermann, E.J. et al.&nbsp;</a> (2012) Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid. 19, 43-44.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="http://www.ncbi.nlm.nih.gov/pubmed/21550574" class="color--orange weight-bold base" target="_blank">Benson, M.D. et al.&nbsp;</a> (2011) Rate of Progression of Transthyretin Amyloidosis. Am J Cardiol.108, 285-289.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="http://www.ncbi.nlm.nih.gov/pubmed/16421881" class="color--orange weight-bold base" target="_blank">Benson, M.D. et al.&nbsp;</a> (2006) Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve. 33, 609-618.                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                    <p class="pipeline-footnote"><small><sup>*</sup><sup>*</sup> Ionis is jointly developing and commercializing eplontersen.</small></p>                                                </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
)
</div>                                        <div id="med-slot-3-1879" class="phase-3 slot-3 partner-Ionis-Owned pipeline-medicines__item showme" data-phase="phase-3">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>Olezarsen<sup></sup><sub></sub></strong></div>
                                                                                                    <div>(ApoC-III)</div>
                                                                                                    <div>Severe Hypertriglyceridemia</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">Ionis-Owned</div>
                                                                                                                                                                                                                            <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="3" style="background-color: #d2216a">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #d2216a"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2<sup>+</sup> LICA<br>
</small></p>
<p>Olezarsen, formerly known as IONIS-APOCIII-L<sub>Rx</sub> and AKCEA-APOCIII-L<sub>Rx</sub>, is a ligand-conjugated (LICA) investigational antisense medicine designed to inhibit the production of apoC-III in the liver. ApoC-III is a protein that regulates triglyceride metabolism in the blood by inhibiting lipoprotein lipase that breakdown triglycerides and by preventing clearance of triglyceride-rich lipoproteins. ApoC-III is an independent risk factor for both pancreatitis and cardiovascular disease.</p>
<p><strong>About <b>Severe Hypertriglyceridemia (SHTG)</b></strong></p>
<p>Severe Hypertriglyceridemia (triglyceride levels ≥ &nbsp;500 mg/dL) can be caused by diet-derived chylomicronemia and excessive liver triglyceride production, often superimposed on genetic predisposition. Its primary manifestation is acute pancreatitis, particularly if triglyceride levels are &gt; 880 mg/dL. A subset of patients with triglyceride levels 500-880 are also at risk for cardiovascular disease. Lowering of plasma triglycerides is desired. Treatment regimens include nutritional intervention, the use of antihyperlipidemic drugs, and therapeutic apheresis. SHTG is a common condition that affects millions of people around the world, including more than 3 million in the U.S.</p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/35025993/" class="color--orange weight-bold base" target="_blank">Tardif J.C. et al.</a> (2022) Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J. ehard820.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/32033914/" class="color--orange weight-bold base" target="_blank">Dron, J.S. et al.</a> (2020) The polygenic nature of mild-to-moderate hypertriglyceridemia. J Clin Lipidol. 14(1):28-34.e2.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/25732519/" class="color--orange weight-bold base" target="_blank">Brahm, A.J. et al.</a> (2015) Chylomicronaemia—current diagnosis and future therapies. Nat Rev Endocrinol. 11(6):352-62                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://www.ncbi.nlm.nih.gov/pubmed/26222559" class="color--orange weight-bold base" target="_blank">Gaudet, D.</a> (2015) JJ. Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. N Engl J Med.373(5):438-47.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="http://www.ncbi.nlm.nih.gov/pubmed/24941082" class="color--orange weight-bold base" target="_blank">Jorgensen, A.B. et al.&nbsp;</a> (2014) Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 371, 32-41.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="http://www.ncbi.nlm.nih.gov/pubmed/24941081" class="color--orange weight-bold base" target="_blank">Kathiresan et al.&nbsp;</a> (2014) Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease. N Engl J Med. 371, 22-31.                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                                                                    </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
)
</div>                                        <div id="med-slot-3-2457" class="phase-2 slot-3 not_Ionis partner-Roche pipeline-medicines__item showme" data-phase="phase-2">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>IONIS-FB-L<sup></sup><sub>Rx</sub></strong></div>
                                                                                                    <div>(Complement Factor B)</div>
                                                                                                    <div>IgA Nephropathy</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">Roche</div>
                                                                                                                                                                                <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="2" style="background-color: #d2216a">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #d2216a"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2<sup>+</sup> LICA</small></p>
<p>IONIS-FB-L<sub>Rx</sub> is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of complement factor B (FB). Genetic association studies have shown that overaction of this cascade has been associated with the development of several complement-mediated diseases, including IgA nephropathy (IgAN). FB, a key regulatory protein, is produced predominately in the liver and circulates at high levels throughout the vascular system, including in the kidney.</p>
<p><strong>About IgA Nephropathy (IgAN)</strong><br>
IgA Nephropathy (IgAN) is the most prevalent primary chronic glomerulonephritis worldwide and is an important cause of chronic kidney disease and renal failure. Also known as Berger’s disease, IgAN is characterized by immunodeposits with dominant or codominant IgA in the glomerular mesangium of the kidneys, resulting in inflammation and tissue damage. Although IgAN may occur at any age, it generally presents in the second or third decade of life. The clinical presentation, disease progression and histologic findings are highly variable among affected individuals. Current therapies are aimed at reduction in proteinuria with administration of angiotensin inhibitors and control of blood pressure. Sometimes immunosuppressive therapies are given; however, this practice is not universally accepted.</p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="https://www.ncbi.nlm.nih.gov/pubmed/30635299" class="color--orange weight-bold base" target="_blank">Thompson, A. et al.</a> (2019) Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. CJASN 14                                                                 </li>
                                                                                                                            <li>
                                                                    <a href="https://www.ncbi.nlm.nih.gov/pubmed/29933843" class="color--orange weight-bold base" target="_blank">Floege, J. et al.</a> (2018) IgA nephropathy: new insights into the role of complement. Kid International. 94, 16-18.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://www.ncbi.nlm.nih.gov/pubmed/28624979" class="color--orange weight-bold base" target="_blank">Yen, S.C. et al.</a> (2017) New insights into the pathogenesis of IgA nephropathy. Pediatr Nephrol 33:763-777.                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                                                                    </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
)
</div>                                        <div id="med-slot-3-1899" class="phase-2 slot-3 partner-Ionis-Owned pipeline-medicines__item showme" data-phase="phase-2">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>IONIS-AGT-L<sup></sup><sub>Rx</sub></strong></div>
                                                                                                    <div>(Angiotensinogen)</div>
                                                                                                    <div>Treatment-Resistant Hypertension</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">Ionis-Owned</div>
                                                                                                                                                                                <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="2" style="background-color: #d2216a">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #d2216a"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p class="p1"><small>Chemistry: Generation 2<sup>+</sup> LICA<br>
</small></p>
<p>IONIS-AGT-L<sub>Rx </sub>is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of angiotensinogen to decrease blood pressure in patients with treatment resistant hypertension (TRH). Despite availability of generic antihypertensive agents, TRH is a major contributor to cardiovascular and renal disease.</p>
<p>Inhibiting the renin-angiotensin-aldosterone system (RAAS) is a well-established method of treating hypertension and complications of hypertension. While angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are widely used, many patients with high blood pressure are not well controlled by these treatment options. Angiotensinogen, the target of IONIS-AGT-L<sub>Rx</sub>, is upstream of ACE inhibitors and ARBs in the RAAS pathway. Therefore, reducing angiotensinogen levels has the potential to decrease blood pressure in patients whose blood pressure is not adequately controlled by currently available treatment options. Furthermore, inhibiting angiotensinogen, which is made in the liver, may maintain renal compensatory mechanisms, which could lead to fewer side effects compared to current standard of care.</p>
<p><strong>About Treatment Resistant Hypertension (TRH)</strong></p>
<p>Approximately 70 million adults in the United States have hypertension, half of which have uncontrolled hypertension. About 12-15 percent of patients with uncontrolled hypertension have resistant hypertension, defined as failure to achieve a blood pressure goal of 140/90 (systolic/diastolic) despite the use of three or more antihypertensive medications. Current estimates approximate that there are up to three million patients with TRH in the U.S. Patients with TRH have been found to have 3-fold increased odds of having fatal and non-fatal cardiovascular events relative to those with controlled hypertension.</p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="https://www.ncbi.nlm.nih.gov/pubmed/30530571" class="color--orange weight-bold base" target="_blank">Wu, C.H. et al.</a> (2019) Antisense oligonucleotides targeting angiotensinogen: insights from animal studies. Biosci Rep. 2019 Jan 11;39(1).                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://www.ncbi.nlm.nih.gov/pubmed/28571891" class="color--orange weight-bold base" target="_blank">Ferrario, C.M. et al.</a> (2017) Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease. Pharmacol Res. 2017 Nov;125(Pt A):57-71.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://www.ncbi.nlm.nih.gov/pubmed/28716988" class="color--orange weight-bold base" target="_blank">Mullick, A.E. et al.</a> (2017) Blood pressure lowering and safety improvements with liver angiotensinogen inhibition in models of hypertension and kidney injury. Hypertension. 2017 Sep;70(3):566-576.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="http://journals.sagepub.com/doi/pdf/10.1177/1753944716642680" class="color--orange weight-bold base" target="_blank">Williams, B.&nbsp;</a> (2016) Drug discovery in renin-angiotensin system intervention: Past and future. Ther Adv Cardiovasc Dis;10:118-125.                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                                                                    </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
)
</div>                                        <div id="med-slot-3-1764" class="phase-2 slot-3 not_Ionis partner-Bayer pipeline-medicines__item showme" data-phase="phase-2">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>Fesomersen<sup></sup><sub></sub></strong></div>
                                                                                                    <div>(Factor XI)</div>
                                                                                                    <div>Thrombotic Disorders</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">Bayer</div>
                                                                                                                                                                                <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="2" style="background-color: #d2216a">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #d2216a"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2<sup>+</sup> LICA<br>
</small></p>
<p class="p1"><span class="s1">Fesomersen, formerly known as</span> IONIS-FXI-L<sub>Rx </sub>is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of Factor XI, a clotting factor produced in the liver that is an important component of the coagulation pathway. High levels of Factor XI increase the risk of blood clot formation inside blood vessels (thrombosis), which can cause heart attacks and strokes. Alternatively, individuals deficient in Factor XI have a lower incidence of thrombosis-related events and little to no increase in bleeding risk. This makes Factor XI an attractive target for an antithrombotic drug because of the potential to separate antithrombotic activity from bleeding risk. Although currently available anticoagulants reduce the risk of thrombosis, these anticoagulants are associated with increased bleeding risk at therapeutic doses, which can lead to major, sometimes fatal bleeding events. In clinical studies evaluating the safety and efficacy of the non-LICA version of IONIS-FL-L<sub>Rx</sub> (IONIS-FXI<sub>Rx</sub>), dose-dependent inhibition of Factor XI activity was demonstrated, which was associated with significant reductions in clotting events and no increase in major bleeding events. These data coupled with data in humans with little to no Factor XI activity provide evidence that IONIS-FXI<sub>Rx</sub> has the potential to be used broadly as an anti-thrombotic in different therapeutic settings for which additional safe and well tolerated anti-thrombotic drugs are needed, especially in patient populations that are at high risk for thrombosis and are also at high risk for bleeding.</p>
<p><strong>About Thrombosis</strong></p>
<p>Thrombosis is the formation of blood clots inside blood vessels. Blood clots can obstruct blood flow to prevent sufficient oxygen flow to tissues and organs. In addition, clot fragments can break off from the blood clot and travel to occlude other parts of the circulation. Thrombosis is responsible for many heart attacks and strokes and is the leading cause of morbidity and mortality worldwide.</p>
<p>Current antithrombotic treatments include anticoagulants such as warfarin, Factor Xa inhibitors and thrombin inhibitors. Although these drugs are effective at lowering the risk of thrombosis, these drugs can place patients at significant risk of bleeding because they target factors required for normal coagulation.</p>
<p>Factor XI is a clotting factor produced in the liver that is an important component in the intrinsic pathway of the coagulation process. Factor XI’s role in blood coagulation is in clot stabilization and expansion and not in clot initiation. People with high levels of Factor XI have increased risk of thrombosis while those with deficient Factor XI have a lower incidence of thromboembolic events and minimal risk of bleeding.</p>
<p><strong>Selected Publications</strong></p>
<ol>
<li><a href="http://www.ncbi.nlm.nih.gov/pubmed/25482425" target="_blank" rel="noopener noreferrer">Buller, H.R. et al.</a> (2014) Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis. N Engl J Med. Epub ahead of print.</li>
<li><a href="http://www.ncbi.nlm.nih.gov/pubmed/23559626" target="_blank" rel="noopener noreferrer">Crosby, J.R. et al.</a> (2013) Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates. Arterioscler Thromb Vasc Biol. 33, 1670-1678.</li>
<li><a href="http://www.ncbi.nlm.nih.gov/pubmed/22246038" target="_blank" rel="noopener noreferrer">Younis, H.S. et al.</a> (2012) Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys. Blood. 119, 2401-2408.</li>
<li><a href="http://www.ncbi.nlm.nih.gov/pubmed/20727068" target="_blank" rel="noopener noreferrer">Lowenberg, E.C. et al.</a> (2010) Coagulation factor XI as a novel target for antithrombotic treatment. J Thromb Haemost.8, 2349-2357.</li>
<li><a href="http://www.ncbi.nlm.nih.gov/pubmed/20807891" target="_blank" rel="noopener noreferrer">Zhang, H. et al.</a> (2010) Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood. 116, 4684-4692.</li>
</ol>
<p><em>Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</em></p>
<p>&nbsp;</p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                    </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
)
</div>                                        <div id="med-slot-3-1901" class="phase-2 slot-3 not_Ionis partner-AstraZeneca pipeline-medicines__item showme" data-phase="phase-2">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>ION449<sup></sup><sub></sub></strong></div>
                                                                                                    <div>(PCSK9)</div>
                                                                                                    <div>CVD</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">AstraZeneca</div>
                                                                                                                                                                                <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="2" style="background-color: #d2216a">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #d2216a"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2.5 LICA<br>
</small></p>
<p class="p1">ION449 (formerly IONIS-AZ4-2.5-L<sub>Rx</sub>), also known as AZD8233, is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce plasma levels of proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is integrally involved in the regulation of LDL-cholesterol. Genetic studies have shown that individuals with life-long reduction of LDL-C due to reduced function of PCSK9 have substantially reduced risk of cardiovascular disease. Pharmacological inhibition of PCSK9 substantially lowers LDL-C. ION449 is designed to reduce the liver production of PCSK9 and lower the plasma level of LDL-C and thus reduce the risk of cardiovascular disease.</p>
<p><strong>About Cardiovascular Disease</strong><br>
Elevated levels of LDL-C are a key risk factor in the development of cardiovascular disease, including heart attack, stroke and peripheral arterial disease. Higher levels of LDL-C in the blood are directly related to greater risk of vascular disease, while reduction of LDL-C leads to a significant decrease in risk. Despite the presence of several lipid-lowering agents, many patients are unable to achieve recommended LDL-C levels and remain at increased risk for cardiovascular disease. The development of additional, highly potent LDL-C lowering drugs can address this persistent unmet need.</p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/30420622/" class="color--orange weight-bold base" target="_blank">Sabatine, MS.</a> (2019) PCSK9 inhibitors: clinical evidence and implementation. Nat Rev Cardiol. 16(3):155-165.                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                                                                    </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
)
</div>                                        <div id="med-slot-3-3260" class="phase-2 slot-3 partner-Ionis-Owned pipeline-medicines__item showme" data-phase="phase-2">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>IONIS-AGT-L<sup></sup><sub>Rx</sub></strong></div>
                                                                                                    <div>(Angiotensinogen)</div>
                                                                                                    <div>Chronic Heart Failure with Reduced Ejection Fraction</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">Ionis-Owned</div>
                                                                                                                                                                                <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="2" style="background-color: #d2216a">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #d2216a"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2<sup>+</sup> LICA</small></p>
<p>IONIS-AGT-L<sub>Rx&nbsp;</sub>is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of liver-derived angiotensinogen (AGT), a central component of the renin-angiotensin-aldosterone system (RAAS).</p>
<p>Inhibition of the RAAS pathway is a well-established therapeutic approach for treating patients with heart failure (HF). While RAAS pathway blockers, such as angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), are part of the standard of care, their use as monotherapy may result in incomplete RAAS blockade. However, two or more RAAS pathway blockers are not recommended, due to the negative side effects in the kidneys and risk of hypotension.</p>
<p>By targeting AGT, which lies furthest upstream in the RAAS pathway, IONIS-AGT-L<sub>Rx</sub>&nbsp; has the potential to achieve a more complete blockade of the RAAS axis compared to ACE inhibitors and ARBs. &nbsp;Furthermore, the selective inhibition of AGT in the liver may provide a better safety profile by avoiding the kidney side effects seen with the current RAAS inhibitors, which is especially important for patients with chronic kidney dysfunction.</p>
<p><strong>About Chronic Heart Failure with Reduced Ejection Fraction</strong>&nbsp;–&nbsp;Heart failure (HF) afflicts approximately 6.5 million patients in the United States and 26 million worldwide. As the population ages, HF incidence is increasing, and more than 550,000 patients are diagnosed with new HF each year. HF is responsible for more hospitalizations than all forms of cancer combined and is the most common diagnosis in hospital patients age 65 years and older. Every year over 1 million patients are hospitalized for HF in the US and Europe, accounting for 6.5 million hospital days. High rates of hospitalizations with frequent readmission (almost 25% of patients with HF are readmitted within 30 days) along with other direct and indirect costs, also place an enormous economic burden on healthcare systems. Despite new advances in medical therapy, the residual risk for patients with HF is still high.</p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/27818490/" class="color--orange weight-bold base" target="_blank">Lu, H. et al.</a> (2016) Structure and functions of angiotensinogen. Hypertens Res. 39(11):827                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/33501848/" class="color--orange weight-bold base" target="_blank">Virani, S.S. et al.</a> (2021) Heart Disease and Stroke Statistics – 2021 Update: A Report From the American Heart Association. Circulation. 143(8):e254-e743.                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                                                                    </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
)
</div>                                        <div id="med-slot-3-2511" class="phase-2 slot-3 partner-Ionis-Owned pipeline-medicines__item showme" data-phase="phase-2">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>ION904<sup></sup><sub></sub></strong></div>
                                                                                                    <div>(Angiotensinogen)</div>
                                                                                                    <div>Treatment-Resistant Hypertension</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">Ionis-Owned</div>
                                                                                                                                                                                <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="2" style="background-color: #d2216a">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #d2216a"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2.5 LICA</small></p>
<p>ION904 is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of angiotensinogen to decrease blood pressure in patients with treatment resistant hypertension (TRH). Despite availability of generic antihypertensive agents, TRH is a major contributor to cardiovascular and renal disease.</p>
<p>Inhibiting the renin-angiotensin-aldosterone system (RAAS) is a well-established method of treating hypertension and complications of hypertension. While angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are widely used, many patients with high blood pressure are not well controlled by these treatment options. Angiotensinogen, the target of ION904, is upstream of ACE inhibitors and ARBs in the RAAS pathway. Therefore, reducing angiotensinogen levels has the potential to decrease blood pressure in patients whose blood pressure is not adequately controlled by currently available treatment options. Furthermore, inhibiting angiotensinogen, which is made in the liver, may maintain renal compensatory mechanisms, which could lead to fewer side effects compared to current standard of care.</p>
<p><strong>About Treatment Resistant Hypertension (TRH)</strong></p>
<p>Approximately 70 million adults in the United States have hypertension, half of which have uncontrolled hypertension. About 12-15 percent of patients with uncontrolled hypertension have resistant hypertension, defined as failure to achieve a blood pressure goal of 140/90 (systolic/diastolic) despite the use of three or more antihypertensive medications. Current estimates approximate that there are up to three million patients with TRH in the U.S. Patients with TRH have been found to have 3-fold increased odds of having fatal and non-fatal cardiovascular events relative to those with controlled hypertension.</p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="https://www.ncbi.nlm.nih.gov/pubmed/30530571" class="color--orange weight-bold base" target="_blank">Wu, C.H. et al.</a> (2019) Antisense oligonucleotides targeting angiotensinogen: insights from animal studies. Biosci Rep. 2019 Jan 11;39(1).                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://www.ncbi.nlm.nih.gov/pubmed/28571891" class="color--orange weight-bold base" target="_blank">Ferrario, C.M. et al.</a> (2017) Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease. Pharmacol Res. 2017 Nov;125(Pt A):57-71.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://www.ncbi.nlm.nih.gov/pubmed/28716988" class="color--orange weight-bold base" target="_blank">Mullick, A.E. et al.</a> (2017) Blood pressure lowering and safety improvements with liver angiotensinogen inhibition in models of hypertension and kidney injury. Hypertension. 2017 Sep;70(3):566-576.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="http://journals.sagepub.com/doi/pdf/10.1177/1753944716642680" class="color--orange weight-bold base" target="_blank">Williams, B.&nbsp;</a> (2016) Drug discovery in renin-angiotensin system intervention: Past and future. Ther Adv Cardiovasc Dis;10:118-125.                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                                                                    </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
)
</div>                                        <div id="med-slot-3-1767" class="phase-1 slot-3 not_Ionis partner-AstraZeneca pipeline-medicines__item showme" data-phase="phase-1">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>ION532<sup></sup><sub></sub></strong></div>
                                                                                                    <div>(APOL1)</div>
                                                                                                    <div>Chronic Kidney Disease</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">AstraZeneca</div>
                                                                                                                                    <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="1" style="background-color: #d2216a">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #d2216a"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2.5<br>
</small></p>
<p class="p1">ION532 (formerly IONIS-AZ5-2.5<sub>Rx</sub> ), also known as AZD2373, is an investigational antisense medicine designed to reduce the production of apolipoprotein L1 (APOL1) for the treatment of APOL1-associated chronic kidney disease (CKD). Genetic studies have shown that two risk alleles (termed G1 and G2) are highly associated with nondiabetic CKD and increased rate of progression towards kidney failure, providing an exciting opportunity for personalized medicine in CKD. These two variants are more frequently found in individuals of West-African ancestry. Reduction of APOL1 with ION532 in a preclinical mouse model of APOL1-related kidney disease demonstrated significantly reduced proteinuria, a hallmark of CKD. ION532 is being developed for the treatment of APOL1-associated nephropathies.</p>
<p><b>About Chronic Kidney Disease</b><br>
Chronic kidney disease (CKD) is a worldwide public health problem, affecting about 10% of the population. Within United States, over 37 million adults have CKD and millions of others are at increased risk. CKD may be caused by diabetes, high blood pressure and other disorders. Without treatment, CKD may progress and eventually lead to kidney failure, which requires dialysis or a kidney transplant to maintain life.</p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/31217349/" class="color--orange weight-bold base" target="_blank">Aghajan, M. et al.</a> (2019) Antisense oligonucleotide treatment ameliorates IFN-γ-induced proteinuria in APOL1-transgenic mice. JCI Insight. 4(12):e126124.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/26947522/" class="color--orange weight-bold base" target="_blank">Friedman D.J et al.</a> (2016) Apolipoprotein L1 and Kidney Disease in African Americans. Trends Endocrinol Metab. 27(4):204–215.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/20688934/" class="color--orange weight-bold base" target="_blank">Freedman, B.I. et al.</a> (2010) The Apolipoprotein L1 (APOL1) Gene and Nondiabetic Nephropathy in African Americans. J. Am Soc Nephrol. 21(9):1422-6.                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                                                                    </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
)
</div>                                        <div id="med-slot-3-2512" class="phase-1 slot-3 partner-Ionis-Owned pipeline-medicines__item showme" data-phase="phase-1">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>ION547<sup></sup><sub></sub></strong></div>
                                                                                                    <div>(FXII)</div>
                                                                                                    <div>Thrombotic Disorders</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">Ionis-Owned</div>
                                                                                                                                    <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="1" style="background-color: #d2216a">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #d2216a"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Generation 2.5 investigational LICA antisense medicine</small></p>
<p>ION547 is an investigational ligand-conjugated (LICA) antisense medicine designed to inhibit the expression of factor XII (FXII). FXII is a clotting factor produced in the liver which plays an important role in the coagulation pathway. Ionis’ studies have shown that inhibiting FXII prevents thrombosis in models of venous, arterial and catheter-induced thrombosis<sup>2,3</sup> without increasing bleeding. In humans naturally lacking FXII, and in FXII-knockout mice, there is normal hemostasis without abnormal bleeding<sup>1</sup>.</p>
<p><strong>About Thrombosis</strong></p>
<p>Thrombosis is the formation of blood clots inside blood vessels. Blood clots can obstruct blood flow to prevent sufficient oxygen flow to tissues and organs. In addition, clot fragments can break off from the blood clot and travel to occlude other parts of the circulation. Thrombosis is responsible for many heart attacks and strokes and is the leading cause of morbidity and mortality worldwide.</p>
<p>Current antithrombotic treatments include anticoagulants such as warfarin, Factor Xa inhibitors and thrombin inhibitors. Although these drugs are effective at lowering the risk of thrombosis, these drugs can place patients at significant risk of bleeding because they target factors required for normal coagulation. </p>
<p><b>Clinical Trials Posting</b></p>
<p><a href="https://clinicaltrials.gov/ct2/show/NCT04934891" target="_blank" rel="noopener noreferrer">https://clinicaltrials.gov/ct2/show/NCT04934891</a></p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/29483100/" class="color--orange weight-bold base" target="_blank">Maas C., Renné T.</a> (2018) Coagulation factor XII in thrombosis and inflammation. Blood 131(17):1903–1909.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/24501216/" class="color--orange weight-bold base" target="_blank">Yau J.W., et al.</a> (2014) Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood 123(13):2102-2107.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="http://www.ncbi.nlm.nih.gov/pubmed/21821705" class="color--orange weight-bold base" target="_blank">Revenko, A.S. et al.&nbsp;</a> (2011) Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood. 118, 5302-5311.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/16009717/" class="color--orange weight-bold base" target="_blank">Reneé T., et al.</a> (2005) Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med. 202(2):271-281.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/15351846/" class="color--orange weight-bold base" target="_blank">Pauer H.U., et al.</a> (2004) Targeted deletion of murine coagulation factor XII gene-a model for contact phase activation in vivo. Thromb Haemost. 92(3):503-508.                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                                                                    </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                        
                                </div>
                            </div>
                                                    <style>
                                .pipeline-section__block:nth-of-type(2) {
                                    background: rgba(236, 111, 35,0.1);
                                }
                                .pipeline-section__block:nth-of-type(2) .pipeline-medicines__item:hover,
                                .pipeline-section__block:nth-of-type(2) .pipeline-medicines__item.active {
                                    background: rgba(236, 111, 35,0.2);
                                }
                            </style>
                            <div id="slot-4" class="pipeline-section__block showme" data-therapeutic-area="slot-4">
                                <h4 class="color--secondary">Metabolic</h4>
                                <div class="pipeline-section__block__header">
                                    <div class="pipeline-section__block__header--space"></div>
                                    <div class="pipeline-section__block__header--partner">Partner</div>
                                    <div class="pipeline-section__block__header--phase d-none d-md-block ishidden pcheader">Preclinical</div>                                       
                                        
                                            <div id="drug-hdr-1" class="pipeline-section__block__header--phase d-md-none">P                                        </div>
                                    		                                     <div class="pipeline-section__block__header--phase d-none d-md-block">Phase 1</div>
		                                                                           
                                        
                                            <div id="drug-hdr-2" class="pipeline-section__block__header--phase d-md-none">P1                                        </div>
                                    		                                     <div class="pipeline-section__block__header--phase d-none d-md-block">Phase 2</div>
		                                                                           
                                        
                                            <div id="drug-hdr-3" class="pipeline-section__block__header--phase d-md-none">P2                                        </div>
                                    		                                     <div class="pipeline-section__block__header--phase d-none d-md-block">Phase 3</div>
		                                                                           
                                        
                                            <div id="drug-hdr-4" class="pipeline-section__block__header--phase d-md-none">P3                                        </div>
                                                                           
                                        
                                            <div id="drug-hdr-5" class="pipeline-section__block__header--phase d-md-none">R                                        </div>
                                                                    </div>
                                <div class="pipeline-medicines">
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
    [0] =&gt; rare
)
</div>                                        <div id="med-slot-4-2581" class="phase-3 slot-4 partner-Ionis-Owned rareDisease pipeline-medicines__item showme" data-phase="phase-3">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>Olezarsen<sup></sup><sub></sub></strong></div>
                                                                                                    <div>(ApoC-III)</div>
                                                                                                    <div>FCS</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">Ionis-Owned</div>
                                                                                                                                                                                                                            <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="3" style="background-color: #ec6f23">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #ec6f23"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2<sup>+</sup> LICA<br>
</small></p>
<p>Olezarsen, formerly known as IONIS-APOCIII-L<sub>Rx</sub> and AKCEA-APOCIII-L<sub>Rx</sub>, is a ligand-conjugated (LICA) investigational antisense medicine designed to inhibit the production of apoC-III, for patients who are at risk of disease due to elevated triglyceride levels. ApoC-III is a protein produced in the liver that regulates triglyceride metabolism in the blood. People with severely elevated triglycerides, such as people with familial chylomicronemia syndrome (FCS), are at high risk for acute pancreatitis and other serious conditions. ApoC-III is also the target of WAYLIVRA, the first approved medicine for patients with FCS.</p>
<p><strong>About familial chylomicronemia syndrome (FCS)</strong></p>
<p>FCS is a rare, genetic disease characterized by extremely elevated triglyceride levels that is estimated to affect 3,000 to 5,000 people worldwide. People with FCS are at high risk of unpredictable and potentially fatal acute pancreatitis. In addition to pancreatitis, FCS patients are at risk of chronic complications due to permanent organ damage, including chronic pancreatitis and pancreatogenic (type 3c) diabetes. They can experience daily symptoms including abdominal pain, generalized fatigue and impaired cognition that affect their ability to work. People with FCS also report major emotional and psychosocial effects including anxiety, social withdrawal, depression and brain fog. Additional information on FCS is available at <a href="https://fcsfocus.com/" target="_blank" rel="noopener noreferrer">www.fcsfocus.com</a>, through the LPLD Alliance at <a href="http://www.lpldalliance.org" target="_blank" rel="noopener noreferrer">http://www.lpldalliance.org</a> and through The FCS Foundation at <a href="http://www.livingwithfcs.org" target="_blank" rel="noopener noreferrer">http://www.livingwithfcs.org</a>. For a full list of organizations supporting the FCS community worldwide, please click <a href="https://fcsfocus.com/learn-more/helpful-links/" target="_blank" rel="noopener noreferrer">here</a>.</p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="https://www.ncbi.nlm.nih.gov/pubmed/31329855" class="color--orange weight-bold base" target="_blank">Alexander, V.J.</a> (2019) N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels. Eur Heart J. 40(33):2785-279                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://www.ncbi.nlm.nih.gov/pubmed/31390500" class="color--orange weight-bold base" target="_blank">Witztum, J.L. et al.</a> (2019) Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. N Engl J Med. 381(6):531-542.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="http://www.ncbi.nlm.nih.gov/pubmed/25470695" class="color--orange weight-bold base" target="_blank">Gaudet, D. et al.</a> (2014) Targeting APOC3 in the Familial Chylomicronemia Syndrome. N Engl J Med. 371, 2200-2206.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="http://www.ncbi.nlm.nih.gov/pubmed/24172179" class="color--orange weight-bold base" target="_blank">Scherer, J. et al.&nbsp;</a> (2014) Issues in hypertriglyceridemic pancreatitis: an update. J. Clin Gastroenterol. 48, 195-203.                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                                                                    </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
    [0] =&gt; rare
)
</div>                                        <div id="med-slot-4-1854" class="phase-2 slot-4 partner-Ionis-Owned rareDisease pipeline-medicines__item showme" data-phase="phase-2">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>Cimdelirsen<sup></sup><sub></sub></strong></div>
                                                                                                    <div>(GHr)</div>
                                                                                                    <div>Acromegaly</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">Ionis-Owned</div>
                                                                                                                                                                                <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="2" style="background-color: #ec6f23">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #ec6f23"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2<sup>+</sup> LICA<br>
</small></p>
<p>Cimdelirsen, formerly known as IONIS-GHR-L<sub>Rx</sub>, is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of the growth hormone receptor (GHr) to decrease the circulating level of insulin-like growth factor-1 (IGF-1). IGF-1 is a hormone primarily produced in the liver that plays an important role in childhood growth and has anabolic effects in adults. Several different diseases result from abnormally low or high levels of IGF-1, or an inappropriate response to this hormone. When produced in excess, IGF-1 results in acromegaly, a chronic, slowly progressing and life-threatening disease.</p>
<p><strong>About GHr and Acromegaly</strong></p>
<p>Acromegaly is a chronic, slowly progressing and life-threatening disease most often caused by oversecretion of growth hormone (GH) by benign pituitary tumors. Elevated levels of GH can overstimulate growth hormone receptors (GHr) and induce excess production of insulin-like growth factor-1 (IGF-1). High levels of circulating GH and IGF-1 lead to this multisystem disease characterized by organ overgrowth and physical disfigurement, such as enlarged hands, feet, and facial features. Patients with acromegaly also experience multiple comorbidities, such as type 2 diabetes, hypertension, and respiratory complications, as well as premature mortality. Because IGF-1 mediates the majority of the growth-promoting action of GH, reducing GHr production could in turn decrease levels of IGF-1 and provide a potential treatment to patients with acromegaly. Current treatments to block IGF-1 include surgical removal of the pituitary gland, which is often unsuccessful. Drug treatments to normalize IGF-1 levels are also available but are associated with potentially serious side effects.</p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="https://www.ncbi.nlm.nih.gov/pubmed/16614389" class="color--orange weight-bold base" target="_blank">Tachas, G. et al.</a> (2006) A GH receptor antisense oligonucleotide inhibits hepatic GH receptor expression, IGF-I production and body weight gain in normal mice. J Endocrinol. 189, 147-154.                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                                                                    </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
)
</div>                                        <div id="med-slot-4-1888" class="phase-2 slot-4 not_Ionis partner-Suzhou-Ribo<sup>*</sup><br /><small><sup>*</sup>China only</small> pipeline-medicines__item showme" data-phase="phase-2">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>IONIS-GCGR<sup></sup><sub>Rx</sub></strong></div>
                                                                                                    <div>(GCGR)</div>
                                                                                                    <div>Diabetes</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">Suzhou-Ribo<sup>*</sup><br><small><sup>*</sup>China only</small></div>
                                                                                                                                                                                <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="2" style="background-color: #ec6f23">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #ec6f23"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2<sup>+</sup><br>
</small></p>
<p>IONIS-GCGR<sub>Rx</sub> is an investigational antisense medicine designed to reduce the production of glucagon receptors, or GCGR, to treat patients with type 2 diabetes. GCGR is a receptor for the hormone glucagon. Glucagon is a hormone that opposes the action of insulin and stimulates the liver to produce glucose, particularly in type 2 diabetes. In patients with advanced diabetes, uncontrolled glucagon action can lead to significant increase in blood glucose level. In addition, reducing GCGR produces more active glucagon-like peptide, or GLP-1, a hormone that preserves pancreatic function and enhances insulin secretion.</p>
<p><strong>About Type 2 Diabetes</strong></p>
<p>Diabetes is a chronic disease in which the blood glucose levels are too high. Although glucose is an important source of energy for your body and is vital to your health, uncontrolled increases in glucose can lead to serious health problems, such as diabetes. Diabetes is separated in type 1 and type 2. In type 1 diabetes, the body does not make insulin. In type 2 diabetes, the more common type, the body does not make or use insulin well and therefore, blood glucose levels are not regulated properly.</p>
<p>Diabetes is an epidemic that continues to grow at an alarming rate. According to the latest Center for Disease Control statistics released, there are currently 29 million people in the U.S. that have diabetes, with type 2 diabetes constituting 90 to 95 percent of those cases. Moreover, an additional 86 million American adults, or one out of every three adults, are prediabetic. It is estimated that 15 to 30 percent of prediabetic people will develop full-fledged metabolic disorder within five years.</p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="http://www.ncbi.nlm.nih.gov/pubmed/25197025" class="color--orange weight-bold base" target="_blank">van Dongen, M.G. et al.&nbsp;</a> (2014) First proof of pharmacology in humans of a novel glucagon receptor antisense drug. J Clin Pharmacol. Epub ahead of print.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="http://www.ncbi.nlm.nih.gov/pubmed/14747292" class="color--orange weight-bold base" target="_blank">Liang, Y. et al.</a> (2004) Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes. 53, 410-417.                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                                                                    </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
)
</div>                                        <div id="med-slot-4-2388" class="phase-2 slot-4 partner-Ionis-Owned pipeline-medicines__item showme" data-phase="phase-2">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>ION224<sup></sup><sub></sub></strong></div>
                                                                                                    <div>(DGAT2)</div>
                                                                                                    <div>NASH</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">Ionis-Owned</div>
                                                                                                                                                                                <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="2" style="background-color: #ec6f23">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #ec6f23"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2<sup>+</sup> LICA<br>
</small></p>
<p>ION224 is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of DGAT2, or diacylglycerol acyltransferase 2, to treat patients with NASH, or nonalcoholic steatohepatitis. NASH is a common liver disease characterized by excessive triglycerides in the liver with concurrent inflammation and cellular damage. DGAT2 is an enzyme that catalyzes the final step in triglyceride synthesis in the liver. Reducing the production of DGAT2 should therefore decrease triglyceride synthesis in the liver. In animal studies, antisense inhibition of DGAT2 significantly improved liver steatosis, lowered blood lipid levels and reversed diet-induced insulin resistance in animal models of obesity and fatty liver disease.<sup>4,5</sup></p>
<p>NASH is sometimes considered a “silent” liver disease because people with early-stage NASH feel well, even though they are starting to accumulate fat in their livers, and may not be aware that they have the disease. However, NASH can develop into more severe diseases such as liver cirrhosis and liver failure. Currently, liver transplant is the only therapeutic option for patients with liver cirrhosis. In addition, NASH has been shown to be a major risk factor for the development of liver cancer.</p>
<p><strong>About NASH</strong></p>
<p>Non-alcoholic fatty liver disease (NAFLD) describes the full spectrum of liver disease progression from fatty liver to non-alcoholic steatohepatitis (NASH) to cirrhosis to hepatocellular carcinoma. While fatty liver is often asymptomatic, NASH, which is characterized by liver steatosis, inflammation, and scarring, can lead to increased risk of cardiovascular disease, need for liver transplantation, and early death. NASH epidemiology studies have estimated 13-32% of the global population has NAFLD, 1.5%-6.5% have NASH, and approximately 9% of NASH patients progress to advanced liver disease. There are currently no commercially available NASH medications.</p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="https://www.ncbi.nlm.nih.gov/pubmed/25920090" class="color--orange weight-bold base" target="_blank">Byrne, C.D. et al.</a> (2015) NAFLD: a multisystem disease. J Hepatol. 621, S47-64.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://www.ncbi.nlm.nih.gov/pubmed/25852263" class="color--orange weight-bold base" target="_blank">Takahashi, Y. et al.&nbsp;</a> (2015) Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 21, 3777-3785.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://www.ncbi.nlm.nih.gov/pubmed/20460905" class="color--orange weight-bold base" target="_blank">Bellentani, S. et al.</a> (2010) Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 28,155-161.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://www.ncbi.nlm.nih.gov/pubmed/17526931" class="color--orange weight-bold base" target="_blank">Choi, C.S. et al.</a> (2007) Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J Biol Chem. 282, 22678-22688.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://www.ncbi.nlm.nih.gov/pubmed/16001399" class="color--orange weight-bold base" target="_blank">Yu, X.X. et al.</a> (2005) Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology. 42, 362-371.                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                                                                    </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
)
</div>                                        <div id="med-slot-4-1927" class="phase-1 slot-4 not_Ionis partner-AstraZeneca pipeline-medicines__item showme" data-phase="phase-1">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>ION839<sup></sup><sub></sub></strong></div>
                                                                                                    <div>(PNPLA3)</div>
                                                                                                    <div>NASH</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">AstraZeneca</div>
                                                                                                                                    <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="1" style="background-color: #ec6f23">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #ec6f23"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2.5 LICA</small></p>
<p>ION839, formerly known as IONIS-AZ6-2.5-L<sub>Rx</sub> and AZD2693, is a ligand-conjugated (LICA) investigational antisense medicine designed to inhibit the production of patatin-like phospholipase domain-containing 3 (PNPLA3) protein. PNPLA3 is a protein that is found on the surface of intracellular lipid droplets. Studies have shown that a common genetic mutation of PNPLA3 is strongly associated with an increased risk for non-alcoholic steatohepatitis (NASH), an accumulation of fat in the liver that causes liver damage. The mutant PNPLA3 protein is resistant to degradation, causing it to accumulate on the surface of lipid droplets, which disrupts the normal process for degrading lipid droplets, leading to increased liver fat accumulation, the underlying pathology of NASH. In a mouse model of NASH that results from the expression of mutant PNPLA3, intervention with an antisense drug targeting PNPLA3 reduced hepatic mutant protein expression. This inhibition of mutant protein expression reduced liver fat accumulation, inflammation, and fibrosis, all hallmarks of NASH pathology in the mutant mouse model.</p>
<p><strong>About NASH</strong><br>
Non-alcoholic fatty liver disease (NAFLD) describes the full spectrum of liver disease progression from fatty liver to non-alcoholic steatohepatitis (NASH) to cirrhosis to hepatocellular carcinoma. While fatty liver is often asymptomatic, NASH, which is characterized by liver steatosis, inflammation, and scarring, can lead to increased risk of cardiovascular disease, need for liver transplantation, and early death. NASH epidemiology studies have estimated 13-32% of the global population has NAFLD, 1.5%-6.5% have NASH, and approximately 9% of NASH patients progress to advanced liver disease. There are currently no commercially available NASH medications.</p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/31019090" class="color--orange weight-bold base" target="_blank">BasuRay, S. et al.</a> (2019) Accumulation of PNPLA3 on Lipid Droplets Is the Basis of Associated Hepatic Steatosis. PNAS. 116(19), 9521-9526                                                                 </li>
                                                                                                                            <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/30772256" class="color--orange weight-bold base" target="_blank">Linden, D. et al.</a> (2019) Pnpla3 Silencing With Antisense Oligonucleotides Ameliorates Nonalcoholic Steatohepatitis and Fibrosis in Pnpla3 I148M Knock-In Mice. Mol Metab. 22, 49-61                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/29166236" class="color--orange weight-bold base" target="_blank">Diehl. A.M. et al.</a> (2017) Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis. N Engl J Med. 377(21), 2063-2072                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/27038645" class="color--orange weight-bold base" target="_blank">Trepo, E. et al.</a> (2016) PNPLA3 Gene in Liver Diseases. J Hepatol. 65(2), 399-412                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                                                                    </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
)
</div>                                        <div id="med-slot-4-3510" class="phase-1 slot-4 not_Ionis partner-AstraZeneca pipeline-medicines__item showme" data-phase="phase-1">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>ION455<sup></sup><sub></sub></strong></div>
                                                                                                    <div>(Undisclosed)</div>
                                                                                                    <div>NASH</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">AstraZeneca</div>
                                                                                                                                    <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="1" style="background-color: #ec6f23">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #ec6f23"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p>ION455, also known as AZD7503, is an investigational antisense medicine designed for the treatment of nonalcoholic steatohepatitis (NASH).</p>
<p><strong><span style="font-family: 'Calibri',sans-serif;">About Nonalcoholic Steatohepatis (NASH) </span></strong><br>
Non-alcoholic fatty liver disease (NAFLD) describes the full spectrum of liver disease progression from fatty liver to non-alcoholic steatohepatitis (NASH) to cirrhosis to hepatocellular carcinoma. While fatty liver is often asymptomatic, NASH, which is characterized by liver steatosis, inflammation, and scarring, can lead to increased risk of cardiovascular disease, need for liver transplantation, and early death. NASH epidemiology studies have estimated 13-32% of the global population has NAFLD, 1.5%-6.5% have NASH, and approximately 9% of NASH patients progress to advanced liver disease. There are currently no commercially available NASH medications.</p>
<p><em><span style="font-family: 'Calibri',sans-serif;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</span></em></p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                    </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                        
                                </div>
                            </div>
                                                    <style>
                                .pipeline-section__block:nth-of-type(3) {
                                    background: rgba(206, 218, 30,0.1);
                                }
                                .pipeline-section__block:nth-of-type(3) .pipeline-medicines__item:hover,
                                .pipeline-section__block:nth-of-type(3) .pipeline-medicines__item.active {
                                    background: rgba(206, 218, 30,0.2);
                                }
                            </style>
                            <div id="slot-5" class="pipeline-section__block showme" data-therapeutic-area="slot-5">
                                <h4 class="color--secondary">Neurological</h4>
                                <div class="pipeline-section__block__header">
                                    <div class="pipeline-section__block__header--space"></div>
                                    <div class="pipeline-section__block__header--partner">Partner</div>
                                    <div class="pipeline-section__block__header--phase d-none d-md-block ishidden pcheader">Preclinical</div>                                       
                                        
                                            <div id="drug-hdr-1" class="pipeline-section__block__header--phase d-md-none">P                                        </div>
                                    		                                     <div class="pipeline-section__block__header--phase d-none d-md-block">Phase 1</div>
		                                                                           
                                        
                                            <div id="drug-hdr-2" class="pipeline-section__block__header--phase d-md-none">P1                                        </div>
                                    		                                     <div class="pipeline-section__block__header--phase d-none d-md-block">Phase 2</div>
		                                                                           
                                        
                                            <div id="drug-hdr-3" class="pipeline-section__block__header--phase d-md-none">P2                                        </div>
                                    		                                     <div class="pipeline-section__block__header--phase d-none d-md-block">Phase 3</div>
		                                                                           
                                        
                                            <div id="drug-hdr-4" class="pipeline-section__block__header--phase d-md-none">P3                                        </div>
                                                                           
                                        
                                            <div id="drug-hdr-5" class="pipeline-section__block__header--phase d-md-none">R                                        </div>
                                                                    </div>
                                <div class="pipeline-medicines">
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
)
</div>                                        <div id="med-slot-5-1830" class="phase-3 slot-5 not_Ionis partner-Biogen pipeline-medicines__item showme" data-phase="phase-3">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>Tofersen<sup></sup><sub></sub></strong></div>
                                                                                                    <div>(SOD1)</div>
                                                                                                    <div>Amyotrophic Lateral Sclerosis</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">Biogen</div>
                                                                                                                                                                                                                            <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="3" style="background-color: #ceda1e">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #ceda1e"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2<sup>+</sup><br>
</small></p>
<p>Tofersen (formerly IONIS-SOD1<sub>Rx</sub>), also known as BIIB067, is an investigational antisense medicine targeting superoxide dismutase 1 (SOD1), which is the second most common and best understood genetic cause of amyotrophic lateral sclerosis (ALS). Patients with a mutation in the SOD1 gene develop a form of ALS referred to as SOD1-ALS. There is substantial evidence that mutations in the SOD1 gene are responsible for a toxic gain of function that can lead to rapid progressive loss of motor neurons in patients with SOD1-ALS. As a result, patients with SOD1-ALS experience muscle weakness, loss of movement, difficulty in breathing and swallowing and eventually succumb to their disease.</p>
<p><strong>About Amyotrophic Lateral Sclerosis</strong></p>
<p>ALS is a rare, fatal neurodegenerative disorder characterized by loss and dysfunction of neurons in motor pathways. It is estimated that there are ~55,000 patients diagnosed with ALS in major markets<sup>1</sup>. Approximately 90 percent of patients with ALS have no known family history, while approximately 10 percent of patients have a known genetic cause for their disease. People with ALS suffer progressive degeneration of motor neurons, which results in a declining quality of life due to muscle weakness, loss of movement and difficulty in breathing and swallowing. Currently, treatment options for patients with ALS are extremely limited with no drugs that significantly slow disease progression.</p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/29470458/" class="color--orange weight-bold base" target="_blank">Mehta, P. et al.</a> (2018) Prevalence of Amyotrophic Lateral Sclerosis — United States, 2014. MMWR Morb Mortal Wkly Rep. 67(7):216–218.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="http://www.ncbi.nlm.nih.gov/pubmed/23541756" class="color--orange weight-bold base" target="_blank">Miller, T.M. et al.</a> (2013) An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 12(5):435-42.                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                                                                    </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
)
</div>                                        <div id="med-slot-5-1827" class="phase-3 slot-5 not_Ionis partner-Roche pipeline-medicines__item showme" data-phase="phase-3">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>Tominersen<sup></sup><sub></sub></strong></div>
                                                                                                    <div>(HTT)</div>
                                                                                                    <div>Huntington’s Disease</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">Roche</div>
                                                                                                                                                                                                                            <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="3" style="background-color: #ceda1e">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #ceda1e"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2<sup>+</sup><br>
</small></p>
<p>Tominersen, formerly known as IONIS-HTT<sub>Rx</sub>&nbsp;and RG6042, is an investigational antisense medicine designed to reduce the production of the huntingtin (HTT) protein, which is the genetic cause of Huntington’s disease (HD). HD is caused by expansion of the CAG trinucleotide sequence in the HTT gene, which produces a toxic protein that progressively destroys neurons in the brain. As a result, HD patients experience progressive loss of mental faculties and physical control as their disease progresses.</p>
<p>The European Medicines Agency has granted orphan drug designation to tominersen for the treatment of patients with HD.</p>
<p><strong>About Huntington’s Disease</strong></p>
<p>HD is an inherited genetic brain disorder that results in the progressive loss of both mental faculties and physical control. It is caused by the expansion of the CAG trinucleotide sequence in the HTT gene. The resulting mutant HTT protein is toxic and gradually destroys neurons. Symptoms usually appear between the ages of 30 and 50 and worsen over a 10 to 25-year period. Ultimately, the weakened individual succumbs to pneumonia, heart failure or other complications. Presently, there is no effective treatment or cure for the disease, and currently available medicines only mask the patient’s symptoms but do not slow down the underlying loss of neurons.</p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="http://www.ncbi.nlm.nih.gov/pubmed/22726834" class="color--orange weight-bold base" target="_blank">Kordasiewicz, H.B. et al.</a> (2012) Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron. 74, 1031-1044.                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                                                                    </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
    [0] =&gt; rare
)
</div>                                        <div id="med-slot-5-1856" class="phase-3 slot-5 not_Ionis partner- AstraZeneca** rareDisease pipeline-medicines__item showme" data-phase="phase-3">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>Eplontersen<sup></sup><sub></sub></strong></div>
                                                                                                    <div>(TTR)</div>
                                                                                                    <div>hATTR Polyneuropathy</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner"> AstraZeneca**</div>
                                                                                                                                                                                                                            <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="3" style="background-color: #ceda1e">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #ceda1e"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2<sup>+</sup> LICA</small></p>
<p>Eplontersen, formerly known as IONIS-TTR-L<sub>Rx </sub>and AKCEA-TTR-L<sub>Rx</sub>, is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of transthyretin, or TTR protein, to treat all types of TTR amyloidosis (ATTR), a systemic, progressive and fatal disease. In patients with ATTR, both the mutant and wild type (wt) TTR protein builds up as fibrils in tissues, such as the peripheral nerves, heart, gastrointestinal system, eyes, kidneys, central nervous system, thyroid and bone marrow. The presence of TTR fibrils interferes with the normal functions of these tissues. As the TTR protein fibrils enlarge, more tissue damage occurs and the disease worsens, resulting in poor quality of life and eventually death.</p>
<p><strong>About TTR Amyloidosis (ATTR)</strong></p>
<p>ATTR amyloidosis is a systemic, progressive and fatal disease in which patients experience multiple overlapping clinical manifestations caused by the inappropriate formation and aggregation of TTR amyloid deposits in various tissues and organs, including peripheral nerves, heart, intestinal tract, eyes, kidneys, central nervous system, thyroid and bone marrow. The progressive accumulation of TTR amyloid deposits in these tissues and organs leads to organ failure and eventually death.</p>
<p>Polyneuropathy due to hATTR is caused by the accumulation of misfolded mutated TTR protein in the peripheral nerves. Patients with polyneuropathy due to hATTR experience ongoing debilitating nerve damage throughout their body resulting in the progressive loss of motor functions, such as walking. These patients also accumulate TTR in other major organs, which progressively compromise their function and eventually leading to death within five to fifteen years of disease onset. There are an estimated 10,000 patients with polyneuropathy due to hATTR worldwide.</p>
<p>ATTR cardiomyopathy is caused by the accumulation of misfolded TTR protein in the cardiac muscle. Patients experience ongoing debilitating heart damage resulting in progressive heart failure, which results in death within 3 to 5 years from disease onset. ATTR cardiomyopathy includes both the genetic and wild-type form of the disease. There are an estimated 240,000 patients with ATTR cardiomyopathy worldwide.</p>
<p>Often patients with the polyneuropathy form of TTR amyloidosis will also have TTR build up in the heart and also experience cardiomyopathy symptoms. Similarly, patients with the cardiomyopathy form of TTR amyloidosis may often have TTR build up in their peripheral nerves and can experience nerve damage and progressive difficulty with motor functions.</p>
<p>For more information on the NEURO-TTRansform study, please visit <a title="https://ionistrials.com/neuro-ttransform/" href="https://ionistrials.com/neuro-ttransform/">https://ionistrials.com/neuro-ttransform/</a></p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="http://www.ncbi.nlm.nih.gov/pubmed/22494066" class="color--orange weight-bold base" target="_blank">Ackermann, E.J. et al.&nbsp;</a> (2012) Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid. 19, 43-44.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="http://www.ncbi.nlm.nih.gov/pubmed/21550574" class="color--orange weight-bold base" target="_blank">Benson, M.D. et al.&nbsp;</a> (2011) Rate of Progression of Transthyretin Amyloidosis. Am J Cardiol.108, 285-289.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="http://www.ncbi.nlm.nih.gov/pubmed/16421881" class="color--orange weight-bold base" target="_blank">Benson, M.D. et al.&nbsp;</a> (2006) Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve. 33, 609-618.                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                    <p class="pipeline-footnote"><small><sup>*</sup><sup>*</sup> Ionis is jointly developing and commercializing eplontersen.</small></p>                                                </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
)
</div>                                        <div id="med-slot-5-2905" class="phase-3 slot-5 partner-Ionis-Owned pipeline-medicines__item showme" data-phase="phase-3">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>ION363<sup></sup><sub></sub></strong></div>
                                                                                                    <div>(FUS)</div>
                                                                                                    <div>Amyotrophic Lateral Sclerosis</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">Ionis-Owned</div>
                                                                                                                                                                                                                            <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="3" style="background-color: #ceda1e">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #ceda1e"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2<sup>+</sup><br>
</small></p>
<p>ION363 is an investigational antisense medicine designed to reduce the production of the Fused in Sarcoma (FUS) protein.&nbsp; ION363 is also known as Jacifusen (not an official USAN name) in honor of Jaci Hermstad, the first patient treated with the drug under an expanded access program. It is in development for patients with a rare genetic form of amyotrophic lateral sclerosis (ALS) caused by mutations in the <em>FUS</em> gene<sup>3</sup>. Mutant FUS causes motor neuron degeneration through a toxic gain of function mechanism<sup>2</sup>. In patients, mutant FUS protein aggregates in motor neurons<sup>4</sup>. Antisense-mediated reduction of mutant FUS protein in a FUS-ALS mouse model prevents motor neuron loss. It is hypothesized that reduction of FUS protein will reverse or prevent disease progression in FUS-ALS patients.</p>
<p><strong>Amyotrophic Lateral Sclerosis</strong></p>
<p>ALS is a rare, fatal neurodegenerative disorder characterized by loss and dysfunction of neurons in motor pathways. It is estimated that there are ~55,000 patients diagnosed with ALS in major markets<sup>1</sup>. Approximately 90 percent of patients with ALS have no known family history, while approximately 10 percent of patients have a known genetic cause for their disease. People with ALS suffer progressive degeneration of motor neurons, which results in a declining quality of life due to muscle weakness, loss of movement and difficulty in breathing and swallowing. Currently, treatment options for patients with ALS are extremely limited with no drugs that significantly slow disease progression.</p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/29470458/" class="color--orange weight-bold base" target="_blank">Mehta, P. et al.</a> (2018) Prevalence of Amyotrophic Lateral Sclerosis — United States, 2014. MMWR Morb Mortal Wkly Rep. 67(7):216–218.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/26842965/" class="color--orange weight-bold base" target="_blank">Sharma, A. et al.</a> (2016) ALS-associated mutant FUS induces selective motor neuron degeneration through toxic gain of function. Nat Commun. 7:10465.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/21813273/" class="color--orange weight-bold base" target="_blank">Da Cruz, S. et al.</a> (2011) Understanding the role of TDP-43 and FUS/TLS in ALS and beyond. Curr Opin Neurobiol. 21:904-919.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/20864052/" class="color--orange weight-bold base" target="_blank">Mackenzie, I.R. et al.</a> (2010) TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 9:995-1007.                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                                                                    </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
)
</div>                                        <div id="med-slot-5-1831" class="phase-2 slot-5 not_Ionis partner-Biogen pipeline-medicines__item showme" data-phase="phase-2">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>IONIS-MAPT<sup></sup><sub>Rx*</sub></strong></div>
                                                                                                    <div>(TAU)</div>
                                                                                                    <div>Alzheimer's Disease &amp; Frontotemporal Degeneration</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">Biogen</div>
                                                                                                                                                                                <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="2" style="background-color: #ceda1e">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #ceda1e"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2<sup>+</sup><br>
</small></p>
<p>IONIS-MAPT<sub>Rx</sub>, also known as BIIB080, is an investigational antisense medicine designed to selectively reduce production of the tau protein in the brain. Microtubule-associated protein tau (MAPT) or tau, is thought to be a contributor or cause of certain neurodegenerative diseases, known as tauopathies, that are characterized by the deposition of abnormal tau protein in neurons and glia in the brain. These disorders include Alzheimer’s disease (AD), Progressive Supranuclear Palsy (PSP), and some forms of frontotemporal degeneration (FTD).</p>
<p><strong>About Alzheimer’s Disease (AD)</strong></p>
<p>It is estimated that in the U.S., 10% of people age 65 and older is living with dementia. Alzheimer’s disease (AD) is the most common form of dementia, accounting for an estimated 70% of cases. AD is a neurodegenerative disorder characterized by cognitive decline and behavioral disturbances that eventually result in a person’s inability to perform daily activities. AD relentlessly progresses to death over 5-20 years. Unlike amyloid deposits that appear diffusely throughout the brain for up to 20 years before the onset of AD, tau deposits are temporally and spatially closely-related to where brain atrophy occurs and cognitive deficits originate.</p>
<p><strong>About Frontotemporal Degeneration</strong></p>
<p>Frontotemporal degeneration (FTD) is a rare form of dementia resulting from neuronal damage in parts of the brain called the frontal and temporal lobes. As neurons die in these regions, these lobes atrophy. FTD typically occurs between the ages of 45 and 64 years old, with patients surviving approximately 9 years from diagnosis. In the early stages of the disease, patients experience substantial personality and social behavior changes, including apathy, loss of empathy, emotional bluntness, impulsiveness, poor judgment, communication impairment, among others. Death is typically the result of disease progression leading to pneumonia, failure to thrive, or cardiopulmonary failure.</p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="http://stm.sciencemag.org/content/9/374/eaag0481" class="color--orange weight-bold base" target="_blank">DeVos, S.L. et al.</a> (2017) Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci. Trans. Med. 9, 374.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://www.ncbi.nlm.nih.gov/pubmed/23904623" class="color--orange weight-bold base" target="_blank">DeVos, S.L. et al.</a> (2013) Antisense reduction of tau in adult mice protects against seizures. J. Neurosci. 33:12887.                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                    <p class="pipeline-footnote"><small><sup>*</sup>This investigational antisense medicine is in a Phase 1/2 study. The primary purpose of the study is the evaluation of the medicine’s safety profile. <u>It is listed here in Phase 2 because the medicine is being tested in patients and not healthy volunteers</u>. This study may be categorized by partners or on regulatory sites, such as <a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>, as a Phase 1 study.</small></p>                                                </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
)
</div>                                        <div id="med-slot-5-1920" class="phase-2 slot-5 not_Ionis partner-Biogen pipeline-medicines__item showme" data-phase="phase-2">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>ION859<sup></sup><sub></sub></strong></div>
                                                                                                    <div>(LRRK2)</div>
                                                                                                    <div>Parkinson's Disease</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">Biogen</div>
                                                                                                                                                                                <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="2" style="background-color: #ceda1e">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #ceda1e"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2<sup>+</sup><br>
</small></p>
<p>ION859 (formerly IONIS-BIIB7<sub>Rx</sub>), also known as BIIB094, is an investigational antisense medicine targeting Leucine Rich Repeat Kinase 2 (LRRK2) messenger ribonucleic acid (mRNA). ION859 is designed to prevent the production of LRRK2 protein and is being developed as a potential therapy for Parkinson’s disease (PD). The most common genetic mutations in PD cases are found in the LRRK2 gene. Increased LRRK2 protein activity is hypothesized to be one of the key drivers of PD pathogenesis. It is hypothesized that reduction of LRRK2 mRNA and, subsequently, reduced synthesis of LRRK2 protein will ameliorate the toxic effects of gain-of-function mutations as well as the primary pathology in PD patients without the LRRK2 mutation.</p>
<p><b>About Parkinson’s Disease</b><br>
Parkinson’s disease is a progressive neurodegenerative disease characterized by loss of neurons in the motor system. Patient’s with Parkinson’s disease can experience tremors, loss of balance and coordination, stiffness, slowing of movement, changes in speech and in some cases cognitive decline. Parkinson’s disease is ultimately fatal. There are treatments that can relieve symptoms, but there is no disease modifying therapy. The exact cause is unknown, but it is believed to be a combination of genetics and environmental factors. There are known hereditary mutations that cause Parkinson’s disease, including dominantly inherited gain-of-function mutations in the LRRK2 gene.</p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="https://www.ncbi.nlm.nih.gov/pubmed/28918051" class="color--orange weight-bold base" target="_blank">Zhao, H.T. et al.</a> (2017). LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model. Molecular Therapy - Nucleic Acids 8, 508-519                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://www.ncbi.nlm.nih.gov/pubmed/21088684" class="color--orange weight-bold base" target="_blank">Cookson, M.R.</a> (2010). The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nature reviews Neuroscience 11, 791-797.                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                                                                    </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
)
</div>                                        <div id="med-slot-5-1766" class="phase-2 slot-5 not_Ionis partner-Dynacure pipeline-medicines__item showme" data-phase="phase-2">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>IONIS-DNM2-2.5<sup></sup><sub>Rx*</sub></strong></div>
                                                                                                    <div>(DNM2)</div>
                                                                                                    <div>Centronuclear Myopathy</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">Dynacure</div>
                                                                                                                                                                                <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="2" style="background-color: #ceda1e">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #ceda1e"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2.5<br>
</small></p>
<p>IONIS-DNM2-2.5<sub>Rx&nbsp;</sub>is an investigational antisense medicine designed to reduce the production of Dynamin 2 (DNM2) protein for the treatment of centronuclear myopathy (CNM). CNM is a group of rare congenital myopathies where cell nuclei are abnormally located in the center of the skeletal muscle cells. DNM2 reduction, either by genetic manipulation or antisense oligonucleotide treatment, improves muscle mass and muscle force in mouse models of main forms of CNM, and extends lifespan in the most severe form of CNM.</p>
<p><b>About Centronuclear Myopathy</b></p>
<p>CNM is a group of rare congenital myopathies where cell nuclei are abnormally located in the center of the skeletal muscle cells. Clinical features include muscle weakness, hypotonia and muscle atrophy, ranging from severe to mild. There are three main forms of CNM. X-linked CNM (XL-CNM, also known as myotubular myopathy) is a life-threatening form of CNM with a neonatal disease onset caused by mutations in myotubularin (MTM1); autosomal recessive CNM (AR-CNM) is a less severe form with a neonatal to childhood onset caused by mutations in amphiphysin 2 (BIN1); autosomal dominant CNM (AD-CNM) is a mild form of CNM with likely an adulthood onset due to mutations in dynamin 2 (DNM2). Estimated incidence of XL-CNM is 1 in 50,000 male live births. AR-CNM and AD-CNM may have similar incidence, but prevalence is higher due to longer survival.</p>
<p><b>Select Publications</b></p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/30291191" target="_blank" rel="noopener noreferrer">Buono, S. et al.</a> “Reducing dynamin 2 (DNM2) rescues DNM2-related dominant centronuclear myopathy” Proc Natl Acad Sci U S A.&nbsp;2018 Oct 23;115(43):11066-11071. Epub 2018 Oct 5.</p>
<p><a href="https://www.nature.com/articles/ncomms15661" target="_blank" rel="noopener noreferrer">Tasfaout, H. et al.</a> “Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice” Nature Communications volume 8, Article number: 15661 (2017).</p>
<p><em>Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</em></p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                    <p class="pipeline-footnote"><small><sup>*</sup>This investigational antisense medicine is in a Phase 1/2 study. The primary purpose of the study is the evaluation of the medicine’s safety profile. <u>It is listed here in Phase 2 because the medicine is being tested in patients and not healthy volunteers</u>. This study may be categorized by partners or on regulatory sites, such as <a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>, as a Phase 1 study.</small></p>                                                </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
)
</div>                                        <div id="med-slot-5-1919" class="phase-2 slot-5 not_Ionis partner-Biogen pipeline-medicines__item showme" data-phase="phase-2">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>ION464<sup></sup><sub></sub></strong></div>
                                                                                                    <div>(SNCA)</div>
                                                                                                    <div>Multiple System Atrophy &amp; Parkinson's Disease</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">Biogen</div>
                                                                                                                                                                                <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="2" style="background-color: #ceda1e">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #ceda1e"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2<sup>+</sup><br>
</small></p>
<p class="p1">ION464 (formerly IONIS-BIIB6<sub>Rx)</sub>, also known as BIIB101, is an investigational antisense medicine targeting alpha-synuclein (SNCA) messenger ribonucleic acid (mRNA). ION464 is designed to prevent the production of alpha-synuclein protein and is being developed as a potential therapy for Parkinson’s disease (PD), Multiple System Atrophy (MSA) and related synucleinopathies. Alpha-synuclein protein aberrantly accumulates in the brains of PD and MSA patients and is thought to be one of the key drivers of pathogenesis. It is hypothesized that reduction of SNCA mRNA and, subsequently, reduced synthesis of alpha-synuclein protein will ameliorate the toxic effects of gain-of-function mutations as well as the primary pathology in PD and MSA patients without SNCA mutations.</p>
<p><strong>About Parkinson’s Disease</strong></p>
<p>Parkinson’s disease (PD) is a progressive neurodegenerative disease characterized by loss of neurons in the motor system. Patient’s with PD can experience tremors, loss of balance and coordination, stiffness, slowing of movement, changes in speech and in some cases cognitive decline. PD is ultimately fatal. There are treatments that can relieve symptoms, but there is no disease modifying therapy.&nbsp; The exact cause is unknown, but it is believed to be a combination of genetics and environmental factors. There are known hereditary mutations that cause PD, including dominantly inherited mutations in the SNCA gene.</p>
<p><strong>About Multiple System Atrophy</strong></p>
<p>Multiple System Atrophy (MSA) is a rare, fatal, rapidly progressing neurodegenerative disease. Patients with MSA typically experience progressive motor dysfunction, with death often occurring less than 10 years after symptom onset. Symptoms in MSA can be similar to Parkinson’s disease, but can also include ataxia, autonomic changes and vision disturbances. Aberrant accumulation of alpha-synuclein in MSA is unique in that it is prominent not only in neurons, but also in glia cells, the supporting cells in the brain.</p>
<p><b>Clinical Trials Posting</b></p>
<p><a href="https://clinicaltrials.gov/ct2/show/NCT04165486" target="_blank" rel="noopener noreferrer">https://clinicaltrials.gov/ct2/show/NCT04165486</a></p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/29273501/" class="color--orange weight-bold base" target="_blank">Cole T.A. et al.</a> (2018) Alpha-synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease. Mol Ther. 26(2):550-567.                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                                                                    </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
)
</div>                                        <div id="med-slot-5-1921" class="phase-2 slot-5 not_Ionis partner-Biogen pipeline-medicines__item showme" data-phase="phase-2">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>ION541*<sup></sup><sub></sub></strong></div>
                                                                                                    <div>(ATXN2)</div>
                                                                                                    <div>Amyotrophic Lateral Sclerosis</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">Biogen</div>
                                                                                                                                                                                <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="2" style="background-color: #ceda1e">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #ceda1e"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2<sup>+</sup><br>
</small></p>
<p>ION541, also known as BIIB105, is an investigational antisense medicine targeting ataxin 2 (ATXN2) RNA. ION541 is designed to reduce the production of ATXN2 protein. It is in development as a potential therapy for patients with most forms of Amyotrophic Lateral Sclerosis (ALS), regardless of family history. Aggregates of TDP-43 protein in motor neurons is a pathology common to more than 90 percent of the ALS population and induces toxicity in motor neurons. ATXN2 has been shown to modulate TDP-43 toxicity<sup>2-3</sup>. In addition, human genetic data has also identified a link between ATXN2 and ALS<sup>4</sup>. It is hypothesized that reduction of ATXN2 will ameliorate the underlying TDP-43 pathology and reverse or prevent disease progression, therefore providing therapeutic benefit to most ALS patients<sup>1</sup>.</p>
<p><strong>About Amyotrophic Lateral Sclerosis</strong></p>
<p>ALS is a rare, fatal neurodegenerative disorder characterized by loss and dysfunction of neurons in motor pathways. It is estimated that there are ~55,000 patients diagnosed with ALS in major markets<sup>1</sup>. Approximately 90 percent of patients with ALS have no known family history, while approximately 10 percent of patients have a known genetic cause for their disease. People with ALS suffer progressive degeneration of motor neurons, which results in a declining quality of life due to muscle weakness, loss of movement and difficulty in breathing and swallowing. Currently, treatment options for patients with ALS are extremely limited with no drugs that significantly slow disease progression.</p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/29470458/" class="color--orange weight-bold base" target="_blank">Mehta, P. et al.</a> (2018) Prevalence of Amyotrophic Lateral Sclerosis — United States, 2014. MMWR Morb Mortal Wkly Rep. 67(7):216–218.                                                                 </li>
                                                                                                                            <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/28405022/" class="color--orange weight-bold base" target="_blank">Becker et al.</a> (2017) Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature 544:367-371.                                                                 </li>
                                                                                                                            <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/17023659/?/" class="color--orange weight-bold base" target="_blank">Neumann et al.</a> (2006) Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Science 314(5796):130-133.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/20740007/" class="color--orange weight-bold base" target="_blank">Elden et al.</a> (2010) Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466:1069-1075.                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                    <p class="pipeline-footnote"><small><sup>*</sup>This investigational antisense medicine is in a Phase 1/2 study. The primary purpose of the study is the evaluation of the medicine’s safety profile. <u>It is listed here in Phase 2 because the medicine is being tested in patients and not healthy volunteers</u>. This study may be categorized by partners or on regulatory sites, such as <a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>, as a Phase 1 study.</small></p>                                                </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
)
</div>                                        <div id="med-slot-5-2389" class="phase-2 slot-5 partner-Ionis-Owned pipeline-medicines__item showme" data-phase="phase-2">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>Zilganersen*<sup></sup><sub></sub></strong></div>
                                                                                                    <div>(GFAP)</div>
                                                                                                    <div>Alexander Disease</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">Ionis-Owned</div>
                                                                                                                                                                                <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="2" style="background-color: #ceda1e">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #ceda1e"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2<sup>+</sup></small></p>
<p>Zilganersen, formerly known as ION373, is an investigational antisense medicine targeting glial fibrillary acidic protein (GFAP) messenger ribonucleic acid (mRNA). Zilganersen is designed to inhibit the production of GFAP and is being developed as a potential therapy for Alexander disease (AxD). Nearly all cases of AxD are caused by gain-of-function mutations in GFAP that lead to spontaneous overproduction and toxic accumulation of GFAP into abnormal protein deposits called Rosenthal fibers in the brain. ASO-mediated reduction of GFAP has the potential to ameliorate the underlying cause of disease pathology and reverse or prevent disease progression.</p>
<p><strong>About Alexander disease</strong></p>
<p>Alexander disease (AxD) is a rare neurological condition characterized as a leukodystrophy, or a disease affecting the myelin sheath (the fatty insulation that protects a nerve fiber and supports signal conduction). Two major types of AxD have been defined. Type I onset typically occurs before 4 years of age and patients can experience head enlargement, seizures, limb stiffness, delayed or declining cognition, and lack of growth. Type II onset typically occurs after the age of 4 and symptoms can include difficulty speaking, swallowing, and making coordinated movements. AxD is most often fatal. There are treatments that can relieve symptoms, but there is no disease modifying therapy yet available to patients.</p>
<p><strong>Clinical trials posting</strong></p>
<p>Not yet posted</p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="https://www.ncbi.nlm.nih.gov/pubmed/29226998" class="color--orange weight-bold base" target="_blank">Hagemann et al.</a> (2018) Antisense suppression of glial fibrillary acidic protein as a treatment for Alexander disease. Annals of Neurology.  83, 27-39.                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                    <p class="pipeline-footnote"><small><sup>*</sup>Zilganersen, formerly known as ION373, is an investigational antisense medicine being evaluated in a two-part pivotal study. In the initial phase of the study, the program status will be listed on our pipeline as Phase 2. Once the second part of the study commences, the program status will be listed as Phase 3. Regulatory sites, such as clinicaltrials.gov, may simply categorize the program as a Phase 3 study.</small></p>                                                </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
)
</div>                                        <div id="med-slot-5-3465" class="phase-2 slot-5 not_Ionis partner-Biogen pipeline-medicines__item showme" data-phase="phase-2">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>ION582*<sup></sup><sub></sub></strong></div>
                                                                                                    <div>(UBE3A-ATS)</div>
                                                                                                    <div>Angelman Syndrome</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">Biogen</div>
                                                                                                                                                                                <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="2" style="background-color: #ceda1e">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #ceda1e"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2<sup>+</sup></small></p>
<p>ION582 is an investigational antisense medicine that targets Ubiquitin Protein Ligase E3A-Antisense Transcript (UBE3A-ATS), which is a long non-coding ribonucleic acid (lncRNA). ION582 reduces the levels of UBE3A-ATS and is being developed as a potential therapy for Angelman Syndrome (AS). Angelman Syndrome is caused by maternal deficiency of the Ubiquitin Protein Ligase E3A (UBE3A). The paternal copy of the UBE3A gene is usually intact but is silenced by the UBE3A-ATS. It has been shown in iPSC neurons derived from AS patients and in an AS mouse model that ASO-mediated suppression of UBE3A-ATS results in UBE3A unsilencing and robust expression of UBE3A mRNA from the paternal allele. ASO-mediated up-regulation of UBE3A mRNA has the potential to restore the levels of UBE3A protein in neurons in patients with AS.</p>
<p><strong>About Angelman syndrome</strong></p>
<p>Angelman syndrome is a rare neurogenetic disorder caused by the loss of function of the maternally inherited UBE3A gene and affects approximately 1 in 15,000 individuals. Angelman syndrome presents early in life with profound and severe developmental delays in motor, language and cognitive functioning, seizures and ataxia. It is a non-degenerative, life-long disorder that generally remains clinically unchanged, resulting in complete dependence on a caregiver throughout their life. Some symptoms can be managed with existing drugs; however, there is no disease modifying therapy.</p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="https://www.ncbi.nlm.nih.gov/pubmed/25470045" class="color--orange weight-bold base" target="_blank">Meng, L. et al.</a> Towards a therapy for Angelman syndrome by targeting a long non-coding RNA. Nature. 2015 Feb 19;518(7539):409-12. doi: 10.1038/nature13975. Epub 2014 Dec 1.                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                    <p class="pipeline-footnote"><small><sup>*</sup>This investigational antisense medicine is in a Phase 1/2 study. The primary purpose of the study is the evaluation of the medicine’s safety profile. It is listed here in Phase 2 because the medicine is being tested in patients and not healthy volunteers. This study may be categorized by partners or on regulatory sites, such as clinicaltrials.gov, as a Phase 1 study.</small></p>                                                </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
)
</div>                                        <div id="med-slot-5-3540" class="phase-1 slot-5 not_Ionis partner-Biogen pipeline-medicines__item showme" data-phase="phase-1">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>ION260<sup></sup><sub></sub></strong></div>
                                                                                                    <div>(ATXN3)</div>
                                                                                                    <div>Spinocerebellar Ataxia Type 3</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">Biogen</div>
                                                                                                                                    <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="1" style="background-color: #ceda1e">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #ceda1e"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2<sup>+</sup>&nbsp;</small></p>
<p>ION260, also known as BIIB132, is an investigational antisense medicine targeting ataxin-3 (<em>ATXN3</em>) messenger ribonucleic acid (mRNA). ION260 is designed to reduce the production of ATXN3 protein. Patients with a trinucleotide repeat expansion in the <em>ATXN3</em> gene develop Spinocerebellar Ataxia Type 3 (SCA3).&nbsp; Preclinical studies have shown that lowering of ATXN3 protein is associated with decreased progression of SCA3-like disease<sup>1</sup>.</p>
<p><strong>About Spinocerebellar Ataxia Type 3</strong></p>
<p>Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease, is a rare, inherited form of ataxia. &nbsp;SCA3 is the most common dominant ataxia, and though prevalence estimates have not been systematically collected, there is likely between 20,000-40,000 patients in major markets<sup>2</sup>. Signs and symptoms typically begin in mid-adulthood, though can arise throughout life. SCA3 is characterized by progressive movement dysfunction. People with this condition initially experience problems with gait, coordination, and balance (ataxia). Other symptoms of SCA3 include speech difficulties (dysarthria), uncontrolled muscle tensing (dystonia), muscle stiffness (spasticity), involuntary eye movements (nystagmus) and tremors.&nbsp;&nbsp; Symptoms progress in SCA3 patients to require wheelchair assistance, and SCA3 is ultimately fatal with patients usually surviving 10 to 20 years after symptom onset.</p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/29908063/" class="color--orange weight-bold base" target="_blank">McLoughlin et al.</a> (2018) Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice. Ann Neurol. 84(1):64-77.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/30975995/" class="color--orange weight-bold base" target="_blank">Klockgether et al.</a> (2019) Spinocerebellar ataxia. Nat Rev Dis Primers. 5(1):24.                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                                                                    </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                        
                                </div>
                            </div>
                                                    <style>
                                .pipeline-section__block:nth-of-type(4) {
                                    background: rgba(26, 34, 40,0.1);
                                }
                                .pipeline-section__block:nth-of-type(4) .pipeline-medicines__item:hover,
                                .pipeline-section__block:nth-of-type(4) .pipeline-medicines__item.active {
                                    background: rgba(26, 34, 40,0.2);
                                }
                            </style>
                            <div id="slot-6" class="pipeline-section__block showme" data-therapeutic-area="slot-6">
                                <h4 class="color--secondary">Infectious Disease</h4>
                                <div class="pipeline-section__block__header">
                                    <div class="pipeline-section__block__header--space"></div>
                                    <div class="pipeline-section__block__header--partner">Partner</div>
                                    <div class="pipeline-section__block__header--phase d-none d-md-block ishidden pcheader">Preclinical</div>                                       
                                        
                                            <div id="drug-hdr-1" class="pipeline-section__block__header--phase d-md-none">P                                        </div>
                                    		                                     <div class="pipeline-section__block__header--phase d-none d-md-block">Phase 1</div>
		                                                                           
                                        
                                            <div id="drug-hdr-2" class="pipeline-section__block__header--phase d-md-none">P1                                        </div>
                                    		                                     <div class="pipeline-section__block__header--phase d-none d-md-block">Phase 2</div>
		                                                                           
                                        
                                            <div id="drug-hdr-3" class="pipeline-section__block__header--phase d-md-none">P2                                        </div>
                                    		                                     <div class="pipeline-section__block__header--phase d-none d-md-block">Phase 3</div>
		                                                                           
                                        
                                            <div id="drug-hdr-4" class="pipeline-section__block__header--phase d-md-none">P3                                        </div>
                                                                           
                                        
                                            <div id="drug-hdr-5" class="pipeline-section__block__header--phase d-md-none">R                                        </div>
                                                                    </div>
                                <div class="pipeline-medicines">
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
)
</div>                                        <div id="med-slot-6-1911" class="phase-2 slot-6 not_Ionis partner-GSK pipeline-medicines__item showme" data-phase="phase-2">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>Bepirovirsen<sup></sup><sub></sub></strong></div>
                                                                                                    <div>(Hepatitis B Infection)</div>
                                                                                                    <div>Hepatitis B Virus Infection</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">GSK</div>
                                                                                                                                                                                <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="2" style="background-color: #1a2228">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #1a2228"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2<sup>+</sup><br>
</small></p>
<p>Bepirovirsen (formerly known as IONIS-HBV<sub>Rx</sub>), also known as GSK3228836, is an investigational antisense medicine designed to reduce the production of viral proteins associated with hepatitis B virus (HBV) infection and replication, including hepatitis B surface antigen, which is present in both acute and chronic infections and is associated with a poor prognosis in patients with chronic HBV infection.</p>
<p><strong>About Hepatitis B virus infection</strong></p>
<p>Hepatitis B virus infection is a serious health problem that can lead to significant and potentially fatal health conditions, including cirrhosis, liver failure and liver cancer. Chronic HBV infection is one of the most common persistent viral infections in the world. Currently available therapies, although effective in reducing circulating HBV in the blood, do not efficiently inhibit HBV antigen production and secretion, which are associated with poor prognosis and increased risk of liver cancer.</p>
<p>&nbsp;</p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="http://www.ncbi.nlm.nih.gov/pubmed/24991538" class="color--orange weight-bold base" target="_blank">Youssef, S.S. et al.&nbsp;</a> (2014) In vitro inhibition of hepatitis C virus by antisense oligonucleotides in PBMC compared to hepatoma cells. Biomed Res Int.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="http://www.ncbi.nlm.nih.gov/pubmed/21484123" class="color--orange weight-bold base" target="_blank">Grimm, D. et al.</a> (2011) HBV life cycle and novel drug targets. Hepatol Int. 5, 644-653.                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                                                                    </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                        
                                </div>
                            </div>
                                                    <style>
                                .pipeline-section__block:nth-of-type(5) {
                                    background: rgba(210, 33, 106,0.1);
                                }
                                .pipeline-section__block:nth-of-type(5) .pipeline-medicines__item:hover,
                                .pipeline-section__block:nth-of-type(5) .pipeline-medicines__item.active {
                                    background: rgba(210, 33, 106,0.2);
                                }
                            </style>
                            <div id="slot-8" class="pipeline-section__block showme" data-therapeutic-area="slot-8">
                                <h4 class="color--secondary">Cancer</h4>
                                <div class="pipeline-section__block__header">
                                    <div class="pipeline-section__block__header--space"></div>
                                    <div class="pipeline-section__block__header--partner">Partner</div>
                                    <div class="pipeline-section__block__header--phase d-none d-md-block ishidden pcheader">Preclinical</div>                                       
                                        
                                            <div id="drug-hdr-1" class="pipeline-section__block__header--phase d-md-none">P                                        </div>
                                    		                                     <div class="pipeline-section__block__header--phase d-none d-md-block">Phase 1</div>
		                                                                           
                                        
                                            <div id="drug-hdr-2" class="pipeline-section__block__header--phase d-md-none">P1                                        </div>
                                    		                                     <div class="pipeline-section__block__header--phase d-none d-md-block">Phase 2</div>
		                                                                           
                                        
                                            <div id="drug-hdr-3" class="pipeline-section__block__header--phase d-md-none">P2                                        </div>
                                    		                                     <div class="pipeline-section__block__header--phase d-none d-md-block">Phase 3</div>
		                                                                           
                                        
                                            <div id="drug-hdr-4" class="pipeline-section__block__header--phase d-md-none">P3                                        </div>
                                                                           
                                        
                                            <div id="drug-hdr-5" class="pipeline-section__block__header--phase d-md-none">R                                        </div>
                                                                    </div>
                                <div class="pipeline-medicines">
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
)
</div>                                        <div id="med-slot-8-1902" class="phase-2 slot-8 not_Ionis partner-Flamingo<div style='margin-top:10px;'>Suzhou-Ribo<sup>*</sup></div><small><sup>*</sup>China only</small> pipeline-medicines__item showme" data-phase="phase-2">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>IONIS-AR-2.5<sup></sup><sub>Rx</sub></strong></div>
                                                                                                    <div>(AR)</div>
                                                                                                    <div>Prostate Cancer</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">Flamingo<div style="margin-top:10px;">Suzhou-Ribo<sup>*</sup></div><small><sup>*</sup>China only</small></div>
                                                                                                                                                                                <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="2" style="background-color: #d2216a">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #d2216a"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2.5<br>
</small></p>
<p>IONIS-AR-2.5<sub>Rx</sub>, formerly known as AZD5312, is an investigational antisense medicine designed to reduce the production of all known forms of androgen receptor, or AR, including variants of the AR gene, to treat patients with prostate cancer. Prostate cancer growth, proliferation and progression are all androgen-dependent, and AR function is involved in disease progression at all stages of prostate cancer. For patients diagnosed with metastatic prostate cancer, current treatments largely involve opposing the action of androgens by blocking the androgen receptor or removing circulating androgens.</p>
<p><strong>About Prostate Cancer</strong></p>
<p>Prostate cancer is the second leading cause of cancer deaths in American men, with approximately 30,000 deaths each year in the United States. For patients diagnosed with metastatic prostate cancer, current treatments largely involve opposing the action of androgens by blocking the androgen receptor or removing circulating androgens. Although androgen deprivation therapy approaches are initially effective in delaying disease progression in patients with metastatic prostate cancer, over time the course of the disease will progress in many of these patients. Resistance to current therapies is frequent and can occur through a variety of mechanisms including the activation of AR signaling in tumor cells through the amplification, overexpression and mutation of the AR gene.</p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="http://www.ncbi.nlm.nih.gov/pubmed/24425228" class="color--orange weight-bold base" target="_blank">Augello, M.A. et al.&nbsp;</a> (2014) AR function in promoting metastatic prostate cancer. Cancer Metastasis Rev. 33, 399-411.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="http://www.ncbi.nlm.nih.gov/pubmed/24837363" class="color--orange weight-bold base" target="_blank">Feraldeschi, R. et al.&nbsp;</a> (2014) Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene. Epub ahead of print.                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                                                                    </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
)
</div>                                        <div id="med-slot-8-1908" class="phase-2 slot-8 not_Ionis partner-Flamingo pipeline-medicines__item showme" data-phase="phase-2">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>Danvatirsen<sup></sup><sub></sub></strong></div>
                                                                                                    <div>(STAT3)</div>
                                                                                                    <div>Cancer</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">Flamingo</div>
                                                                                                                                                                                <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="2" style="background-color: #d2216a">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #d2216a"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2.5<br>
</small></p>
<p>Danvatirsen, formerly known as IONIS-STAT3-2.5<sub>Rx </sub> and AZD9150, is an investigational antisense medicine designed to reduce the production of signal transducer and activator of transcription 3, or STAT3, for the treatment of patients with cancer. STAT3 is a protein involved in the translation of key factors critical for tumor cell growth and survival. STAT3 is over-active in a variety of cancers, including brain, lung, breast, bone, liver and multiple myeloma. Overactivity in STAT3 is believed to prevent cell death and promote tumor cell growth.</p>
<p><strong>About STAT3 and Cancer</strong></p>
<p>STAT3, or signal transducer and activator of transcription 3, is an important mediator of signaling in the JAK2/STAT3 pathway. Mutations in STAT3 and other regulatory genes could result in constitutively active STAT3. Numerous studies have demonstrated constitutive STAT3 activation promotes tumor cell growth and survival. Indeed, activated STAT3 are present in a wide variety of human tumors, including hematological malignancies (leukemia, lymphomas, and multiple myeloma) as well as diverse solid tumors (head and neck, breast, lung, gastric, hepatocellular, colorectal and prostate cancer).</p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="http://www.ncbi.nlm.nih.gov/pubmed/24388873" class="color--orange weight-bold base" target="_blank">Siveen, K.S. et al.&nbsp;</a> (2014) Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. Biochim Biophys Acta. 1845, 136-154.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="http://www.ncbi.nlm.nih.gov/pubmed/23692080" class="color--orange weight-bold base" target="_blank">Burel, S.A. et al.</a> (2013) Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys. Nucleic Acid Ther. 23, 213-227.                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                                                                    </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
)
</div>                                        <div id="med-slot-8-1775" class="phase-2 slot-8 not_Ionis partner-AstraZeneca pipeline-medicines__item showme" data-phase="phase-2">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>ION736*<sup></sup><sub></sub></strong></div>
                                                                                                    <div>(FOXP3)</div>
                                                                                                    <div>Cancer</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">AstraZeneca</div>
                                                                                                                                                                                <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="2" style="background-color: #d2216a">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #d2216a"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2.5<br>
</small></p>
<p>ION736 (formerly IONIS-AZ7-2.5<sub>Rx</sub>), also known as AZD8701, is an investigational antisense medicine designed to reduce the production of Forkhead Box P3 (FOXP3) for the treatment of patients with cancer. FOXP3 is a protein involved in the function of immuno-suppressive T regulatory cells (Tregs). Tregs, which are found at high levels in various types of cancers, often predict poor survival and poor response to immune checkpoint therapeutics. Preclinical studies have demonstrated that FOXP3 downregulation resulted in an increased immune response and anti-tumor activity. Moreover, the combination of antisense inhibition of FOXP3 with other immune-oncology drugs led to enhanced anti-tumor activity.</p>
<p><em>Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</em></p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                    <p class="pipeline-footnote"><small><sup>*</sup>This investigational antisense medicine is in a Phase 1/2 study. The primary purpose of the study is the evaluation of the medicine’s safety profile. <u>It is listed here in Phase 2 because the medicine is being tested in patients and not healthy volunteers</u>. This study may be categorized by partners or on regulatory sites, such as <a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>, as a Phase 1 study.</small></p>                                                </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
)
</div>                                        <div id="med-slot-8-1769" class="phase-1 slot-8 not_Ionis partner-Flamingo pipeline-medicines__item showme" data-phase="phase-1">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>Frenlosirsen<sup></sup><sub></sub></strong></div>
                                                                                                    <div>(IRF4)</div>
                                                                                                    <div>Multiple Myeloma</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">Flamingo</div>
                                                                                                                                    <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="1" style="background-color: #d2216a">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #d2216a"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2.5</small></p>
<p class="p1">Frenlosirsen, formerly known as ION251 and IONIS-IRF4-2.5<sub>Rx</sub>, is an investigational antisense medicine.</p>
<p class="p1">Interferon Regulatory Factor 4 (IRF4) is a transcription factor expressed in lymphocytes, where it directs terminal differentiation of B-cells to plasma cells and also has roles in T cell functions such as T cell exhaustion. IRF4 has emerged as a key regulator of multiple genes controlling the survival of multiple myeloma (MM) tumor cells as well as other B-cell malignancies. IRF4 is overexpressed in MM as a result of several mechanisms including activating mutations in the DNA binding domain and translocations. Even limited depletion of IRF4 leads to rapid cell death of MM tumor cells, and as such MM is considered to be “addicted” to IRF4. Taken together, selective inhibition of IRF4 with a therapeutic antisense oligonucleotides (ASO) is an attractive strategy for the treatment of MM with the potential for potent MM cell kill with limited effects on normal cells.​</p>
<p><strong>About Multiple Myeloma</strong></p>
<p>Multiple Myeloma (MM) is an incurable cancer characterized by uncontrolled proliferation of bone marrow plasma cells. Despite their initial responses to current therapies, almost all MM patients eventually relapse with a median overall survival time of 13 months following relapse, presenting a strong need for new treatments. Interferon Regulatory Factor 4 (IRF4) is a transcription factor involved in immune cell development and is essential for plasma cell differentiation. IRF4 has emerged as a key regulator of multiple genes controlling the survival of MM and other B-cell malignancy such as c-Myc and is aberrantly expressed in MM as a result of activating mutations and translocations.</p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/18568025/" class="color--orange weight-bold base" target="_blank">Shaffer, A.L. et al.</a> IRF4 addiction in multiple myeloma. Nature 2008;454:226-31.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/8999800/" class="color--orange weight-bold base" target="_blank">Mittrucker, H.W. et al.</a> Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science 1997;275:540-3.                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                                                                    </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
)
</div>                                        <div id="med-slot-8-2391" class="phase-1 slot-8 not_Ionis partner-MD Anderson pipeline-medicines__item showme" data-phase="phase-1">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>ION537<sup></sup><sub></sub></strong></div>
                                                                                                    <div>(YAP1)</div>
                                                                                                    <div>Cancer</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">MD Anderson</div>
                                                                                                                                    <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="1" style="background-color: #d2216a">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #d2216a"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2.5</small></p>
<p>ION537 is an investigational antisense medicine designed to reduce the production of yes-associated protein 1 (YAP1) to treat patients with cancer. YAP1 is a transcription factor that preclinical studies have shown to be critical in certain hepatocellular and head and neck cancers. YAP1 acts as a transcriptional regulator by activating the transcription of genes involved in cell proliferation and suppressing apoptotic genes.</p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/27300434/" class="color--orange weight-bold base" target="_blank">Zanconato, F. et al.</a> (2016) YAP/TAZ at the Roots of Cancer. Cancer Cell. 29(6):783-803.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/25665005/" class="color--orange weight-bold base" target="_blank">Lin, L. et al.</a> (2015) The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet. 47(3):250-256.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="" class="color--orange weight-bold base" target="_blank">Xu, M.Z. et al.</a> (2009) Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer. 115:4576-4585.                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                                                                    </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                        
                                </div>
                            </div>
                                                    <style>
                                .pipeline-section__block:nth-of-type(6) {
                                    background: rgba(236, 111, 35,0.1);
                                }
                                .pipeline-section__block:nth-of-type(6) .pipeline-medicines__item:hover,
                                .pipeline-section__block:nth-of-type(6) .pipeline-medicines__item.active {
                                    background: rgba(236, 111, 35,0.2);
                                }
                            </style>
                            <div id="slot-9" class="pipeline-section__block showme" data-therapeutic-area="slot-9">
                                <h4 class="color--secondary">Ophthalmology</h4>
                                <div class="pipeline-section__block__header">
                                    <div class="pipeline-section__block__header--space"></div>
                                    <div class="pipeline-section__block__header--partner">Partner</div>
                                    <div class="pipeline-section__block__header--phase d-none d-md-block ishidden pcheader">Preclinical</div>                                       
                                        
                                            <div id="drug-hdr-1" class="pipeline-section__block__header--phase d-md-none">P                                        </div>
                                    		                                     <div class="pipeline-section__block__header--phase d-none d-md-block">Phase 1</div>
		                                                                           
                                        
                                            <div id="drug-hdr-2" class="pipeline-section__block__header--phase d-md-none">P1                                        </div>
                                    		                                     <div class="pipeline-section__block__header--phase d-none d-md-block">Phase 2</div>
		                                                                           
                                        
                                            <div id="drug-hdr-3" class="pipeline-section__block__header--phase d-md-none">P2                                        </div>
                                    		                                     <div class="pipeline-section__block__header--phase d-none d-md-block">Phase 3</div>
		                                                                           
                                        
                                            <div id="drug-hdr-4" class="pipeline-section__block__header--phase d-md-none">P3                                        </div>
                                                                           
                                        
                                            <div id="drug-hdr-5" class="pipeline-section__block__header--phase d-md-none">R                                        </div>
                                                                    </div>
                                <div class="pipeline-medicines">
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
)
</div>                                        <div id="med-slot-9-1777" class="phase-2 slot-9 not_Ionis partner-Roche pipeline-medicines__item showme" data-phase="phase-2">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>IONIS-FB-L<sup></sup><sub>Rx</sub></strong></div>
                                                                                                    <div>(Complement Factor B)</div>
                                                                                                    <div>Geographic Atrophy/AMD</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">Roche</div>
                                                                                                                                                                                <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="2" style="background-color: #ec6f23">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #ec6f23"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2<sup>+</sup> LICA<br>
</small></p>
<p class="p1">IONIS-FB-L<sub>Rx </sub>is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of complement factor B (FB). Genetic association studies have shown that overaction of this cascade has been associated with the development of several complement-mediated diseases, including dry age-related macular degeneration (AMD). FB, a key regulatory protein, is produced predominately in the liver and circulates at high levels throughout the vascular system, including in capillaries in the eye. <sup>1-5</sup></p>
<p><strong>About AMD</strong></p>
<p>AMD is the leading cause of central vision loss in developed countries. It is estimated that more than three million people in the United States will be affected by the disease by 2030.<sup>6</sup> AMD is believed to be a systemic disease with local disease manifestation at the aging retinal macula. AMD gradually destroys vision in the center of the visual field due to progressive damage of the retina.<sup>7</sup></p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="http://iovs.arvojournals.org/article.aspx?articleid=2563167" class="color--orange weight-bold base" target="_blank">Grossman et al.</a> (2017) Reduction in Ocular Complement Factor B Protein in Mice and Monkeys by Systemic Administration of Factor B Antisense Oligonucleotide. Mol Vision. 23: 561-571.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="http://www.molvis.org/molvis/v18/a243/mv-v18-a243-silva.pdf" class="color--orange weight-bold base" target="_blank">Silva, A.S. et al.</a> (2012) Plasma levels of complement proteins from the alternative pathway in patients with age-related macular degeneration are independent of Complement Factor H Tyr402His polymorphism. Mol Vision. 18: 2288-2299. Koskimies et al. Complement In_amm. 1991;8(5-6):257-60.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="http://iovs.arvojournals.org/article.aspx?articleid=2127979" class="color--orange weight-bold base" target="_blank">Loyet et al.</a> (2012) Activation of the alternative complement pathway in vitreous is controlled by genetics in age-related macular degeneration. IOVS. 53(10): 6628-6637.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/32310222/" class="color--orange weight-bold base" target="_blank">Gavrillaki, E. and Brodsky, R.A.</a> (2020) Complementopathies and precision medicine. J Clin Invest. 130(5):2152-2163.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="http://www.nature.com/ng/journal/v38/n4/abs/ng1750.html" class="color--orange weight-bold base" target="_blank">Gold et al.</a> (2006) Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nature Genetics. 38:458-462.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://www.nei.nih.gov/learn-about-eye-health/resources-for-health-educators/eye-health-data-and-statistics/age-related-macular-degeneration-amd-data-and-statistics" class="color--orange weight-bold base" target="_blank">Age-Related Macular Degeneration (AMD) Data and Statistics</a>                                                                 </li>
                                                                                                                            <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/30060980/" class="color--orange weight-bold base" target="_blank">Keenan T.D., et al.</a> (2018) Progression of Geographic Atrophy in Age-related Macular Degeneration: AREDS2 Report Number 16. Ophthalmology. 125(12):1913-1928.                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                                                                    </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                        
                                </div>
                            </div>
                                                    <style>
                                .pipeline-section__block:nth-of-type(7) {
                                    background: rgba(206, 218, 30,0.1);
                                }
                                .pipeline-section__block:nth-of-type(7) .pipeline-medicines__item:hover,
                                .pipeline-section__block:nth-of-type(7) .pipeline-medicines__item.active {
                                    background: rgba(206, 218, 30,0.2);
                                }
                            </style>
                            <div id="slot-10" class="pipeline-section__block showme" data-therapeutic-area="slot-10">
                                <h4 class="color--secondary">Pulmonology &amp; Allergy</h4>
                                <div class="pipeline-section__block__header">
                                    <div class="pipeline-section__block__header--space"></div>
                                    <div class="pipeline-section__block__header--partner">Partner</div>
                                    <div class="pipeline-section__block__header--phase d-none d-md-block ishidden pcheader">Preclinical</div>                                       
                                        
                                            <div id="drug-hdr-1" class="pipeline-section__block__header--phase d-md-none">P                                        </div>
                                    		                                     <div class="pipeline-section__block__header--phase d-none d-md-block">Phase 1</div>
		                                                                           
                                        
                                            <div id="drug-hdr-2" class="pipeline-section__block__header--phase d-md-none">P1                                        </div>
                                    		                                     <div class="pipeline-section__block__header--phase d-none d-md-block">Phase 2</div>
		                                                                           
                                        
                                            <div id="drug-hdr-3" class="pipeline-section__block__header--phase d-md-none">P2                                        </div>
                                    		                                     <div class="pipeline-section__block__header--phase d-none d-md-block">Phase 3</div>
		                                                                           
                                        
                                            <div id="drug-hdr-4" class="pipeline-section__block__header--phase d-md-none">P3                                        </div>
                                                                           
                                        
                                            <div id="drug-hdr-5" class="pipeline-section__block__header--phase d-md-none">R                                        </div>
                                                                    </div>
                                <div class="pipeline-medicines">
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
    [0] =&gt; rare
)
</div>                                        <div id="med-slot-10-1865" class="phase-3 slot-10 partner-Ionis-Owned rareDisease pipeline-medicines__item showme" data-phase="phase-3">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>Donidalorsen<sup></sup><sub></sub></strong></div>
                                                                                                    <div>(PKK)</div>
                                                                                                    <div>Hereditary Angioedema</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">Ionis-Owned</div>
                                                                                                                                                                                                                            <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="3" style="background-color: #ceda1e">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #ceda1e"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2<sup>+</sup> LICA<br>
</small></p>
<p class="p1"><span class="s1">Donidalorsen, formerly known as&nbsp;</span>IONIS-PKK-L<sub>Rx</sub>, is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of prekallikrein, or PKK, to treat patients with hereditary angioedema, or HAE. PKK plays an important role in the activation of inflammatory mediators associated with acute attacks of HAE. HAE is a rare genetic disease characterized by rapid and painful attacks of inflammation in the hands, feet, limbs, face, abdomen, larynx and trachea. HAE can be fatal if swelling occurs in the larynx. In patients with frequent or severe attacks, doctors may use prophylactic treatment approaches to prevent and reduce the severity of HAE attacks. However, current prophylactic treatment approaches are very limited and have major tolerability issues due to challenging administration requirements leaving patients with few therapeutic options.</p>
<p><strong>About Hereditary Angioedema</strong></p>
<p>HAE is a rare genetic disease that is characterized by rapid and painful attacks of inflammation in the hands, feet, limbs, face, abdomen, larynx and trachea. HAE affects approximately 20,000 patients in the United States and Europe and can be fatal if swelling occurs in the larynx. In patients with frequent or severe attacks, doctors may use prophylactic treatment approaches to prevent and reduce the severity of HAE attacks. However, current prophylactic treatment approaches are very limited and have major tolerability issues due to challenging administration requirements leaving patients with few therapeutic options.</p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="http://www.ncbi.nlm.nih.gov/pubmed/23582057" class="color--orange weight-bold base" target="_blank">Bhattacharjee, G. et al.&nbsp;</a> (2013) Inhibition of vascular permeability by antisense-mediated inhibition of plasma kallikrein and coagulation factor 12. Nucleic Acid Ther. 23, 175-187.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="http://www.ncbi.nlm.nih.gov/pubmed/21821705" class="color--orange weight-bold base" target="_blank">Revenko, A.S. et al.&nbsp;</a> (2011) Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood. 118, 5302-5311.                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                                                                    </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                        
                                </div>
                            </div>
                                                    <style>
                                .pipeline-section__block:nth-of-type(8) {
                                    background: rgba(26, 34, 40,0.1);
                                }
                                .pipeline-section__block:nth-of-type(8) .pipeline-medicines__item:hover,
                                .pipeline-section__block:nth-of-type(8) .pipeline-medicines__item.active {
                                    background: rgba(26, 34, 40,0.2);
                                }
                            </style>
                            <div id="slot-12" class="pipeline-section__block showme" data-therapeutic-area="slot-12">
                                <h4 class="color--secondary">Hematology</h4>
                                <div class="pipeline-section__block__header">
                                    <div class="pipeline-section__block__header--space"></div>
                                    <div class="pipeline-section__block__header--partner">Partner</div>
                                    <div class="pipeline-section__block__header--phase d-none d-md-block ishidden pcheader">Preclinical</div>                                       
                                        
                                            <div id="drug-hdr-1" class="pipeline-section__block__header--phase d-md-none">P                                        </div>
                                    		                                     <div class="pipeline-section__block__header--phase d-none d-md-block">Phase 1</div>
		                                                                           
                                        
                                            <div id="drug-hdr-2" class="pipeline-section__block__header--phase d-md-none">P1                                        </div>
                                    		                                     <div class="pipeline-section__block__header--phase d-none d-md-block">Phase 2</div>
		                                                                           
                                        
                                            <div id="drug-hdr-3" class="pipeline-section__block__header--phase d-md-none">P2                                        </div>
                                    		                                     <div class="pipeline-section__block__header--phase d-none d-md-block">Phase 3</div>
		                                                                           
                                        
                                            <div id="drug-hdr-4" class="pipeline-section__block__header--phase d-md-none">P3                                        </div>
                                                                           
                                        
                                            <div id="drug-hdr-5" class="pipeline-section__block__header--phase d-md-none">R                                        </div>
                                                                    </div>
                                <div class="pipeline-medicines">
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
    [0] =&gt; rare
)
</div>                                        <div id="med-slot-12-1866" class="phase-2 slot-12 partner-Ionis-Owned rareDisease pipeline-medicines__item showme" data-phase="phase-2">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>Sapablursen<sup></sup><sub></sub></strong></div>
                                                                                                    <div>(TMPRSS6)</div>
                                                                                                    <div>β-Thalassemia</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">Ionis-Owned</div>
                                                                                                                                                                                <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="2" style="background-color: #1a2228">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #1a2228"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2<sup>+</sup> LICA<br>
</small></p>
<p>Sapablursen, formerly known as IONIS-TMPRSS6-L<sub>Rx</sub>, is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of transmembrane protease, serine 6, or TMPRSS6, to treat anemia and iron toxicity in patients with beta-thalassemia; a disease caused by mutations in the beta globin gene. TMPRSS6 is a protein produced in the liver that plays an important role in the regulation of the body’s iron homeostasis through the control of the iron regulatory protein hepcidin. Inhibition of TMPRSS6 leads to increased production of hepcidin, which results in more effective red blood cell production (erythropoiesis) in the bone marrow and reduced iron toxicity in the liver as a result of improved control of iron availability. Results from preclinical and clinical studies suggest that reducing levels of TMPRSS6 may be an effective strategy to control iron availability, improve liver iron toxicity and increase red blood cell production under conditions of beta-thalassemia.</p>
<p><strong>About Beta-thalassemia</strong></p>
<p>Beta-thalassemia is an inherited blood disorder caused by a genetic mutation in the beta globin gene resulting in defective red blood cell production. Patients with beta-thalassemia can experience severe anemia, splenomegaly, marrow expansion, bone deformities, as well as iron toxicity. While the severity of anemia varies between patients, iron toxicity is a common complication leading to high rates of mortality as a result of iron accumulation in major organs, such as the heart and liver. Currently there are no effective therapies for patients with beta-thalassemia. The current standard of care is managing patients’ symptoms with blood transfusions, hydroxyurea, iron chelation and splenectomy.</p>
<p>Beta-thalassemia can be further subdivided into patients with transfusion-dependent thalassemia (TDT) and non-transfusion dependent thalassemia (NTDT), such as beta-thalassemia intermedia. Although transfusions are not needed to support life in patients with NTDT, the associated complications of the disease are severe and often fatal.</p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="https://www.ncbi.nlm.nih.gov/pubmed/23524968" class="color--orange weight-bold base" target="_blank">Guo, S. et al.</a> (2013) Reducing TMPRSS6 ameliorates hemochromatosis and ?-thalassemia in mice. J Clin Invest. 123(4):1531-41.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://jci.org/articles/view/68889" class="color--orange weight-bold base" target="_blank">Finberg, K.E.</a> (2013) Striking the target in iron overload disorders. J Clin Invest. 123:1424-1427.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="http://www.nejm.org/doi/full/10.1056/NEJMcibr1304338?query=featured_hematology-oncology&amp;" class="color--orange weight-bold base" target="_blank">Camaschella, C.</a> (2013) Treating Iron Overload. N Engl J Med 2013; 368:2325-2327.                                                                </li>
                                                                                                                            <li>
                                                                    <a href="http://www.haematologica.org/content/98/6/833" class="color--orange weight-bold base" target="_blank">Musallam, K.M. et al.</a> (2013) Non-Transfusion-Dependent Thalassemias. Haematologica. June 2013; 98:833-44.                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                                                                    </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                            <div class="med_cont">
	                                        <div style="display:none;">xArray
(
)
</div>                                        <div id="med-slot-12-3506" class="phase-2 slot-12 partner-Ionis-Owned pipeline-medicines__item showme" data-phase="phase-2">
                                            <div class="pipeline-medicines__item__name">
	                                                                                            <div><strong>Sapablursen<sup></sup><sub></sub></strong></div>
                                                                                                    <div>(TMPRSS6 )</div>
                                                                                                    <div>Polycythemia Vera</div>
                                                                                            </div>
                                            <div class="pipeline-medicines__item__partner">Ionis-Owned</div>
                                                                                                                                                                                <div class="pipeline-medicines__item__phase">                                                <div class="pipeline-medicines__item__chart visible" data-phase-length="2" style="background-color: #1a2228">
                                                    <span class="pipeline-medicines__item__chart--arrow" style="border-left-color: #1a2228"></span>
                                                </div>
                                            </div>
                                        </div>
                                        
                                                                                    <div class="pipeline-medicines__details">
                                                <div class="pipeline-medicines__details__content">
                                                    <p><small>Chemistry: Generation 2<sup>+</sup> LICA<br>
</small></p>
<p>Sapablursen, formerly known as IONIS-TMPRSS6-L<sub>Rx</sub>, is a ligand-conjugated (LICA) <span class="normaltextrun">investigational antisense medicine designed to reduce the production of transmembrane protease, serine 6, or TMPRSS6, in patients with polycythemia vera. Polycythemia vera is caused by a mutation in the JAK2 gene and results in excessive production of red blood cells. TMPRSS6 is a protein produced in the liver that plays an important role in the production of the iron regulatory hormone hepcidin. Hepcidin reduces iron absorption from the gut and reduces iron re-cycling in the body. Overall, increased hepcidin production reduces the number of red blood cells that are produced and represents a novel treatment strategy for polycythemia vera. Results from preclinical studies confirm that sapablursen controls excessive red blood cell production in a model of polycythemia vera.</span><span class="eop">&nbsp;</span></p>
<p class="paragraph"><span class="normaltextrun"><b>About Polycythemia Vera&nbsp;</b></span><span class="eop">&nbsp;</span></p>
<p class="paragraph"><span class="normaltextrun">Polycythemia vera (PV) is a type of chronic blood cancer characterized by excessive production of blood cells in the bone marrow, primarily red blood cells. Affected individuals may also have excess white blood cells and excess blood clotting cells called platelets. These extra cells cause the blood to be thicker than normal. As a result, abnormal blood clots are more likely to form and block the flow of blood through arteries and veins. Individuals with PV have an increased risk of deep vein thrombosis, a type of blood clot that occurs in the deep veins of the arms or legs. If a blood clot travels through the bloodstream and lodges in the lungs, it can cause a life-threatening clot known as a pulmonary embolism. Affected individuals also have an increased risk of heart attack and stroke caused by blood clots in the heart and brain blood vessels.</span><span class="eop">&nbsp;</span></p>
<p class="paragraph"><span class="normaltextrun">PV typically develops in adulthood, around age 60, although it may occur in younger individuals. This condition may not cause any symptoms in its early stages. Some people with PV experience headaches, fatigue, dizziness, ringing in the ears, impaired vision, night sweats, and red or itchy skin, especially after warm showers. Other complications of PV include an enlarged spleen, stomach ulcers, gout, heart disease, and progression into a more aggressive cancer like leukemia.</span><span class="eop">&nbsp;</span></p>
<p class="paragraph"><span class="eop">&nbsp;</span><span class="normaltextrun">The prevalence of PV varies worldwide. The condition affects approximately 160,000 people in the United States. For unknown reasons, men develop PV more frequently than women. In the majority of PV cases, a specific genetic variant known as a JAK2 mutation can be found, which can be used to identify and confirm the disease.</span><span class="eop">&nbsp;</span></p>
                                                </div>
                                                <div class="pipeline-medicines__details__publications">
                                                                                                            <strong>Select Publications</strong>
                                                        <ol style="overflow:hidden;margin-bottom:0;">
                                                            <div class="togglePub">                                                                <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/34890402/" class="color--orange weight-bold base" target="_blank">Casu, C. et al.</a> (2021) Tmprss6-ASO as a tool for the treatment of Polycythemia Vera mice. PLoS One. 16(12):e0251995                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665926/" class="color--orange weight-bold base" target="_blank">Guglielmelli, P. et al.</a> (2021) JAK2V617F variant allele frequency &gt;50% identifies patients with polycythemia vera at high risk for venous thrombosis.&nbsp;Blood Cancer J. 11(12):199                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/32974939/" class="color--orange weight-bold base" target="_blank">Tefferi, A., Barbui, T.</a> (2020) Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol.&nbsp;95(12):1599-1613                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/31151982/" class="color--orange weight-bold base" target="_blank">Spivak, J.L.</a> (2019) How I treat polycythemia vera.&nbsp;Blood. 134(4):341-352                                                                </li>
                                                                                                                            <li>
                                                                    <a href="https://pubmed.ncbi.nlm.nih.gov/30042411/" class="color--orange weight-bold base" target="_blank">Ginzburg, Y.Z. et al.</a> (2018) Dysregulated iron metabolism in polycythemia vera: etiology and consequences. Leukemia. 32(10):2105–2116                                                                </li>
                                                                                                                    </div></ol>
                                                        
                                                                                                                <p style="margin-top:12px;font-style:italic;">Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.</p>
                                                                                                    </div>
                                                <a class="pipeline-medicines__details__close color--orange weight-bold base" href="#">Close</a>
                                            </div>
											
                                            
                                                                                </div>
                                                                        
                                </div>
                            </div>
                                        </div>
                <p class="error"></p>
            </div>
        </div>
    </div>
</section>
    <section class="cards-section">
        <div class="container">
            <div class="row">
                                    <div class="card col-md-6">
                                                    <div class="card__image d-none d-md-block" style="background-image: url(https://www.ionispharma.com/wp-content/uploads/2019/04/ionis-innovation-desktop-bootstrap3-1170px_03.jpg);">
                            </div>
                            <div class="card__image d-md-none">
                                <img src="https://www.ionispharma.com/wp-content/uploads/2019/04/ionis-innovation-desktop-bootstrap3-1170px_03.jpg">
                            </div>
                                                <div class="card__content">
                                                            <h4 class="card__content__title">Future-creating, antisense medicines</h4>
                                                            <div class="card__content__text">
                                    Our antisense technology has allowed us to create treatments that disrupt the disease process, may change its course, and we hope make a positive difference in patients' lives.
                                </div>
                                                            <div class="card__content__link">
                                    <a class="link color--white" href="/our-medicines/">Learn about our medicines</a>
                                </div>
                                                    </div>

                    </div>
                                    <div class="card col-md-6">
                                                    <div class="card__image d-none d-md-block" style="background-image: url(https://www.ionispharma.com/wp-content/uploads/2019/04/0002_Group-1-1.jpg);">
                            </div>
                            <div class="card__image d-md-none">
                                <img src="https://www.ionispharma.com/wp-content/uploads/2019/04/0002_Group-1-1.jpg">
                            </div>
                                                <div class="card__content">
                                                            <h4 class="card__content__title">Once in a lifetime breakthroughs again and again</h4>
                                                            <div class="card__content__text">
                                    Meet Chuck. Active throughout his life, hATTR, a rare disease, started to rob him of the things he loved: riding his bicycle, dancing, racing motorcycles, and picking up his grandchildren. Just about to give up, news of a clinical trial renewed his hope.
                                </div>
                                                            <div class="card__content__link">
                                    <a class="link color--white" href="/patients-community/patient-experiences/">See who inspires Ionis</a>
                                </div>
                                                    </div>

                    </div>
                            </div>
        </div>
    </section>


        </main><!-- #main -->
    </div><!-- #primary -->


</div><!-- #content -->
<footer id="main-footer" class="main-footer">
    <div class="container">
    <div class="row">
        <div class="footer-column footer-content col-12 col-md-8">
            <div class="footer-menu-wrapper">
                                    <div class="copyright">
						<div id="text-2" class="widget widget_text">
							<div class="textwidget">
								<p>©1989 – 2022 Ionis Pharmaceuticals® is a registered trademark of Ionis Pharmaceuticals, Inc.</p>
								<p>Akcea Therapeutics® is a wholly owned subsidiary of Ionis Pharmaceuticals, Inc.</p>
							</div>
						</div>
                                            </div>
                                    <div class="menu-list">
                        <div id="nav_menu-2" class="widget widget_nav_menu"><div class="menu-footer-container"><ul id="menu-footer" class="menu"><li id="menu-item-631" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-631"><a href="https://www.ionispharma.com/contact-us/">Contact</a></li>
<li id="menu-item-1807" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1807"><a href="https://www.ionispharma.com/suppliers/">Suppliers</a></li>
<li id="menu-item-587" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-587"><a href="https://www.ionispharma.com/legal-notice/">Legal Notice</a></li>
<li id="menu-item-586" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-586"><a href="https://www.ionispharma.com/privacy-policy/">Privacy Policy</a></li>
<li id="menu-item-2368" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2368"><a href="https://www.ionispharma.com/social-policies/">Social Media Policies</a></li>
</ul></div></div>                    </div>
                            </div>
        </div>
        <div class="right-lines">
            <img src="https://www.ionispharma.com/wp-content/themes/ionis-2/dist/assets/svg/footer-lines.svg">
        </div>
    </div>
</div>
</footer>
</div><!-- #page -->


  <!--copyscapeskip-->
  <aside id="moove_gdpr_cookie_info_bar" class="moove-gdpr-align-center moove-gdpr-dark-scheme gdpr_infobar_postion_bottom moove-gdpr-info-bar-hidden" role="note" aria-label="GDPR Cookie Banner" style="display: none;">
    <div class="moove-gdpr-info-bar-container">
      <div class="moove-gdpr-info-bar-content">
        
<div class="moove-gdpr-cookie-notice">
  <p>We are using cookies to give you the best experience on our website.</p><p>You can find out more about which cookies we are using or switch them off in <span role="link" tabindex="1" data-href="#moove_gdpr_cookie_modal" class="change-settings-button">settings</span>.</p></div>
<!--  .moove-gdpr-cookie-notice -->        
<div class="moove-gdpr-button-holder">
		  <button class="mgbutton moove-gdpr-infobar-allow-all gdpr-fbo-0" aria-label="Accept" tabindex="1" role="button">Accept</button>
	  </div>
<!--  .button-container -->      </div>
      <!-- moove-gdpr-info-bar-content -->
    </div>
    <!-- moove-gdpr-info-bar-container -->
  </aside>
  <!-- #moove_gdpr_cookie_info_bar -->
  <!--/copyscapeskip-->
<script type="text/javascript" src="https://www.ionispharma.com/wp-content/themes/ionis-2/ionis.js?ver=1.2" id="script-js"></script>
<script type="text/javascript" src="https://www.ionispharma.com/wp-includes/js/dist/vendor/regenerator-runtime.min.js?ver=0.13.9" id="regenerator-runtime-js"></script>
<script type="text/javascript" src="https://www.ionispharma.com/wp-includes/js/dist/vendor/wp-polyfill.min.js?ver=3.15.0" id="wp-polyfill-js"></script>
<script type="text/javascript" id="contact-form-7-js-extra">
/* <![CDATA[ */
var wpcf7 = {"api":{"root":"https:\/\/www.ionispharma.com\/wp-json\/","namespace":"contact-form-7\/v1"}};
/* ]]> */
</script>
<script type="text/javascript" src="https://www.ionispharma.com/wp-content/plugins/contact-form-7/includes/js/index.js?ver=5.6.2" id="contact-form-7-js"></script>
<script type="text/javascript" src="https://www.ionispharma.com/wp-content/themes/ionis-2/dist/js/pages/default.js?ver=1559860160" id="default-scripts-js"></script>
<script type="text/javascript" src="https://www.ionispharma.com/wp-content/themes/ionis-2/dist/js/modules/pipeline-new-section.js?ver=1611683856" id="pipeline-new-section-script-js"></script>
<script type="text/javascript" src="https://www.ionispharma.com/wp-content/plugins/easy-fancybox/js/jquery.fancybox.min.js?ver=1.3.24" id="jquery-fancybox-js"></script>
<script type="text/javascript" id="jquery-fancybox-js-after">
var fb_timeout, fb_opts={'overlayShow':true,'hideOnOverlayClick':true,'showCloseButton':true,'margin':20,'centerOnScroll':false,'enableEscapeButton':true,'autoScale':true };
if(typeof easy_fancybox_handler==='undefined'){
var easy_fancybox_handler=function(){
jQuery('.nofancybox,a.wp-block-file__button,a.pin-it-button,a[href*="pinterest.com/pin/create"],a[href*="facebook.com/share"],a[href*="twitter.com/share"]').addClass('nolightbox');
/* Vimeo */
jQuery('a[href*="vimeo.com/"],area[href*="vimeo.com/"]').filter(function(){return this.href.match(/\/(?:[0-9]+|video\/)/);}).not('.nolightbox,li.nolightbox>a').addClass('fancybox-vimeo');
jQuery('a.fancybox-vimeo,area.fancybox-vimeo,li.fancybox-vimeo a').each(function(){jQuery(this).fancybox(jQuery.extend({},fb_opts,{'type':'iframe','width':640,'height':360,'keepRatio':1,'titleShow':false,'titlePosition':'float','titleFromAlt':true,'onStart':function(a,i,o){var splitOn=a[i].href.indexOf("?");var urlParms=(splitOn>-1)?a[i].href.substring(splitOn):"";o.allowfullscreen=(urlParms.indexOf("fullscreen=0")>-1)?false:true;o.href=a[i].href.replace(/https?:\/\/(?:www\.)?vimeo\.com\/([0-9]+)\??(.*)/gi,"https://player.vimeo.com/video/$1?$2&autoplay=1");}}))});};
jQuery('a.fancybox-close').on('click',function(e){e.preventDefault();jQuery.fancybox.close()});
};
var easy_fancybox_auto=function(){setTimeout(function(){jQuery('#fancybox-auto').trigger('click')},1000);};
jQuery(easy_fancybox_handler);jQuery(document).on('post-load',easy_fancybox_handler);
jQuery(easy_fancybox_auto);
</script>
<script type="text/javascript" id="wpcf7cf-scripts-js-extra">
/* <![CDATA[ */
var wpcf7cf_global_settings = {"ajaxurl":"https:\/\/www.ionispharma.com\/wp-admin\/admin-ajax.php"};
/* ]]> */
</script>
<script type="text/javascript" src="https://www.ionispharma.com/wp-content/plugins/cf7-conditional-fields/js/scripts.js?ver=2.2.3" id="wpcf7cf-scripts-js"></script>
<script type="text/javascript" id="moove_gdpr_frontend-js-extra">
/* <![CDATA[ */
var moove_frontend_gdpr_scripts = {"ajaxurl":"https:\/\/www.ionispharma.com\/wp-admin\/admin-ajax.php","post_id":"538","plugin_dir":"https:\/\/www.ionispharma.com\/wp-content\/plugins\/gdpr-cookie-compliance","show_icons":"all","is_page":"1","strict_init":"1","enabled_default":{"third_party":0,"advanced":0},"geo_location":"false","force_reload":"false","is_single":"","hide_save_btn":"false","current_user":"0","cookie_expiration":"365","script_delay":"2000","close_btn_action":"1","close_cs_action":"1","gdpr_scor":"true","wp_lang":""};
/* ]]> */
</script>
<script type="text/javascript" src="https://www.ionispharma.com/wp-content/plugins/gdpr-cookie-compliance/dist/scripts/main.js?ver=4.8.12" id="moove_gdpr_frontend-js"></script>
<script type="text/javascript" id="moove_gdpr_frontend-js-after">
var gdpr_consent__strict = "false"
var gdpr_consent__thirdparty = "false"
var gdpr_consent__advanced = "false"
var gdpr_consent__cookies = ""
</script>

    
  <!--copyscapeskip-->
  <!-- V1 -->
  <div id="moove_gdpr_cookie_modal" class="gdpr_lightbox-hide" role="complementary" aria-label="GDPR Settings Screen">
    <div class="moove-gdpr-modal-content moove-clearfix logo-position-left moove_gdpr_modal_theme_v1">
          
        <button class="moove-gdpr-modal-close" aria-label="Close GDPR Cookie Settings">
          <span class="gdpr-sr-only">Close GDPR Cookie Settings</span>
          <span class="gdpr-icon moovegdpr-arrow-close"></span>
        </button>
            <div class="moove-gdpr-modal-left-content">
        
<div class="moove-gdpr-company-logo-holder">
  <img src="https://www.ionispharma.com/wp-content/uploads/2019/05/Ionis-Logo-Sig-300x98.png" alt="Ionis Logo TM" width="300" height="98" class="img-responsive">
</div>
<!--  .moove-gdpr-company-logo-holder -->        <ul id="moove-gdpr-menu">
          
<li class="menu-item-on menu-item-privacy_overview menu-item-selected">
  <button data-href="#privacy_overview" class="moove-gdpr-tab-nav" aria-label="Privacy Overview">
    <span class="gdpr-svg-icon">
      <svg class="icon icon-privacy-overview" viewBox="0 0 26 32">
        <path d="M11.082 27.443l1.536 0.666 1.715-0.717c5.018-2.099 8.294-7.014 8.294-12.442v-5.734l-9.958-5.325-9.702 5.325v5.862c0 5.376 3.2 10.24 8.115 12.365zM4.502 10.138l8.166-4.506 8.397 4.506v4.813c0 4.838-2.893 9.19-7.347 11.034l-1.101 0.461-0.922-0.41c-4.352-1.894-7.194-6.195-7.194-10.957v-4.941zM12.029 14.259h1.536v7.347h-1.536v-7.347zM12.029 10.394h1.536v2.483h-1.536v-2.483z" fill="currentColor"></path>
      </svg>      
    </span> 
    <span class="gdpr-nav-tab-title">Privacy Overview</span>
  </button>
</li>

  <li class="menu-item-strict-necessary-cookies">
    <button data-href="#strict-necessary-cookies" class="moove-gdpr-tab-nav" aria-label="Strictly Necessary Cookies">
      <span class="gdpr-svg-icon">
        <svg class="icon icon-strict-necessary" viewBox="0 0 26 32">
          <path d="M22.685 5.478l-9.984 10.752-2.97-4.070c-0.333-0.461-0.973-0.538-1.434-0.205-0.435 0.333-0.538 0.947-0.23 1.408l3.686 5.094c0.179 0.256 0.461 0.41 0.768 0.435h0.051c0.282 0 0.538-0.102 0.742-0.307l10.854-11.699c0.358-0.435 0.333-1.075-0.102-1.434-0.384-0.384-0.998-0.358-1.382 0.026v0zM22.301 12.954c-0.563 0.102-0.922 0.64-0.794 1.203 0.128 0.614 0.179 1.229 0.179 1.843 0 5.094-4.122 9.216-9.216 9.216s-9.216-4.122-9.216-9.216 4.122-9.216 9.216-9.216c1.536 0 3.021 0.384 4.378 1.101 0.512 0.23 1.126 0 1.357-0.538 0.205-0.461 0.051-0.998-0.384-1.254-5.478-2.944-12.314-0.922-15.283 4.557s-0.922 12.314 4.557 15.258 12.314 0.922 15.258-4.557c0.896-1.638 1.357-3.482 1.357-5.35 0-0.768-0.077-1.51-0.23-2.253-0.102-0.538-0.64-0.896-1.178-0.794z" fill="currentColor"></path>
        </svg>
      </span> 
      <span class="gdpr-nav-tab-title">Strictly Necessary Cookies</span>
    </button>
  </li>




        </ul>
        
<div class="moove-gdpr-branding-cnt">
  
		<a href="https://wordpress.org/plugins/gdpr-cookie-compliance/" target="_blank" rel="noopener noreferrer nofollow" class="moove-gdpr-branding">Powered by&nbsp; <span>GDPR Cookie Compliance</span></a>
		</div>
<!--  .moove-gdpr-branding -->      </div>
      <!--  .moove-gdpr-modal-left-content -->
      <div class="moove-gdpr-modal-right-content">
        <div class="moove-gdpr-modal-title">
           
        </div>
        <!-- .moove-gdpr-modal-ritle -->
        <div class="main-modal-content">

          <div class="moove-gdpr-tab-content">
            
<div id="privacy_overview" class="moove-gdpr-tab-main">
      <span class="tab-title">Privacy Overview</span>
    <div class="moove-gdpr-tab-main-content">
  	<p>This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.</p>
  	  </div>
  <!--  .moove-gdpr-tab-main-content -->

</div>
<!-- #privacy_overview -->            
  <div id="strict-necessary-cookies" class="moove-gdpr-tab-main checkbox-selected" style="display:none">
    <span class="tab-title">Strictly Necessary Cookies</span>
    <div class="moove-gdpr-tab-main-content">
      <p>Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.</p>
      <div class="moove-gdpr-status-bar checkbox-selected">
        <div class="gdpr-cc-form-wrap">
          <div class="gdpr-cc-form-fieldset">
            <label class="cookie-switch" for="moove_gdpr_strict_cookies">    
              <span class="gdpr-sr-only">Enable or Disable Cookies</span>        
              <input type="checkbox" aria-label="Strictly Necessary Cookies" value="check" name="moove_gdpr_strict_cookies" id="moove_gdpr_strict_cookies">
              <span class="cookie-slider cookie-round" data-text-enable="Enabled" data-text-disabled="Disabled"></span>
            </label>
          </div>
          <!-- .gdpr-cc-form-fieldset -->
        </div>
        <!-- .gdpr-cc-form-wrap -->
      </div>
      <!-- .moove-gdpr-status-bar -->
              <div class="moove-gdpr-strict-warning-message" style="margin-top: 10px; display: none;">
          <p>If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.</p>
        </div>
        <!--  .moove-gdpr-tab-main-content -->
                                              
    </div>
    <!--  .moove-gdpr-tab-main-content -->
  </div>
  <!-- #strict-necesarry-cookies -->
            
            
            
          </div>
          <!--  .moove-gdpr-tab-content -->
        </div>
        <!--  .main-modal-content -->
        <div class="moove-gdpr-modal-footer-content">
          <div class="moove-gdpr-button-holder">
			  		<button class="mgbutton moove-gdpr-modal-allow-all button-visible" role="button" aria-label="Enable All">Enable All</button>
		  					<button class="mgbutton moove-gdpr-modal-save-settings button-visible" role="button" aria-label="Save Settings" style="display: inline-block;">Save Settings</button>
				</div>
<!--  .moove-gdpr-button-holder -->        </div>
        <!--  .moove-gdpr-modal-footer-content -->
      </div>
      <!--  .moove-gdpr-modal-right-content -->

      <div class="moove-clearfix"></div>

    </div>
    <!--  .moove-gdpr-modal-content -->
  </div>
  <!-- #moove_gdpr_cookie_modal -->
  <!--/copyscapeskip-->
 	

<script type="text/javascript"> _linkedin_partner_id = "1840162"; window._linkedin_data_partner_ids = window._linkedin_data_partner_ids || []; window._linkedin_data_partner_ids.push(_linkedin_partner_id); </script><script type="text/javascript"> (function(){var s = document.getElementsByTagName("script")[0]; var b = document.createElement("script"); b.type = "text/javascript";b.async = true; b.src = "https://snap.licdn.com/li.lms-analytics/insight.min.js"; s.parentNode.insertBefore(b, s);})(); </script> <noscript> <img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1840162&fmt=gif" /> </noscript>



<div id="fancybox-tmp"></div><div id="fancybox-loading"><div></div></div><div id="fancybox-overlay"></div><div id="fancybox-wrap" class="fancybox-ie"><div id="fancybox-outer"><div class="fancybox-bg" id="fancybox-bg-n"></div><div class="fancybox-bg" id="fancybox-bg-ne"></div><div class="fancybox-bg" id="fancybox-bg-e"></div><div class="fancybox-bg" id="fancybox-bg-se"></div><div class="fancybox-bg" id="fancybox-bg-s"></div><div class="fancybox-bg" id="fancybox-bg-sw"></div><div class="fancybox-bg" id="fancybox-bg-w"></div><div class="fancybox-bg" id="fancybox-bg-nw"></div><div id="fancybox-content"></div><a id="fancybox-close"></a><div id="fancybox-title"></div><a id="fancybox-left"><span class="fancy-ico" id="fancybox-left-ico"></span></a><a id="fancybox-right"><span class="fancy-ico" id="fancybox-right-ico"></span></a></div></div></body></html>